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PREFACE 
 
In 2002, Prof. Doutor Mário Caetano Pereira and Prof. Doutor Carlos 
Vasconcelos created a multidisciplinary Clinics in Clinical Immunology Unit to 
follow patients with autoimmune diseases at high risk of developing peripheral 
vascular complications – Consulta Multidisciplinar de Raynaud. I was invited to 
participate and as so, visited Royal Free Hospital and Prof. Carol Black 
Department. A similar multidisciplinary model was started in our Hospital.  
As a Raynaud subject, I was always sensible to the suffering of my patients, 
in particular secondary RP patients with systemic sclerosis. These patients, mostly 
women in childbearing age, dealt with great difficulties in managing their daily 
activities and in many cases could not even take care of their children due to the 
severe digital ulcers. Additionally they had great absenteeism from work, a high 
impact in quality of life with all the huge negative economic and social 
consequences.  
Over the years, my greatest concern was how could I identify the patients 
that underlie microangiopathy that inevitably would progress to severe digital 
ulcers. The greatest challenge was that digital ulcers are not associated neither to 
severity or progression of underlying disease.  
With a strong institutional and patients commitment I began this 3-year long 
journey.  This thesis is the report of this extensive process. It cannot express the 
long days spent in the clinics, battling to conciliate clinical practice with research, 
fighting the financial constraints, the hope for good results and the sadness and 
tiredness with each failed attempt. 
I wrote this thesis with the aim to help to clarify what I have perceived as a 
critical gap in understanding the vascular disease underlying severe ischemic 
peripheral disease and to use these data in the whole process of prevention and 
care, as the basis for delivering quality of life to all my patients. 
It has been an outstanding and extremely rewarding journey.  
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ABSTRACT 
 
Background 
Raynaud's phenomenon (RP) is a common, well-characterized clinical 
disorder characterized by recurrent episodes of digital artery vasospasm 
triggered by exposure to cold or emotional stress. RP can be classified as primary 
(idiopathic; PRP) or secondary (SRP) when associated with several diseases or 
conditions. The pathogenesis of RP is still not entirely understood; recent insights 
into the pathogenic mechanisms underlying RP, particularly vascular, neuronal, 
and intravascular abnormalities, might help identify crucial key points and 
potential targets for early therapeutic interventions.  
Ninety-five percent of patients with systemic sclerosis (SSc), 20-30% of those 
with systemic lupus erythematous (SLE), 20-30% of those with Sjögren’s 
syndrome, and 25% of those with myositis will have RP as the first clinical 
manifestation of the disease. The co-existence of RP, positive antinuclear 
antibody (ANA), and microvascular abnormalities diagnosed by nailfold 
videocapillaroscopy (NVC) is a core diagnostic triad of associated autoimmune 
connective tissue disease (CTD). Koenig et al. demonstrated in a prospective 
study of 586 patients, followed up for 3,197 person-years, that the incidence of 
progression of isolated RP to definite SSc was 12.6% and 13.6% to other CTDs.  
Ischemic digital ulcers (DUs) are a true burden for all patients with SRP and, 
in particular, SSc patients. DUs are very painful, with prolonged and slow healing, 
have a high risk of infection, and are extremely disabling, with severe impairment 
of simple daily activities. In SSc patients, ~30% of the patients per year develop 
ischemic digital tip ulcerations, 35-60% of SSc patients will experience at least 
one ulcer in the course of the disease, and about 75% of the affected patients 
have their first DU episode within 5 years of their first non-Raynaud symptom. 
Data from the French registry identified 44% of SSc patients as having one or 
more ischemic DUs, resulting in hospitalization for 33% of cases, with 46% 
requiring systemic antibiotics; 31–71% of patients have recurrent DUs. 
There is an unmet need to properly measure vascular disease activity in SRP 
patients.  Currently available instruments still have many limitations. It could be 
challenging to identify simple, applicable clinical diagnostic tools to allow the 
early identification of RP patients at high risk for peripheral ischemic vascular 
complications and thus enable early preventative target therapy.  
 
Objectives 
Measures of disease activity can be used to describe and compare study 
populations and identify potential risk factors for microangiopathy. Given that 
research methods in RP and DU are rapidly advancing, they
| ABSTRACT / RESUMO 
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determine eligibility for diagnosis and management and as a tool to evaluate 
outcomes.   
The main objectives of this thesis were: i) identification of risk factors for 
DU in patients with RP, and ii) to evaluate SSc patients’ risk of developing a first 
episode of DU or to have a recurrence of DU during a 3-year-long follow-up 
period. 
 
Methods 
This research study was designed to provide an analysis of the clinical 
characteristics, endothelial dysfunction parameters, and vascular biomarkers in 
RP patients. An effort was made to consolidate knowledge and contribute to the 
discussion of the contradictory findings described in the literature. 
A prospective observational cohort study with a 3-year clinical follow-up was 
conducted to evaluate 109 selected patients that attended the Multidisciplinary 
Raynaud Outpatient Clinic of the Clinical Immunology Unit at Centro Hospitalar 
do Porto in Portugal (77 SSc patients and 32 with primary RP). Thirty-four control 
patients (healthy, sex/age matched, non-obese, and without self-reported 
cardiovascular risk factors) participated in the study.  
SSc patients were divided into two groups: the DU group, which included 38 
patients with an active ulcer at the beginning of our follow-up study, with or 
without a past history of DU; and a DU-naïve group that included 39 patients with 
no history of DU until enrolment.  
The following were assessed in all patients and controls: clinical and 
demographic parameters, Allen test, flow-mediated dilatation (FMD), NVC, 
autoantibody screening and endothelial dysfunction, and angiogenesis vascular 
biomarkers. When included in the study cohort, patients were instructed to come 
to the hospital clinics whenever a new digital tropic lesion occurred.  If no DU 
developed, patients were seen on a regular basis at 3- to 6-month intervals, as 
indicated by disease severity. Final observations were in the fourth trimester of 
2014. We lost no patients during the entire course of our follow-up period.  
The primary outcome was the occurrence of at least one or more new 
ischemic fingertip DUs in the 3-year follow-up period. In addition, we applied 
survival analysis to new occurrences of DU during the study period, regarding 
endothelium dysfunction (FMD, endothelin-1 (ET-1), and asymmetric 
dimethylarginine (ADMA)), angiogenic biomarkers (vascular endothelial growth 
factor (VEGF), endostatin, and endoglin), and microvascular damage (NVC and 
microangiopathy evolution score (MES)).  
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The institutional ethical review board of Centro Hospitalar do Porto 
approved this study. All subjects signed informed consent forms before inclusion 
in the study. Data were collected by analysis of clinical file data and by clinical 
interview. 
 
Results 
This is the first study that demonstrates that both endothelial dysfunction 
and an angiogenic stimulus are present in PRP.  Clearly, our findings suggest that 
endothelial dysfunction suggested by increased serum levels of ET-1 and a pro-
angiogenic state due to increased serum levels of VEGF might be triggered by the 
repeated vasospasms; however, when comparing PRP and SRP associated with SSc 
but without DU, no major differences were found regarding the vascular 
biomarkers investigated. We show that severe obliterative peripheral 
vasculopathy is present only in SRP patients with DU as expressed by increased 
peripheral resistance, low FMD response to shear stress, decreased peak systolic 
velocity (PSV) and end diastolic velocity (EDV), and high resistive índex (RI), 
mostly due to endothelial cell injury with endothelial dysfunction associated with 
impaired angiogenesis.  
Regarding risk factors for DU in RP patients, we identified that FMD, PSV, 
and EDV were significantly lower in patients with DU than in SSc non-DU, PRP, and 
control patients. Regarding qualitative NVC patterns, FMD levels were statistically 
significantly different between groups. FMD, PSV, and EDV were significantly 
lower in the late pattern than in active and early patterns; no differences were 
found between active and early patterns. We observed successive decreases of 
PSV and EDV and increased vascular resistance, measured by resistive index (RI), 
with progression of the microvascular damage diagnosed by NVC. Regarding 
vascular biomarkers, we report high serum levels of ET-1 and ADMA, low serum 
levels of VEGF, and increased endoglin serum as independent risk factors of DU 
in patients.  
We identified the following as potential predictive factors of new ischemic 
DU episodes in SRP: history of at least one DU before enrolment in the study, 
anti-scleroderma-70 autoantibodies, telangiectasia, NVC late pattern, high MES 
score, low FMD%, a positive Allen test, and increased ET-1 serum levels. 
Multivariate Cox analysis confirmed increased MES score, low FMD%,  increased  
ET-1, and ADMA serum levels as independent predictors of the development of a 
new DU. With respect to angiogenic biomarkers, only VEGF was identified as a 
predictive risk factor for the occurrence of at least one new DU during the three-
year follow-up. 
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Patients with FMD levels ≤ 9.5% (p=0.001), ET-1 serum levels > than 11.9 
pmol/ml (p<0.001), ADMA serum levels > than 0.49 µmol/l (p=0.075), and MES 
scores greater than 2 (p<0.001) had significantly more new DUs in our 3-year 
survival analysis.  Low VEGF serum levels < 422.47 pg/ml had significantly more 
DUs (p=0.028).  
Our study identified FMD > 9.41% (HR: 0.37 95%CI: 0.14-0.99), ET-1 >11.85 
pmol/L (HR: 3.81 95%CI: 1.41-10.26), and late NVC pattern (HR: 2.29 95%CI 0.97-
5.38) as predictors of DU recurrence in the 3-year follow-up and when estimating 
the probability of occurrence of the first DU in DU-naïve patients; only late NVC 
pattern (HR: 12.66 95%CI: 2.06-77.89) was an independent predictor.  
 
Conclusions 
In our investigation, we confirmed that macrovascular disease, endothelium-
dependent flow-mediated dilation, ET-1, microvascular damage detected in 
capillaroscopy, and the angiogenic biomarker VEGF are risk factors for DU events.  
Late NVC pattern was the most robust predictor of new DU episodes, 
recurrent or the first event. Additionally, endothelial dysfunction parameters were 
strong predictors of DU recurrence. 
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RESUMO 
 
Introdução 
O fenômeno de Raynaud (FR) é uma patologia clínica comum, caracterizada 
por episódios recorrentes de vasospasmo das artérias digitais desencadeados 
pela exposição ao frio ou pelo stress emocional.  O FR pode ser classificado como 
sendo primário (FRP) idiopático ou secundário (FRS) se associado a outras 
patologias ou condições. A patogénese do FR não é ainda totalmente conhecida. 
Os recentes avanços sobre os mecanismos patogénicos subjacentes ao FR, em 
particular os vasculares, neuronais e intravasculares, permitem ajudar a conhecer 
melhor a etiopatogenia, permitindo uma melhor identificação dos potenciais 
alvos para uma intervenção terapêutica precoce. 
Tem sido descrito na literatura que 95% dos doentes com esclerose 
sistémica (ES), 20-30% com lúpus eritematoso sistémico (LES), 20-30% com S. 
Sjogren e 25% com miosite terão como primeira manifestação clínica da doença o 
FR. A tríade FR, anticorpo antinuclear positivo (ANA) e alterações microvasculares 
diagnosticados por videocapilaroscopia periungueal (NVC) são fundamentais para 
o diagnóstico de doença autoimune associada. Koenig et al demonstraram num 
estudo prospectivo que nos 586 pacientes com FR seguidos durante 3.197 
pessoas-ano, a incidência da progressão do FR isolado para ES foi de 12,6%, e 
13,6% evoluíram para outras doenças do tecido conjuntivo. 
As úlceras digitais isquémicas (UD) são extremamente incapacitantes 
estando sobretudo presentes nos doentes com ES. São muito dolorosas, com 
tempo de cicatrização prolongado e lento, têm um alto risco de infecção e são 
comprometedoras de uma forma grave da qualidade de vida dos doentes. 
Aproximadamente ~30% / ano dos doentes com ES desenvolvem UD. Durante a 
evolução da sua doença 35-60% dos doentes vão ter pelo menos um episódio de 
UD sendo que em 75% o seu primeiro episódio UD ocorre nos primeiros 5 anos 
após a primeira manifestação de FR. 
 Os dados do Registro francês demostraram que 44% dos doentes com ES 
tiveram um ou mais episódios de UD, de que resultou hospitalização em 33% dos 
casos e 46% exigiu antibióticos sistêmicos. A recorrência das UD é elevada na ES 
variando entre os 31 aos 71%. 
Há pouca informação sobre a avaliação e medição da doença vascular nos 
doentes com FRS. Os instrumentos atualmente disponíveis tem ainda muitas 
limitações. Como tal constitui um desafio a identificação de ferramentas de 
diagnóstico clínicos simples, capazes de serem aplicada no dia-a-dia de forma a 
permitir a identificação precoce de doentes com FR em risco de desenvolver 
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complicações vasculares isquémicas periféricas permitindo a instituição de  uma 
terapêutica- alvo preventiva precoce. 
 
Objetivos 
A quantificação da doença vascular pode ser usada para descrever e 
comparar populações de estudos, como método de diagnóstico, permitir 
identificar os factores de risco potenciais para as complicações microangiopáticas 
e servir como ferramenta de medida na avaliação do resultado de novos 
tratamentos. 
Os principais objectivos desta tese foram: i) identificação de fatores de risco 
para UD em doentes com FR; ii) avaliar o valor preditivo de marcadores 
vasculares nos doentes com FRS com ES de desenvolver um primeiro episódio de 
UD ou ter uma recorrência de UD ao longo de um período de seguimento de 3 
anos. 
 
Métodos 
Este estudo foi desenhado para avaliar as características clínicas, os 
parâmetros de disfunção endotelial e os biomarcadores vasculares em doentes 
com FR.  Foi nosso objectivo consolidar o conhecimento atual e contribuir para a 
discussão de resultados contraditórios descritos na literatura. 
Realizamos um estudo de coorte observacional, prospectivo, com um 
seguimento clínico de 3 anos de 109 doentes (77 doentes com FRS e ES e 32 com 
FRP) da Consulta Multidisciplinar Raynaud da Unidade de Imunologia Clínica do 
Centro Hospitalar do Porto, em Portugal. Trinta e quatro indivíduos saudáveis, 
pareados por sexo e idade, não-obesos, sem factores de risco cardiovascular 
foram convidados a participar como grupo controle. 
Os doentes com FRS e ES foram divididos em dois grupos: grupo UD (38 
doentes com uma úlcera ativa no início do nosso estudo) e grupo não-UD (39 
doentes sem história de UD durante toda a evolução da sua doença até á inclusão 
no estudo).  
Foram analisados  parâmetros clínicos e demográficos, avalaida a doença 
macrovascular com o teste de Allen e a fluxo mediada pelo dilatação (FMD), 
doença microvascular através da videocapilaroscopia periungueal (NVC), foi feita 
a pesquisa de autoanticorpos e medidos os biomarcadores de doença vascular de 
disfunção endotelial (endotelina-1-[ET-1] e dimetilarginina assimétrica- [ADMA]) e 
de angiogênese (fator de crescimento endotelial vascular- [VEGF], endostatina e 
endoglina) em todos os doentes e no grupo controle. Os doente foram orientados 
no sentido de recorrem ao hospital sempre que uma nova lesão vascular 
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periférica se desenvolvesse e no caso de não ocorrerem episódios de UD os 
doentes eram avaliados numa base regular com intervalos de 3-6 meses, 
conforme indicado pela gravidade da doença. A última observação foi no último 
trimestre de 2014. Não se perderam doentes no seguimento.   
O “endpoint” primário foi a ocorrência de pelo menos uma ou mais UD 
isquêmicas no período de acompanhamento de 3 anos. Além disso, aplicamos os 
testes de análise de sobrevivência, para avaliar a ocorrência de novas UD durante 
o período do estudo, aos biomarcadores vasculares: i) disfunção endotelial (FMD, 
ET-1 e ADMA, ii) biomarcadores angiogênicos (VEGF, endostatina e endoglina) e 
iii) lesão microvascular pela analise qualitativa e semi-quantitativa na 
capilaroscopia.  
A Comissão de Ética institucional do Centro Hospitalar do Porto aprovou 
este estudo. Todos os sujeitos assinaram o consentimento informado antes da 
inclusão no estudo. Os dados foram colhidos por consulta de processo clínico e 
por entrevista clínica. 
 
Resultados 
Do que nos é permitido saber, este é o primeiro estudo a demonstrar que a 
disfunção endotelial e o estímulo angiogénico estão simultaneamente presentes 
nos doentes com FRP. Estes dados foram demonstradas pelo aumento dos níveis 
séricos de ET-1 e de VEGF. No entanto, quando comparamos os doentes com FRP 
com os FRS sem UD não encontramos nenhuma diferença significativa no que 
respeita aos biomarcadores vasculares investigados. Assim, um dado novo e útil 
desta investigação é que vasculopatia periférica obliterante grave só está 
presente nos doentes com FRS e ES com UD. Estes dados são confirmados pelo 
aumento da resistência periférica, baixa resposta ao “shear stress” com índices 
de resistência elevados, tradutores da lesão da célula endotelial e uma 
angiogenese ineficaz.  
Como fatores de risco para UD identificamos o FMD e a velocidade 
diastólica final (EDV), dado estarem significativamente dimuidos nos doentes com 
UD comparados com restantes grupos. Avaliando o FMD nos diferentes padrões 
qualitativos da capilaroscopia foram encontradas diferenças estatísticas entre os 
grupos. O FMD e EDV eram significativamente menores no padrão tardio em 
relação ao padrão ativo e precoce. Não há diferenças significativas entre os 
padrões ativos e precoce. Com a progressão do dano microvascular observou-se 
um aumento da resistência vascular periférica. No que respeita aos 
biomarcadores vasculares, verificamos que níveis aumentados de ET-1, ADMA e 
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de endoglina e a diminuição do estimulo angiogénico motivada por baixos níveis 
séricos de VEGF eram como fatores de risco independentes de UD.   
Foi nosso objetivo determinar os fatores preditivos de aparecimento de 
novos episódios de UD nos doentes com FRS.  A história de pelo menos uma UD 
prévia á inclusão no estudo, a presença de auto-anticorpos anti-esclerodermia-70 
e de telangiectasias, o padrão tardio na capilaroscopia, uma resposta diminuída 
ao “shear stress”, um teste de Allen positivo e os níveis séricos de ET-1 
aumentada foram identificados com factores preditivos de novos episódios de 
UD. A análise multivariada Cox confirmou que a lesão microvascular avançada, a 
resposte reduzida de FMD%, o aumento dos níveis séricos de ET-1 e de ADMA 
como fatores preditivos independentes do desenvolvimento de uma nova UD. 
Relativamente aos biomarcadores angiogénicos, apenas o VEGF foi identificado 
como tendo valor preditivo para a ocorrência de pelo menos uma nova UD nos 3 
anos de seguimento clinico.   
Os doentes com FMD% ≤ 9,5% (p = 0,001), nível sérico de ET-1 >11,9pmol / 
ml (p <0,001), de ADMA> de 0,49 pmol / l (p = 0,075) de VEGF <422,47 pg / ml 
(p = 0,028).e a lesão microvascular com pontuação superior a 2 (p <0,001) 
apresentaram significativamente mais novas UD  na análise de sobrevivência aos 
3 anos.  
O nosso estudo identificou o FMD% > 9,41% (HR: 0,37 IC 95%: 0,14-0,99); 
ET-1> 11,85 pmol / L (HR: 3,81 IC 95%: 1,41-10,26) e tardia padrão NVC (HR: 
2,29 IC 95% 0,97-5,38) como preditivos da recorrência de UD. O padrão tardio na 
capilaroscopia (HR: 12.66 CI 95%: 2,06-77,89) foi o único factor preditivo de 
aparecimento da primeira UD nos doentes incluídos sem histórico de 
complicações vasculares periféricas.  
 
Conclusões 
A nossa investigação confirmou que a doença macrovascular, o FMD 
endotélio-dependente, os níveis séricos de ET-1 e de VEGF e a lesão 
microvascular são factores de risco para o desenvolvimento de UD: 
O padrão tardio na capilaroscopia é o factor preditivo com maior peso quer 
na recorrência quer no aparecimento de novos episódios de UD. Na recorrência 
de UD a disfunção endotelial desempenha um papel fulcral. 
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In Portugal, Centro Hospitalar do Porto was a pioneer hospital by creating 
the Multidisciplinary Raynaud Clinic following Royal´s Free Hospital model. We 
have had an active role in this clinic as responsible for the evaluation of Raynaud 
patients with severe peripheral vasculopathy. We focused in the evaluation of SRP 
with vascular complications, in particular patients with systemic sclerosis (SSc), 
and this work was the structural basis of the main objectives of this thesis. In 
order to compare patients with similar disease, we have excluded from this study 
patients with SRP and other autoimmune disease beyond SSc. 
 
The main objectives of this thesis are: 
 
1. to study endothelial dysfunction, microvascular damage, angiogenesis and 
vascular biomarkers in patients with RP.  
2. to identify risk factors for digital ulcers in patients with RP. 
3. to determine potential predictive factors of appearance of new episodes of 
ischemic digital ulcers in secondary Raynaud patients. 
 
The first chapter focuses on the thesis rationale and research questions. 
 
The second chapter provides two Prisma-driven systemic reviews on main 
topics of the thesis:  RP and predictive risk factors of DU in SRP – SSc associated 
patients. We also review the vascular pathology highlighting the role of 
endothelial dysfunction, microvascular damage, angiogenesis and vascular 
biomarkers in patients with RP.  
 
The third chapter describes patients and methodology. 
 
The fourth chapter displays the research results: 
 
1. Clinical assessment and characterization of our cohort in the beginning of 
the study.  
2. Microvascular damage, endothelial dysfunction and ischemic peripheral 
vasculopathy in secondary RP. 
3. Description of the clinical correlation of endothelial dependent flow-
mediated dilatation and capillaroscopic findings, using two different 
classifications qualitative “scleroderma pattern” and semi-quantitative 
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“microangiopathy evolution score”, with digital ulcers in patients with 
Secondary RP; comparison of these parameters between primary and 
secondary Raynaud patients and comparison with control group.  
4. Description of impaired angiogenesis as a feature of digital ulcers in 
systemic sclerosis. 
5. Identification of the predictive value of vascular disease biomarkers for 
digital ulcers in systemic sclerosis patients. 
6. Risk factors for peripheral vasculopathy in systemic sclerosis patients.  
 
The fifth chapter summarizes and discusses the results, limitations of the 
study, conclusions and suggestions for further research. 
 
 
 
SCIENTIFIC AND CLINICAL OUTPUTS | 
PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | XXIII 
SCIENTIFIC AND CLINICAL OUTPUTS 
 
PUBLICATIONS 
 
1. FULL TEXT MANUSCRIPTS 
 
2011 “Fenómeno de Raynaud” 
 Silva I, Loureiro T, Almeida I, Mansilha A, Vasconcelos C.  
 Published in Angiologia e Cirurgia Vascular 03/2011; 7(1):13-20. Indexed 
to SciELO Citation Index da Web of Knowledge ISSN: 1646-706X and 
Latindex. 
2014 “A PRISMA-Driven Systematic Review For Predictive Risk Factors Of 
Digital Ulcers In Systemic Sclerosis Patients” 
  Silva I, Almeida J, Vasconcelos C 
 Published in Autoimmun Rev. 2015 Feb;14(2):140-52. doi: 
10.1016/j.autrev.2014.10.009.  
2015  “Endothelial dysfunction and nailfold videocapillaroscopy pattern as 
predictors of digital ulcers in systemic sclerosis: a cohort study and 
review of the literature“ 
 Silva I, Teixeira A, Oliveira J, Almeida I, Águas A, Almeida R, Vasconcelos C 
 Published in Clinical reviews in Allergy and Immunology DOI 
10.1007/s12016-015-8500-0 
2015  “Digital ulcers in Systemic Sclerosis: role of flow-mediated dilatation 
and capillaroscopy as risk assessment tools” 
 Silva I, Loureiro T, Teixeira A, Almeida I, Mansilha A, Vasconcelos C: 
Accepted in European Journal of Dermatology  
2015  “Predictive value of vascular disease biomarkers for digital ulcers in 
systemic sclerosis patients” 
 Silva I, Teixeira A, Oliveira J, Almeida I, Almeida R, Vasconcelos C 
 Published in Clin Exp Rheumatol. 2015 Sep-Oct;33 Suppl 91(4):127-130. 
Epub 2015 Aug 5 
2015  “Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis”  
 Silva I, Almeida C, Teixeira A, Oliveira J, Almeida I, Almeida R, Vasconcelos C 
 Accepted in Clinical Rheumatology  
2015  “Microvascular damage, endothelial dysfunction and ischemic 
peripheral vasculopathy in secondary Raynaud phenomenon” 
 Silva I, Teixeira A, Oliveira J, Almeida I, Almeida R, Vasconcelos C 
 Submitted 
| SCIENTIFIC AND CLINICAL OUTPUTS  
XXIV | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
2015  “Raynaud Phenomenon” 
 I Silva, G Teixeira, M Bertão, R Almeida, C Vasconcelos 
 Submitted 
2015  “Vascular biomarkers and correlation with peripheral vasculopathy in 
Raynaud phenomenon” 
 Silva I, Teixeira A, Oliveira J, Almeida I, Almeida R, Vasconcelos C 
 Submitted 
 
2. BOOK CHAPTERS 
 
2013  “Bosentano – orientações para o doente; Iloprost orientações para o 
doente” 
 Ivone Silva  
 in “Manual Prático de Fármacos nas Doenças Autoimunes. Editor: Unidade 
de Imunologia Clinica. Edição 2013, pages 220-237 
2015  “Vascular pathology in connective tissue disease” 
 Ivone Silva, Armando Mansilha  
 in “Tips and tricks and decision making in vascular surgery” edited by 
Prof. P. Settembrini, Edizioni Minerva Medica S.p.A. in press. 
 
3. ABSTRACTS PUBLISHED IN INDEXED JOURNALS 
 
2010  Silva I, Almeida I, Vasconcelos C, Almeida R “Can Raynaud phenomenon 
be an alert sign of microvascular abnormalities” International Angiology  
April 2010 Vol 29 (Suppl 2 to No. 2): S0034; pag 11. 
2010  Silva I, Almeida I, Quelhas I, Vasconcelos C. “Úlceras digitais – uma 
abordagem multidisciplinary”. Acta Reumatol Port. 2010; 35:69-156 
(SUP): S117; pag 152. 
2011  I. Silva, T. Loureiro, C. Vasconcelos, J. Oliveira, M.E. Matos, R. Almeida. 
“Impaired angiogenesis: a Prediction for digital ulcers in Raynaud 
phenomenon” J Vasc Res 2011;48(suppl 1) P117. 
Doi:10.1159/000332604. 
2012  Silva, Ivone, Almeida, Isabel, Marinho, António, Vasconcelos, Carlos. 
“Predictors of Digital Ulcers in Systemic Sclerosis: Correlation Between 
Clinical and Hemodynamic Features, Capillaroscopy, Endothelium 
Dysfunction and Angiogenesis Biomarkers”. Arthritis Rheum 2012;64 
Suppl 10 :1483 DOI: 10.1002/art.39215. 
SCIENTIFIC AND CLINICAL OUTPUTS | 
PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | XXV 
2012  I. Silva, T. Loureiro, J. Oliveira, M. Matos, C. Vasconcelos, R. Almeida. 
“Endothelium dysfunction assessment: a useful tool as an alert sign for 
microvascular complications in RP”. Rheumathlogy 2012; 51Suppl 2: 
PS102 ii60. 
2012  I. Silva, T. Loureiro, R. Almeida, C. Vasconcelos “Flow mediated dilatation 
and end diastolic flow: an useful tool for prediction of digital ulcers in 
patients with secondary Raynaud phenomenon”. International Angiology 
2012; 31-Suppl 1 to No.3p158. 
2013  I. Silva, T. Loureiro, I. Almeida, R. Almeida, C. Vasconcelos. Decreased 
flow mediated dilatation and nailfold capillaroscopic findings can be 
predictors of digital ulcers in systemic sclerosis patients. Ann Rheum Dis 
2013;72(Suppl3):499. FRI0373. 
2014  Silva I, Vasconcelos C. “Microvascular damage, endothelium dysfunction 
and angiogenesis biomarkers as predictors of digital ulcers in systemic 
sclerosis” Cardiovascular Research Supplements (2014) 103, S9–S46Doi: 
http://dx.doi.org/10.1093/cvr/cvu082.126 S34. 
 
4. PRIZES 
 
2011  Sociedade Portuguesa de Angiologia e Cirurgia Vascular – Melhor 
comunicação   “A disfunção endotelial como factor de risco de 
complicações microvasculares no fenómeno de Raynaud”. Ivone Silva, 
Tiago Loureiro, Isabel Almeida, Carlos Vasconcelos, Armando Mansilha, 
Rui Almeida. 
2011  Sociedade Portuguesa de Angiologia e Cirurgia Vascular – Melhor 
comunicação jovem  “A vasodilatação mediada pelo fluxo e a severidade 
clínica do fenómeno de Raynaud” Tiago Loureiro, Ivone Silva, Clara 
Nogueira, Carolina Vaz, Luís Loureiro, Diogo Silveira, Sérgio Teixeira, Rui 
Almeida. 
2012  II Fórum Esclerose sistémica e úlceras digitais: Vasculopatia na Esclerose 
Sistémica: Prémio melhor Poster ”Endothelium dysfunction assesment: a 
useful tool as an alert sign for microvascular complications in Raynaud 
phenomenon”. I. Silva, T. Loureiro, J. Oliveira, M. Matos, C. Vasconcelos, 
R. Almeida. 
 
| SCIENTIFIC AND CLINICAL OUTPUTS  
XXVI | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
5. GRANTS 
 
2011  Research grant from Sociedade Portuguesa de Angiologia e Cirurgia 
Vascular. 
2012  PhD research grant from da Teaching and Research Department 
(Departamento de Ensino e Investigação) of Oporto Hospital Center 
(reference 054/10 (036-DEFI/051-CES). 
 
  
 
 
CHAPTER 1  
INTRODUCTION  
  
 
INTRODUCTION | CHAPTER 1 
 PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | 1 
CHAPTER 1 | INTRODUCTION 
1.1 RATIONALE 
 
Raynaud’s phenomenon (RP) generally manifests as an exaggerated 
vasoconstriction of the cutaneous vascular system in response to cold exposure 
(1).  Primary RP (PRP) is an uncomfortable but ultimately benign condition that is 
mainly caused by an altered functional response of the cutaneous circulation (2, 
3). There is a progressive pathological remodeling within the microvasculature, 
macrovasculature, and extravascular compartments, resulting in substantial 
tissue pathology and injury (2). A disorder of the vascular thermoregulatory 
control mechanisms is believed to be the main cause of the vasospastic attacks 
(1).  Although these can be initiated by reflex activation of the sympathetic 
adrenergic vasoconstrictor system, e.g., in response to stress, they are mainly 
due to local cold exposure (1).  
RP is a common clinical manifestation with a prevalence of 3-5% in the 
general population (4).  The mean age of affected patients ranges from 47.2 
years in Europe (5) to 53.5 years in the US (6). An annual incidence of 0.25% in 
the general population was reported in France, whereas in the US (Framingham 
offspring cohort study), RP occurred in 2.2% of women and 1.5% of men over 7 
years (2). RP has a large geographic variation due to climatic variations, being 
more frequent in cold and wet climates. It’s generally agreed that hormonal 
factors can play a role in the genesis of the phenomenon, as indicated by the 
increased incidence of RP-like vasospastic reactions during the pre-ovulatory 
period and estrogen induction of endothelial dysfunction in secondary RP (SRP); 
these hormonal factors may thus account for the higher prevalence of RP in 
women (7). The role of genetic factors is still unclear, although a polygenic 
predisposition is suggested by studies of familial groups and by the different 
prevalence of RP among various ethnic groups (8).  
Secondary Raynaud phenomenon (SRP) is commonly associated with 
autoimmune conditions, such as systemic sclerosis (SSc). Cutolo et al. reported 
that 14.6% of 129 patients with PRP developed abnormal capillary patterns over a 
mean period of 29.4 months, allowing early identification of the patients most 
likely to develop a SSc­spectrum disorder (9). 
RP, in the context of SSc, frequently progresses to digital ulceration and/or 
critical digital ischemia in areas of skin with microangiopathy. Digital ulcers (DUs) 
are frequent among patients with SSc, with 15%–25% having active DU (10) and at 
least 40−50 % of all patients with SSc experiencing one or more DU at some point 
in their disease course (11). 
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 DUs are painful, slow to heal, frequently complicated by secondary 
infections, and have disabling effects on patients, particularly regarding grip, 
feeding, dressing, and hand hygiene (12). Severe DU episodes frequently need 
hospitalization and require time away from the workplace (13). Data from the 
French registry identified 44% of patients as having one or more ischemic DUs, 
resulting in hospitalization for 33% of cases; 46% required systemic antibiotics 
(13).  
The etiology of DU is multifactorial and may differ depending on DU 
localization. Fingertip DUs are attributable not only to the underlying 
vasculopathy but also the persistent vasospasm of RP (14). Instead, DUs on the 
dorsal aspect of the fingers are, in the majority of cases, due to epidermal 
thinning and cutaneous retraction, leading to cracks on the skin overlying the 
joints (15). DUs may develop on the fingers or toes and can occur over the 
extensor surface of the joint, on the finger creases, under the nails, and, in the 
majority of cases, on the fingertips. DUs may also develop from a pre-existing 
calcinosis and sometimes from digital pitting scars (15). 
Although new insights into the management of DU have emerged, it still 
remains challenging to identify patients at risk of developing DUs. Several reports 
identified vascular biomarkers and capillaroscopic indexes as predictive of new 
DUs; however, these tools are very expensive and not applicable for routine use. 
Still, these research studies are fundamental, as the molecular analysis of the 
vascular mediators associated with SSc and particularly with peripheral 
microangiopathy may identify new therapeutic targets that lead to the prevention 
of further vascular injury or the improvement of SSc disease. 
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1.2 OBJECTIVES 
 
1. To explore endothelial dysfunction in the pathogenesis of peripheral 
vasculopathy in RP patients 
a. Research question: 
i. Is endothelium-dependent flow-mediated dilatation an early 
diagnostic tool for severe peripheral vascular complications in 
patients with RP and what is its predictive value?  
2. To analyse the role of capillaroscopy abnormalities in peripheral 
vasculopathy 
a. Research question: 
i. Can a qualitative “scleroderma pattern” or semi-quantitative 
“microangiopathy evolution score” identify patients at risk for DU 
and predict new episodes? 
3. To evaluate the role of vascular biomarkers in predicting DU in SSc 
patients 
a. Research question: 
i. Can serum levels of endothelial dysfunction (ET-1 and ADMA) and 
angiogenic (VEGF, endostatin, and endoglin) biomarkers identify 
patients at risk and/or predict the occurrence of new DUs? 
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2.1 RAYNAUD PHENOMENON 
 
ABSTRACT 
Raynaud's phenomenon is a well common clinical disorder characterized by 
recurrent vasospasm episodes of digital arteries, arterioles, pre-capillary and 
post-capillary venules triggered by exposure to cold or emotional stress. RP can 
be classified as primary (idiopathic), or secondary to several diseases or 
conditions. The pathogenesis of RP is still not entirely clear or understood, but 
recent insights into the pathogenic mechanisms underlying Raynaud's 
phenomenon include vascular, neuronal and intravascular abnormalities, which 
may identify crucial key points and potential targets for therapeutic intervention.  
In this review we summarize the epidemiology, pathogenesis, clinical 
manifestations and assessments as well as the recent advances in therapeutic 
approaches. 
 An extensive review of recent literature was conducted, according to the 
guidelines proposed at the PRISMA statement. MEDLINE database (PubMed) and 
Thomson Reuters Web of Knowledge platform were searched for articles 
published in peer-reviewed journals with the last search run on February 2015 
and published in English language. The keyword search terms included: Raynaud 
phenomenon, epidemiology, pathogenesis, thermoregulation, endothelium 
dysfunction, risk factors, clinical features, nailfold videocapillaroscopy treatment. 
Inclusion criteria were: (1) Randomized controlled trials; (2) Reviews, 
systematic reviews and meta-analysis of randomized controlled trials (3) English 
language. Studies lacking clinical end points of relief, case reports and open label 
trials were excluded.  
 
Keywords 
Raynaud phenomenon / etiology / physiopathology / complications / 
diagnosis / drug therapy 
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INTRODUCTION 
Maurice Raynaud first described Raynaud’s phenomenon (RP) in 1862. By 
definition RP are bouts of reversible vasospastic ischemia of the extremities 
which most frequently involves hands and toes, less frequently nose and 
earlobes, and very rarely tongue (1, 2).  Episodic color changes of the fingers 
classically turn into white (ischemia), blue (cyanosis) and red (reperfusion), but 
the three color stages are not needed to be present RP diagnosis (3, 4). When a 
patient presents with RP, the clinician must diagnose whether RP is primary or 
secondary, due to different clinical significance, treatment and prognosis.  
Primary RP (PRP), also known as Raynaud's disease, is a functional vascular 
disorder that occurs as a sporadic exaggerated response to cold or emotional 
stress. PRP does not progress to irreversible tissue injury (5, 6) and has usually a 
benign clinical course (3).  Secondary RP (SRP), also known as Raynaud's 
Syndrome, appears in response to the same triggers, however it occurs in the 
setting of an underlying structural vascular disease and is often associated with 
digital ulcers (DU), scarring or gangrene (3).  
 
EPIDEMIOLOGY  
The real prevalence of RP varies between studies mostly due to different 
geographic conditions such as climate. PRP is a common condition, with a 
prevalence of 3-5% in the general population (2). In a systematic review and meta-
analysis based on six studies assessing the general population, the lowest 
prevalence of PRP was found in Japan, with an overall prevalence of 1,6 (2,1% in 
women vs. 1,1% in men) and the highest overall prevalence was in the USA with a 
median prevalence of 7,5% (7,8% in women vs. 5,8% in men) (7). Onset age is 
usually below 40 years and a family history of RP may be present (3).  By contrast, 
SRP is much rarer in the general population, but has a high prevalence among 
patients with connective tissue diseases such as Systemic Sclerosis (SSc) (90%), 
systemic lupus erythematous (30%), rheumatoid arthritis (20%), Sjögren’s 
syndrome and polymiositis (8, 9). SRP is an important red flag that raises 
suspicion for underlying very early SSc (10, 11).  
Recent reports alert that RP can be considered a sign or precursor of 
undiagnosed vascular disease. The presence of RP among whites was associated 
with 1,6 fold increase in the hazard cardiovascular disease (CDV)-related death 
(12). Risk factors of RP are complex and not consensual. Some studies suggested 
that smoking increased risk of RP in male, but heavy alcohol consumption and 
hormonal factors increased risk only in women (2, 13).  The contribution of 
genetic factors is not clear, however familiar aggregation and some rare 
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syndromes such as hereditary angiopathy with nephropathy, aneurysms, and 
muscle cramps HANAC syndrome suggest a polygenic etiology (2). 
 
RAYNAUD PATHOGENESIS 
Pathogenesis of RP is undoubtedly complex, once both central and ‘local’ 
mechanisms are involved. Vascular, neural and intravascular abnormalities can 
impair blood flow and/or cause endothelial injury.  The blood vessel wall 
(endothelium), the neural control of the vascular tone (deficiency of the 
vasodilator calcitonin gene-related peptide, α
2-
adrenoreceptors activation) and 
many circulating factors  (activated platelets, impaired fibrinolysis, increased 
viscosity, oxidant stress) all together play a role in the pathogenesis of RP (14). 
During body cooling or ambient temperature reduction, blood flow falls to 
markedly low levels in patients with RP and in SRP individuals it can fall to 
absolute zero (15). In response to local finger cooling patients with RP 
demonstrate increased sensitivity to cold with more severe and prolonged blood 
flow reduction. Additionally with local warming blood flow recovery was higher in 
PRP (15) probably due to structural alterations in SRP.  
 
Vascular mechanisms  
Finger blood flow compromises both nutritional blood flow and through 
arteriovenous anastomoses (AVA). In control subjects total and AVA blood flow 
are reduced in colder environments but no changes in nutritional blood flow are 
observed. In contrast, nutritional and AVA blood flow is reduced in RP subjects, 
with a more marked reduction in nutritional blood flow in SRP SSc-associated 
patients (15). 
The pallor phase of RP is due to cold induced vasoconstriction (arterial and 
venous vasospasm). Sympathetic neurotransmission can actually be more 
effective in cutaneous veins than in arteries, due to better penetration of nerve 
fibers in the low-pressure cutaneous veins. This leads to a direct release of 
norepinephrine smooth muscle cells in veins wall that have an extremely high 
activation of α
2-
adrenoreceptors  (α
2 
AR), making them highly responsible for to 
the local cold-induce amplification of sympathetic constriction (15). 
The cyanotic phase is often attributed to local hypoxia. However, it is likely 
mediated by early vasodilation of venous cutaneous system with deoxygenated 
blood flow, while AVA remain constricted (15). 
Hyperemic phase might be a consequence of delayed dilation of AVA 
allowing a large influx of fully oxygenated flow into the dilated venous system. 
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Functional abnormalities 
RP occurs when the balance of vascular tone is disturbed, favoring 
vasoconstriction. Endothelial activation and/or damage lead to underproduction 
and efficacy of vasodilators and/or overproduction of vasoconstrictors. A 
complex and still not fully understood response to whole body and local cooling 
add a challenge to the unraveling pathogenesis of RP (5). 
 
i) Vasodilatation 
Doubts persist whether there is underproduction of endothelium 
vasodilators such as nitric oxide (NO) and prostacyclin, or whether they are 
impaired in RP (5). Further complicating the role of NO, patients with SSc, have 
increased plasma levels of an endogenous inhibitor of endothelial NOS—
asymmetric dimethyl arginine— (ADMA) leading to reduced NO production (16). 
Endothelium-dependent vasodilation is preserved in PRP, while in SRP an impaired 
vasodilation occurs and worsens through disease progression. This might be due 
to endothelium dysfunction and to structural changes in blood vessels wall. 
 
ii) Vasoconstriction  
Injured endothelial cells (ECs) overproduce vasoconstrictors such as 
endothelin­1 (ET-1) and angiotensin II. Although some studies suggest a role of 
ET-1 in PRP, this evidence is much weaker than that for SRP (5). Also an imbalance 
in the renin–angiotensin system, favoring angiotensin II is thought to occur in SRP 
(5). New insights in the increased understanding of signal transduction pathways 
in vascular smooth muscle highlights the fact that ‘vascular’ and ‘neural’ 
mechanisms cannot be considered isolated (5, 17). 
 
Structural abnormalities 
Microvasculopathy with alterations in morphology and function can easily be 
detected at the nailfold bed with Nailfold Videocapillaroscopy (NVC). Structural 
morphological and functional changes of capillaries allow differentiation between 
PRP and SRP, as major structural abnormalities does not exist in PRP. 
Architectural disorganization, as a result of microvascular injury, includes 
giant capillaries, microhemorrhages, capillary loss, avascular areas and 
morphological changes with branched/ramified/bushy capillaries suggesting 
angiogenesis. Homogenous enlarged loops (diameter >50 mm) are probably the 
first sign of microvascular disease (18) and should be valorised even if only a 
single giant capillary is present. When the capillary wall ruptures, leakage of red 
blood cells is observed as microhemorrhages. With disease progression, 
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increases capillary loss avascular areas reflect areas of hypoxia, and consequently 
greater risk of microvascular complications, namely digital ulcers. The response 
to hypoxia activates angiogenesis, resulting in branched/ramified/bushy 
capillaries, mostly ineffective in tissue perfusion. 
 
Intravascular factors 
Among intravascular factors, platelet activation has received the biggest 
attention, but defective fibrinolysis, increased thrombin generation, reduced red 
blood cell deformability, white blood cell activation and increased viscosity are all 
likely to have a role (5). Some mechanisms involved in oxidative stress could be 
considered ‘intravascular’, such as hypoxic–reperfusion injury and white blood 
cell activation. Oxidative stress can also provide a link between vascular and 
intravascular abnormalities and fibrosis (5). 
Polycythemia and macrocryoglobulinemia are paradigmatic examples of how 
intravascular alteration may predispose to RP. Further factors have been studied: 
platelet activation released thromboxane A2, thromboglobulin, serotonin, 
platelet-derived microparticles, and platelet-derived growth factor; impaired 
fibrinolysis has been documented by the increased serum levels of tissue 
plasminogen activator and von Willebrand factor; oxidative stress results from 
repeated episodes of vasospasm followed by reperfusion which may contribute to 
endothelium damage through lipid peroxidation of endothelial cells membranes; 
red blood cell lipid membranes are another substrate of intravascular reactive 
oxygen species and associated to an increased peroxidation of membrane lipids; 
and leukocyte hyper-activation released substances which affect the 
microcirculation. The evidence for oxidative stress in PRP is much weaker than 
that in SRP (2, 5). 
 
Neuronal  
The autonomic nervous system regulates the vascular tone through a 
number of chemical substances (mediators), which trigger either vasodilation 
(calcitonin gene-related peptide, neurokinin A, substance P and vasoactive 
intestinal peptide) or vasoconstriction (adrenergic agonists and nerve growth 
factor) (19). 
 
i) Local mechanisms 
a) Impaired vasodilatation 
Calcitonin gene-related peptide (CGRP) is a potent vasodilator produced by 
central and peripheral neurons, which binds a heterodimer receptor composed of 
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the G protein-coupled receptor (GPCR) referred as calcitonin receptor-like 
receptor and to the receptor activity modifying protein (RAMP-1). CGRP triggers 
the intracellular synthesis of adenylate cyclase in smooth muscle cells (SMC) that 
increases cyclic adenosine monophosphate (cAMP), leading to SMC relaxation 
(19). Immunoreactivity of calcitonin gene­related peptide is reduced in the skin of 
the patient's fingers with SSc and PRP, but this effect is more pronounced in SSc. 
Other vasodilators including substance P, neurokinin A and vasoactive intestinal 
peptide have been less well studied (5). 
 
b) Vasoconstriction 
Ensuring that blood flow to individual organs matches their individual needs 
is not achieved by central command (engaged in maintaining blood pressure and 
restricting blood flow– except brain and heart) but at the local level (17). 
Skin circulation has two distinct types of sympathetic nerve fibers: (i) a 
traditional sympathetic adrenergic innervation, norepinephrine, that initiates 
cutaneous vasoconstriction by activating two distinct families of receptors on 
vascular smooth muscle cells (VSM), α
1
 and α
2
-adrenoceptors (AR) and (ii) a 
sympathetic cholinergic innervation, acetylcholine, that indices vasodilatation 
(17).  
Cold causes a remarkable functional and spatial rescue of α
2C
-AR from the 
transGolgi to the cell surface, where they can respond to stimulation (20). 
Although α
2C
-ARs are important effectors in the cutaneous vascular response to 
cooling, they do not appear to respond directly to cold and therefore should be 
considered ‘thermoeffectors’ rather than ‘thermosensors’. 
Immediately upon cooling, there is increased generation of reactive oxygen 
species (ROS) from VSM mitochondria in cutaneous arteries (20). This is the 
earliest detectable cold-induced response in cutaneous arteries, suggesting that 
the mitochondria may be the ‘thermosensors’ responsible for initiating cold-
induced vasoconstriction in cutaneous blood vessels. These mitochondrial ROS do 
not appear to be pathogenic, but, as an alternative, activating novel REDOX 
signaling through the RhoA/Rho kinase (ROCK) pathway (21) that promotes cold-
induced translocation of α
2C
-AR to the cell surface. The most important 
byproducts of local cellular metabolism such as decreased O
2
, increased CO
2
 and 
metabolites such as adenosine can also suppress the activity of sympathetic 
nerves by inhibiting the release of norepinephrine and counter central command 
to decrease blood flow – functional sympatholysis (17). Under normal 
physiological conditions, this ongoing conflict between central command and 
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local organ requirements creates a highly efficient and effective control system 
(17). 
 
ii) Central mechanisms 
Despite the fact that many patients describe having RP in response to stress, 
the possible role of central nervous system is not well studied (5). 
 
CLINICAL INVESTIGATION 
 
Clinical assessment 
Diagnosis of RP is based on the history of episodic bi- or triphasic color 
change of fingers or toes - pallor (ischemia), cyanosis (anoxia) and rubor (reactive 
hyperemia). Accompanying symptoms may be numbness and pain.  
In a Delphi exercise round, 12 invited experts agreed recently in three-step 
outline for a newly proposed diagnostic method. Consensus achieved that at least 
biphasic color changes are required to make the diagnosis of RP. They also 
agreed that white/pallor and blue/cyanosis were the two most important colors 
to make a diagnosis and patients must report cold temperatures as one of the 
triggers for their RP attacks. Besides cold, other triggers (e.g. emotional stress) 
were deemed helpful but not required to make a diagnosis of RP. In addition, 
standardized questionnaires, photographs of episodes provided by patients, 
history of attacks at other sites other than the hands, numbness and paresthesia 
were thought to be helpful but not required to make a diagnosis of RP. Color 
charts, family history and a history of drug-induced or smoking induced attacks 
were not useful. The minimal number of attacks, duration time, a well 
demarcated color change and the requirement for a physician assessment did not 
meet agreement standards (6). 
Clinical history and physical examination are very important in RP patient’s 
evaluation. Investigation must include the RP onset, frequency, severity and 
duration of attacks.  
Physical examination should evaluate peripheral pulses (exclude peripheral 
vascular disease), blood pressure in both arms (unequal blood pressure suggests 
proximal vascular stenosis/occlusion), seek for palpable cervical rib, associated 
signs of alopecia, altered skin texture, calcinosis or telangiectasia and trophic 
skin changes on tips of fingers and toes. 
Recent advances in the diagnosis of RP have recognized that abnormalities 
in nailfold capillary pattern and specific autoantibodies are independent risk 
factors for CTD (5). One study reported that in 586 RP patients followed for 3,197 
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patients years, 1.8% with a normal capillary pattern and negative ANA, 25.8% with 
an abnormal capillary pattern, 5.4% with a specific autoantibody and in 79.5% of 
those with both an abnormal capillary pattern and an SSc­specific autoantibody 
developed SSc (5). 
PRP onset is more common in the second or third decade, but it can present 
at any age. The classical criteria proposed by LeRoy and Medsger (22) were: (i) 
episodic attacks of acral pallor or cyanosis, usually  symmetrical (usually affects 
both hands); (ii) strong symmetric peripheral pulses are present; (iii) no digital 
pitting scars, tissue necrosis, ulceration or gangrene is found; (iv) normal 
nailfold, erythrocyte sedimentation rate (ESR) and negative antinuclear antibody 
tests. Mean age of onset is 14 years and up to 27% have RP onset after the forties 
(23). 
Regarding-PRP, round 2 of the Delphi exercise with expert´s panel, 
concluded that an age of onset less than or equal to 25 was helpful but not 
required to make a diagnosis. There was also strong agreement that normal 
capillaroscopy findings should be incorporated into the diagnostic requirements. 
This introduces some challenges, as there is a wide range of nailfold patterns 
seen in healthy individuals (31). Thus, for the purposes of being precise, “normal” 
is tentatively defined as patterns that fit within clusters 1 and 2, which were 
described as “normal” and “perfect normal” by Ingegnoli et al (31). These two 
clusters account for 93% of healthy individuals. 
Unlike previous RP criteria, the panel agreed that a normal ESR and a normal 
ANA were not required for a diagnosis of primary RP. The panel felt that these 
tests have too low specificities to be reliable as specific criteria and those 
patients with low but nevertheless abnormal values are too common. Thus, in 
comparison to previously published reports, the requirement for a negative ESR 
was entirely eliminated and the panel eased the requirement for a negative ANA 
to negative or low titer ANA (e.g. 1:40 by indirect immunofluorescence)(6). In 
summary requests for definition of PRP are meeting 3 step criteria for diagnosis 
of RP: (i) normal capillaroscopy (e.g. clusters 1 and 2, which were described as 
“normal” and “perfect normal” by Ingegnoli et al (24)); (ii) negative physical 
examination for findings suggestive of secondary causes (e.g. ulcerations, tissue 
necrosis or gangrene, sclerodactily, calcinosis, or skin fibrosis); (iii) no history of 
connective tissue disease and (iv) negative or low titer ANA (e.g. 1:40 by indirect 
immunofluorescence) (6, 24). 
In secondary RP there is an underlying disease. Table 2.1.1. 
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Connective tissue diseases: 
• Systemic sclerosis (SSc) and SSc spectrum     
   disorders 
• Inflammatory muscle disease 
• Systemic lupus erythematous 
• Sjögren's syndrome 
• Vasculitis 
Presence of clinical features of CTD  
First symptom of disease in many patients 
 
Hand-arm-vibration syndrome (“vibration white 
finger”) 
Mimics Raynaud when presents with pain, cold bluish 
or pale extremity 
 
Cervical rib/thoracic outlet syndrome Unilateral with paraesthesia’s pain and discoloration 
of the fingers 
Other causes of large vessel disease:  
• Atherosclerosis 
• Thromboangiitis obliterans (Buerger's disease) 
Extremity pain and ischemia 
 
“Intravascular” disease:  
• Paraproteinemia 
• Cryoglobulinemia 
• Cryofibrinogenemia 
Physical obstruction of the microcirculation or 
immunologically 
• Malignancy Occlusion of the microcirculation through malignant 
cells. 
Paraneoplasic effect.  
Production of cryoproteins and Antiphospholipid 
antibodies 
Certain drugs or chemicals:  
• Beta blockers 
• Clonidine 
• Ergotamine 
• Vinyl chloride 
Mimics Raynaud by peripheral vasoconstriction 
Other causes/associations, including: 
• Hypothyroidism As result of impaired thermoregulation, it is a 
potential cause of a exacerbating factor for RP 
• Carpal tunnel syndrome Painful dysthesia of the extremities. 
There is limited evidence base associating this two 
idiopathic conditions, but it has been reported to be 
as high as 60%  
Carpal tunnel syndrome is a well recognised 
complication of SSc (compression of median nerve 
during oedematous phase)  
• Frostbite Increased risk of frostbite in Raynaud’s. 
• Chillbains Discrete acral lesions rather than digit discoloration  
• Acrocyanosis  Non-paroxysmal 
 Painless.  
Symmetrical discolorations 
• Livedo reticularis Resolves with warming 
• Erythromelalgia Pain and burning attacks after exposure to mild 
warmth.  
Alleviated by cooling. 
Table 2.1.1: Main causes of secondary Raynaud phenomenon 
 
The onset age is later, usually after the thirties, episodes are painful, 
intense and asymmetrical, ischemic skin lesions are frequently present, clinical 
features suggestive of a connective-tissue disease are common (e.g. arthritis, 
sicca symptoms, sclerodactylia, calcinosis, puffy fingers, telangiectasia), nailfold 
capillaroscopy shows evidence of microvascular disease and autoreactive 
antibodies are present.  
Due to time constraints imposed on the Delphi exercise, the expert’s did 
not attempt consensus criteria for secondary RP. However, the panel was 
undoubtedly in agreement that physical exam findings such as sclerodactily, 
calcinosis, fibrosis, ulcerations and an abnormal capillaroscopy examination 
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could be used to make a diagnosis of secondary RP in patients who meet the 
diagnostic criteria for RP. Autoreactive antibodies (specifically ANA, anti-
centromere, and anti-RNA polymerase) were ranked as helpful and in some cases 
diagnostic for secondary RP (6). However, agreement could not be established for 
the usefulness of anti-SCL 70 antibodies. Although this is an excellent start, 
future exercises will be required to develop diagnostic criteria for SRP. 
Systemic sclerosis as one of the main underlying secondary cause of RP has 
recently been discussed and new criteria have been reviewed. It was determined 
that skin thickening of the fingers extending proximal to the 
metacarpophalangeal joints is sufficient for the patient to be classified as having 
SSc; if that is not present, 7 additive items apply, with varying weights for each: 
(i) skin thickening of the fingers, (ii) fingertip lesions, (iii) telangiectasia, (iv) 
abnormal nailfold capillaries, (v) interstitial lung disease or pulmonary arterial 
hypertension, (vi) RP, (vii) SSc-related autoantibodies. Sensitivity and specificity in 
the validation sample were, respectively, 0.91 and 0.92 for the new classification 
criteria and 0.75 and 0.72 for the 1980 ACR classification criteria. All selected 
cases were classified in accordance with consensus- based expert opinion (25). 
These criteria will help to identify earlier patients with RP to be classified correctly 
as having the disease. 
 
Assessment Methods for Raynaud Phenomenon 
i) Capillaroscopy 
Microvasculopathy with alterations in morphology and function can easily be 
detected at the nailfold bed with NVC. Capillaroscopy is a valuable, accessible, 
non-invasive, easy, safe and cheap tool with important diagnostic and prognostic 
value in patients with RP. Structural morphological and functional changes in 
capillaries allow differentiation between PRP and SRP, as structural abnormalities 
do not occur in primary Raynaud phenomenon. 
Recently, three major “normal” morphologic capillaroscopic patterns were 
proposed by Ingegnoli et al: (i) “normal” pattern mainly with 2 to 5 U-shaped 
loops/mm and ≤2 tortuous loops/mm; (ii) “perfect "normal” pattern with ≥ 5U – 
shaped loops/mm and (iii) “unusual normal” with at least 1 meandering or bushy 
loop, or 1 microhemorrhages or with >4 crossed loops/mm (24). 
Previous description of PRP NVC was 1 capillary within each single dermal 
papilla; morphological homogeneity of diameter and regular distribution of 
capillaries, hairpin or “U – shape” shaped capillaries, major axis of capillaries 
perpendicular to the distal row, ratio efferent: afferent limb<2:1, good level of 
skin transparency and no morphological abnormalities (18). 
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“Scleroderma pattern” is characterised by architectural capillary 
derangement, giant loops, enlarged loops, haemorrhage, angiogenesis and 
avascular areas. Nailfold capillaroscopy is the best technique for examining 
disease progression over time and the responsiveness to vasoactive treatment. 
Cutolo et al described an useful and reproducible qualitative NVC “Scleroderma 
patterns” with 3 different evolutive patterns: early, active and late (18). Several 
studies have been done in an attempt to identify NVC changes and its correlation 
to organ disease, in order to identify a possible predictive role of NVC in CTD. 
Main differences in NVC between PRP and SRP are summarized in Table 2.1.2. 
 
 
Frequency of capillaroscopy examination in patients with RP in not 
consensual. If capillaroscopy has a “normal” pattern and patients have negative 
autoreactive antibodies the probability of developing SSc is 1.8% in long-term 
follow-up (26). In our clinical practice we repeat capillaroscopy and antibodies 
within 2 years and if normal characteristics persist we refer the patient to general 
practitioner. If either capillaroscopy or antibodies have abnormalities, follow-up 
every 6 months is recommended, due to 16% of patients might transit to a SRP 
within 5-year follow-up (27). 
 
NVC Pattern  Primary Raynaud Phenomenon Secondary Raynaud Phenomenon 
Morphological 
features 
 
-Regular capillaries 
-Uniform distribution, shape and diameter 
-Hair pin or U-shape capillaries 
-Architectural derangement is the 
morphological feature in SSc 
Enlarged loops -Absent 
 -Potential marker of microangiopathy 
-Scleroderma spectrum: Giant capillary 
- Valorise even single enlarged loop 
Haemorrhages 
- Microhemorrhages (punctate   
haemorrhage) may be present 
 - present after traumatic injury or 
onychophagia  
-Earliest finding of Scleroderma spectrum 
- Microhemorrhages;  
 
Angiogenesis -Absent 
-Capillary neoformation: highly convoluted 
and branched capillary loop clusters  
-Meandering, ramified/bushy, bizarre 
capillaries 
Capillary Density  -Normal 
- Avascular areas  
- Desert-like appearance of nail fold 
- Less than 30 capillary per 5mm 
-Poor prognosis 
Table 2.1.2: Main capillaroscopic findings in primary and secondary Raynaud phenomenon. NVC: 
nailfold videocapillaroscopy 
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ii) Non-invasive methods 
Non-invasive methods can help to differentiate between PRP and SRP, by 
assessing digital vascular structure and function objectively.   
A lack of consensus on the utility of these methods still persists. We 
summarize the most useful clinical and research methods for micro-, 
macrovascular and function assessment in RP patients (Table 2.1.3). A number of 
new technologies are emerging and in the near future structural and dynamic 
evaluation of microvasculature might bring new insights to RP diagnosis.  
 
 
iii) Other methods 
Unilateral RP suggests large vessel disease such as thoracic outlet 
syndrome, atherosclerosis and trauma. When macrovascular disease is suspected 
in RP patients, it might be necessary further investigation with invasive methods 
such as digital subtraction angiography (DSA). Alternative methods may be 
magnetic resonance angiogram (MRA) or computed tomography angiogram 
(CTA). DSA has the advantage that, if indicated, endovascular intervention may be 
simultaneously performed.  
Most of these techniques have been widely adopted in clinical practice and, 
at present, all of them remain primarily as research tools. There is considerable 
interest in application of these noninvasive techniques in the research setting, 
TECNIQUE OBJECTIVE CLINICAL OUTPUT 
Cold stress test  
(CST) 
Assess sympathetic vasoconstriction  
to cold exposure 
Microvascular 
Reactivity to cold exposure 
Infrared thermography 
Measures skin temperature  
as an indirect measure of skin 
perfusion 
(can include CST) 
Microvascular  
Differentiation PRP/SRP 
Response to treatment 
Laser Doppler flowmetry Measures skin perfusion 
Microvascular 
Differentiation PRP/SRP 
Disease progression 
Response to treatment 
Arterial Doppler ultrasound 
Ankle Braquial Pressure Index 
Measures vessel flow and size 
Macrovascular 
Differentiation PRP/SRP 
Flow-mediated dilatation 
Measures endothelial-dependent 
dilatation in response to increased 
shear stress 
Macrovascular 
Differentiation PRP/SRP 
Disease progression 
Finger systolic pressure 
measurement 
Measures finger systolic pressure as  
a response to temperatures variations 
Macrovascular 
Differentiation PRP/SRP 
Plethysmographgy 
Relationship between arterial flow  
and microvascular perfusion 
Measures changes in venous blood 
flow /volume 
Macrovascular 
Differentiation PRP/SRP 
Table 2.1.3: Main investigations methods used in clinical and research approaches of Raynaud 
phenomenon patients. 
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alone or in combination, with the aim of improving diagnostic accuracy, 
measuring disease progression and treatment response (5). 
 
MANAGEMENT 
It is consensual that for PRP, conservative measures as warming, 
biofeedback, hand exercises, relaxation therapy, smoking cessation and avoiding 
triggers, as cold and stress are beneficial and sufficient most of the times to 
control the disease. Primrose oil has in our experience demonstrated good 
results in controlling number and duration of attacks. Nevertheless, given the 
adverse effects of smoking on vasculature and the exacerbation of symptoms in 
the cold, the non-pharmacologic lifestyle modifications should also be 
encouraged on all RP patients. However, SRP usually implies pharmacologic 
therapies.  
After years of study, there is a lot of conflicting data and limited evidence 
for the effects of each drug. The absence of significant values are due to high 
placebo response, no standardization of outcome measures in RCT, lack of 
reliable biomarkers or surrogate end points, and the fact that the symptoms and 
course of this disease are highly influenced by context factors such as seasonal 
variations and personal lifestyle (28). 
Calcium channel blockers (CCB) are widely used as first-line therapy, but 
adverse effects are not uncommon. We recommended starting with low and long 
acting doses. The most well studied CCB nifedipine has showed effects in 
reducing attack frequency and severity. When ineffective or not tolerated, 
Angiotensin II Receptor Blockers (ARB) and alpha blockers may be an alternative, 
as they also have demonstrated some good results in reducing Raynaud’s 
frequency and severity. Phosphodiesterase (PDE) inhibitors are a recent addition 
to Raynaud’s treatment, since they were proven to be safe and have shown some 
benefit. However, longer studies are required to lead to more consistent results. 
The new formulation of topical nitroglycerin can be useful, once it adds the 
nitrate vasodilatory effect with tolerable side effects. Selective Serotonin Re-
uptake Inhibitors (SSRI) may have advantage when vasodilatory symptoms are not 
tolerated with the drugs mentioned above. Botulinium toxin, in all case series and 
case reports has showed overall improvement in patients’ pain as well as a 
reduction in soft tissue ulceration, but its still lacking a randomized, placebo-
controlled study. Evidence proved no effect for Angiotensin-Converting Enzyme 
(ACE) inhibitors neither for ginkgo biloba.  
For severe Raynaud and active DU, IV prostanoids, in particular iloprost 
should be used first, as recommended by the EULAR agreement, in spite of a high 
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rate of adverse effects and no consensus between European and North American 
rheumatologists (29). Recently the use of continuous 5-day perfusion of iloprost 
through an elastomeric pump, the overall adverse events have been overcome 
and is now a more accessible, and tolerated useful treatment. Additionally this 
new approach can be done in ambulatory basis reducing hospitalization and 
costs. For DU prevention, the new endothelin-1 receptor antagonist, bosentan, 
has demonstrated to reduce the number of new digital ulcers in patients with SSc. 
If on-going disease, consider thoracic or digital sympathectomy, surgical and 
invasive treatments, but with potential to reduce recurrence of DU. 
We show in Table 2.1.4 the conclusions of the latest studies published in 
the last 5 years. We found no reliable studies for antiplatelet therapy, 
mesoglycan, pentoxyfiline, Rho kinase inhibitor (fasudil), alpha-2C 
adrenoreceptors blockers or N-acetylcisteine. 
 
Authors Study Design Year Conclusions Ref 
Calcium channel blockers (Nifedipine, Nicardipine, Diltiazem) 
Act on vascular smooth muscle to cause arteriolar vasodilation and an increase in peripheral blood flow 
McMahan et al  Review 2010 Better results on PRP than SRP due to untolerated high doses of 
nifedipine needed in SRP. 
Long acting formulations are useful to minimize side effects 
and increase tolerability.  
Also effective in the treatment of DU. 
(30) 
Levien  Review 2010 Reduces the frequency and severity of attacks in both PRP and 
SRP. 
Remains the most widely used class of drugs in management 
of RP 
(31) 
Pope et al  Systematic 
review of PRP 
2011 Nifedipine reduces the frequency and severity of Raynaud’s 
attacks, but it is associated with adverse effects, such as 
tachycardia, headache and flushing. 
Nicardipine may also be used.  
No evidence for amlodipine or diltiazem. 
(32) 
Sinnathurai et al  Review of RP in 
SSc 
2013 No sufficient data found to support the reduction of digital 
ulcers. 
Diltiazem only in PRP. 
(33) 
Seehusen et al  Evidence-based 
research 
2014 
(34) 
Ennis et al Cochrane review 2014 
Both reviewed 7 RCTs, with a total of 296 participants, 
analysing nifedipine and nicardipine in PRP.  
Both concluded that they are modestly effective in reducing the 
frequency of attacks and no clear evidence of reducing severity 
of RP attacks.  
(35) 
Alfa-adrenergic blockers (Prazosin) 
Alfa-2 receptors are present throughout much of the vascular system and play a significant role in cutaneous 
thermoregulation. 
Pope et al Systematic 
review of PRP 
2011 
Might successfully treat PRP but there were no large enough 
studies to enable conclusions. 
(32) 
Huisstede et al   Meta-analysis of 
SRP 
2011 Conflicting evidence for the effectiveness in the treatment of 
SRP 
Poor improvement percentage in the high quality RCT, with 1 
of 5 patients improving in the experimental treatment and 0 of 
5 in the placebo group. 
(8) 
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Sinnathurai et al  Review of RP in 
SSc 
2013 Prazosin was moderately effective in treating SSc SRP 
Significant decrease in frequency of attacks, but a small 
number of patients was studied (n=40). 
(33) 
Angiotensin II receptor antagonists (Losartan) 
Arterial vasodilators 
Herrick  
 
Review 
 
2011 
 
(36) 
Huisstede et al  Meta-analysis of 
SRP 
2011 
Widely used when CCB are ineffective or not tolerated 
Reduces frequency and severity of Raynaud’s attacks in both 
PRP and SRP, with no difference compared to nifedipine (8) 
Selective Serotonin Re-uptake Inhibitors (Fluoxetine and Ketanserin) 
Increases regional blood flow by blocking the uptake of the vasoconstrictor serotonin. May have an anti-fibrotic 
effect 
Stewart Systematic 
review of oral 
vasodilators for 
PRP 
2012 Systematic review of Ketanserin for PRP found significant 
reduction for the severity score.  
No statistically difference on the frequency or duration of 
attacks. 
(37) 
Sinnathurai et al  Review of RP in 
SSc 
2013 Statistically significant decrease in severity of RP with 
fluoxetine when compared to nifedipine. 
(33) 
Prostaglandins (Iloprost, Cisaprost and Alprostadil) 
Act as a potent vasodilator and may also inhibit platelet aggregation and influence vascular remodelling 
Sinnathurai et al  Review of RP in 
SSc 
2013 Endovenous iloprost reduces frequency and severity of attacks 
and development of DU.  
Rate of side effects may be as high as 92%, consisting in 
headache, flushing and nausea, but all reversible and 
controlled by the rate of infusion.  
(33) 
Huisstede et al  Meta-analysis of 
SRP 
2011 Evidence for the effectiveness of oral and IV iloprost.  
Limited evidence was found for the infusion protocol of IV 
iloprost 10 times in 2 weeks instead of 20 times in 6 months.  
No evidence for the effectiveness of cisaprost.  
No evidence in favour of high doses of IV iloprost instead of 
regular doses in RP frequency and duration. 
No evidence for the effectiveness of IV alprostadil. 
(8) 
Levien  Review 2010 Conflicting data with oral iloprost.  
Daily infusion of alprostadil was no more effective than 
placebo. 
(31) 
McMahan et al  Review 2010 Cyclic iloprost can be used for severe Raynaud’s and DU, with 
some benefit in digital ischemia prevention. 
(30) 
Oral endothelin receptor antagonist (Bosentan) 
Levels of endothelin are increased in the serum of patients with RP and SSc, acting as vasoconstrictor and 
contributing to the fibrotic and vasculopathic aspects of SSc 
Nguyen et al RCT:   
17 patients,  
24 weeks Follow-
Up 
201 Bosentan did not improve frequency, duration, pain or severity 
of RP attacks.  
Had a significant decrease in functional scores. 
Bosentan is not effective in SSc-related RP without pre-existing 
DU 
(38) 
Arefiev et al  Review  2011 Effective in prevention of new DU. (39) 
Levien  
 
Review 
 
2010 
 
(31) 
McMahan et al  Review 2010 
Mention to 2 RCTs which documented significant reduction in 
the development of new ulcers but no difference in the healing 
of existing ulcers (30) 
Matucci-Cerinic 
et al  
RCT: 188 
patients with SSc 
and DU, 24 
weeks Follow-Up 
2011 
Bosentan is useful in prevention of new DU in patients with SSc. 
No healing improvement.  
(7) 
Phosphodiesterase type 5 inhibitors (Sildenafil, Taladafil and Vardenafil) 
Works by elevating levels of cGMP, causing intracellular calcium levels to fall, leading to vascular smooth muscle 
relaxation 
McMahan et al  Review 2010 A RCT associated sildenafil with decrease of frequency and 
duration of Raynaud’s and decreased RCS. 
(30) 
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Levien  Review 2010 Conflicting data with sildenafil and taladafil, with both drugs 
having a RCT each that found reduction of frequency and 
duration of Raynaud’s attacks and another RCT that described 
no benefit at all. 
(31) 
Herrick et al   RCT: 57 patients 
with SRP,  
6 months Follow-
Up 
2011 Tested modified-release sildenafil with significant reduction in 
attack frequency of RP.  
The decrease in Raynaud's Condition Score (RCS) duration of 
attacks and RP pain was not significantly different from placebo 
group. 
(40) 
Caglayan et al RCT: 53 patients 
(6 primary, 47 
secondary),  
6 weeks Follow-
Up 
2012 Significant reduction in RCS and a decrease in number and 
cumulative duration of Raynaud attacks per day in patients on 
vardenafil compared to placebo. 
Better results in PRP and SRP patients with limited cutaneous 
systemic scleroderma. 
(41) 
McMahan et al  
 
Review 
 
2010 
 
(30) 
Sinnathurai et al 
 
Review of RP in 
SSc 
2013 
Both review 2 RCTs about oral taladafil: First RCT found no 
significant results, but with a large confounding placebo 
response; Second RCT(42) found it useful as add-on therapy for 
SRP resistant to vasodilators, with significant improvement in 
attacks frequency and duration and in healing and prevention 
of DU. 
(33) 
Nitrates (MQX-503: New formulation of topical nitroglycerin) 
Vasodilating properties 
Levien  Review 2010 Improvement in blood flow RCS and severity of attacks 
No changes in the frequency or duration of attacks.  
(31) 
Sinnathurai et al  Review of RP in 
SSc 
2013 
 
(33) 
McMahan et al  Review 2010 
Both reviewed a RCT that showed efficacy in terms of RCS. 
Better with RPR than in SRP.  
No changes in the attacks frequency or duration.  (30) 
Angiotensin converting enzyme inhibitors (Captopril, Enalapril and Quinapril) 
Vasodilating properties 
McMahan et al  Review 2010 No benefit in treatment of SRP or digital ulcers as a first-line or 
monotherapy, as the larger study, with 2-3 years follow up, was 
unable to show any benefit. 
(30) 
Huisstede et al  Meta-analysis of 
SRP 
2011 No evidence for the effectiveness of the use of quinapril on 
SRP. 
(8) 
Stewart Systematic 
review of oral 
vasodilators for 
PRP 
2012 Captopril and enalapril, and enalapril alone are associated with 
small increase in the frequency of attacks per week compared 
with placebo on PRP.  
For captopril alone, the difference between the treatment 
groups for frequency and duration of attacks was non-
significant. 
(37) 
Sinnathurai et al  Review of RP in 
SSc 
2013 
Limited evidence for the efficacy of these agents (33) 
Botulinium Toxin 
Efficacy is theoretically attributed to two potential mechanisms: modulation of abnormal adrenergic innervation 
and reduction of pain through antinociceptive pathways. 
Levien  Review 2010 Decreased pain and numbness. 
Decreased frequency of vasospastic attacks, healing of digital 
ulcers. 
(31) 
Mannava et al  Review 2011 Decreasing pain and improving hand function.  (43) 
Iorio et al  
 
Review 
 
2011 
 
(45) 
Neumeister et al   Review 2014 
Both analysed 5 studies, including Neumeister, 2010 (44). All 
showed overall improvement in patient pain as well as a 
reduction in soft tissue ulceration.  (46) 
Digital Sympathectomy 
Adrenergic effect only at the site of adventitial stripping with limited decrease of vasoconstriction distally and no 
decrease in vasoconstriction of the proximal vasculature 
Merrit  Review 2015 Reduce the frequency and severity of ischemic Raynaud attacks (47) 
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and decrease recurrence of ischemic ulcerations. 
Anti-oxidants 
Improves microcirculatory network, possibly modulating the structural microvascular modifications 
Bruni et al RCT: 30 patients  
6 months Follow-
Up 
2014 Compared treatment with nifedipine alone and nifedipine plus 
antioxidant complex in Primary RP.  
Significant improvement on RCS. 
(48) 
Ginkgo Biloba 
Improves peripheral blood circulation through decreased aggregation and enhanced deformability of 
erythrocytes, exhibits vasoregulatory activity via regulation of the balance between prostacyclin and 
thromboxane and protects against endothelial dysfunction through modulation of nitric oxide generation 
Bredie et al  RCT: 41 patients 
10 weeks Follow-
Up  
2012 An excellent safety profile but no significant effect in 
frequency, duration or severity of the RP attacks (49) 
Statins (Atorvastatin) 
Endothelial protective action 
Levien  
 
Review 
 
2010 
 
(31) 
Sinnathurai et al  Review of RP in 
SSc 
2013 
Both referred a RCT with significant reduction of DU and a 
significant improvement on SHAQ-DI (Scleroderma Health 
Assessment Questionnaire) and on Visual Analogue Scale for 
RP and DU severity and pain scales. 
(33) 
McMahan et al  Review 2010 Evidence of significantly decrease in the number of DU. (30) 
Huisstede et al  Meta-analysis of 
SRP 
2011 Limited evidence for the effectiveness of the use of 
atorvastatin. 
(8) 
Table 2.1.4: Literature review on Raynaud’s management PRP, Primary Raynaud's Phenomenon; SRP, 
Secondary Raynaud's Phenomenon; DU, Digital Ulcers; SSc, Systemic Sclerosis; RCT, Randomized 
Controlled Trial; CCB, Calcium Channel Blockers; RCS, Raynaud's Condition Score 
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2.2 MECHANISMS UNDERLYING PERIPHERAL VASCULOPATHY 
 
2.2.1. ENDOTHELIUM DYSFUNCTION 
 
Vascular endothelium is a highly specialized, complex and metabolically 
active organ that performs a number of essential biological functions. It provides 
a compatible interface to facilitate blood circulation, inhibits excessive platelet 
aggregation and leucocyte adhesion, produces a balance of vasoconstrictive and 
vasodilatory molecules that coordinate vascular tone and serve to inhibit 
extracellular matrix (ECM) deposition and prevents smooth muscle cell 
proliferation (1). 
The prominent endocrine functions of the endothelium work to regulate 
vascular tone, through the production of vasoconstrictive and vasodilatory 
molecules, to maintain blood fluidity, to regulate platelet function and to control 
inflammation (1). Healthy functioning of the endothelium is critical for 
remodeling of blood vessels, through angiogenesis and vasculogenesis, during 
times of tissue growth and repair (1).  
Nitric oxide (NO), prostanoids including prostacyclin (PGI
2
) and 
prostaglandin E
2
 (PGE
2
), and endothelium derived hyperpolarizing factor (EDHF) 
possess potent vasodilatory actions. Bradykinin, norepinephrine and serotonin 
are neurohumoral mediators that cause release of endothelium-derived relaxing 
factors, further contribute to the effect of vasodilation (2). Potent 
vasoconstrictors include endothelin, angiotensin-converting enzymes (ACE) which 
convert angiotensin I to angiotensin II, thromboxane A
2
 and F
2a
, endothelial 
derived constricting factors (EDCF) that are derived from cyclooxygenase, 
leukotriene’s and free radicals. The endothelium responds to a wide range of 
physicochemical signals such as shear stress, wall stretching and hypoxia 
resulting in production and release of these vasoactive factors (3). 
The term “endothelial dysfunction” has evolved over the years in the scientific 
literature. Endothelial dysfunction can be used to describe any pathological 
condition involving imbalance between relaxing and contracting vascular factors, 
pro-coagulant and anti-coagulant substances and between pro-inflammatory and 
anti-inflammatory mediators. Endothelial activation represents a spectrum of 
responses under both physiologic and pathophysiologic conditions (4). 
Endothelial dysfunction is likely to result from endothelial cell injury 
triggered via a number of different mechanisms, including bacterial or viral 
infection, oxidative stress through abnormal regulation of reactive oxygen 
species, hypoxia, turbulent blood flow and shear stress, environmental irritants 
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such as tobacco and hyperlipidemia (1). These factors all lead to the generation 
of an inflammatory process and endothelial cell activation. However, if the 
stressors are too severe or excessive, endothelial activation can lead to a 
maladaptive and dysfunctional response with consequent permanent endothelial 
damage, leading to morbidity or mortality (5). 
Endothelial dysfunction and free-radical damage are primary events 
throughout the course of the SSc disease, which result in vascular obliteration 
and diminished blood flow to the organs involved (6) and are prominent features 
of RP and DU. There are several serological biomarkers that reflect the 
vasculopathy of the disease, such as vasoconstrictor ET-1 (7), cell adhesion 
molecules (including selectin, anti-endothelial antibodies, and the controversial 
vasodilator nitric oxide (NO) (7) and the inhibitor of endothelial NO synthase  
(eNOS) ADMA. 
The most prominent clinical manifestations of endothelial dysfunction are 
linked to deregulation of vascular tone leading to vascular spasm and reduced 
blood flow. Most of accumulated evidence suggests an imbalance between the 
levels of vasoconstrictor and vasodilator mediators. Moreover, there are defects 
in the mechanism of nitric oxide production by endothelial nitric oxide 
synthetase, an effect that impairs vSMCs survival and promotes apoptosis. 
Additionally, the potent vasodilator endothelin-1 (ET-1) is upregulated in SSc 
serum and tissues. The imbalance between vasodilator and vasoconstrictor 
signals leaves ECs vulnerable to apoptotic signals and promotes an environment 
of ischemia, hypoxia, and profibrosis through the release of cytokines and 
profibrotic growth factors, including TGF-β and ET-1(8). This complex array of 
molecular interactions involves a number of cell types including the endothelial 
cells and their attendant perivascular supporting cells (pericytes and vascular 
smooth muscle cells [vSMCs]), as well inflammatory cells, all profoundly 
influenced by the presence of growth factors, cytokines, chemokines and potent 
vasoactive factors. Together, this diverse range of factors is believed to initiate 
and drive the vascular pathogenesis that leads to severe vessel disease and 
occlusion (1). 
The endothelial response to injury can be divided into two ‘levels’ of 
response: an initial rapid response and a slower phenotypic response. The initial 
rapid response involves, among other factors, changes in levels of nitric oxide, 
prostaglandins, ET-1, von Willebrand factor and tissue plasminogen activator. The 
slower response depends on fundamental changes in cell surface characteristics, 
and alterations in the underlying basement membrane and the vascular smooth 
muscle cells (vSMCs) that surround the endothelium. These changes are brought 
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about by molecules that are particularly potent growth factors involved in the 
deposition of ECM, and activation and proliferation of the vSMCs, pericytes and 
other mesenchymal cell types associated with the blood vessel wall (1). This 
ultimately results in vessel remodeling, with profound changes in cellular 
architecture. 
In most of research the term “endothelial dysfunction” has been used 
specifically to refer to an impairment of endothelium-dependent vasodilation. 
This is also the definition of endothelial dysfunction adopted in this thesis.  
As a response to increase in shear stress, several vasodilators are released 
such as NO, prostaglandins and endothelium-derived hyperpolarizing factor (9). 
This response is commonly known as flow-mediated dilatation (FMD), and has 
been largely used for endothelium-dependent dysfunction assessment. NO is 
probably the major mediator of vasodilation and reduced NO bioavailability has 
been broadly accepted as a marker of endothelium dysfunction (10).  
Controversial results have been published regarding endothelial dysfunction 
assessment in SSc patients. In respect to FMD, there are studies favouring 
reduction of FMD in SSc compared to control groups (11-15) no reduction of FMD 
(16) and similar FMD (17, 18). These studies were not designed to analyse 
relationship of FMD and DU. A systematic review and meta-analysis (19) analyzed 
FMD assessment in SSc patients demonstrating that most of the studies (71%) 
assessing the FMD% found significantly lower brachial artery FMD% in SSc patients 
compared to controls. A low brachial artery FMD%, in particular, is an 
independent predictor of cardiovascular risk (19).  
Calcification and fibrosis reduce vascular compliance and subsequently 
affect NO signaling by limiting vascular stretch (14), indicating that 
macrovascular disease and probably arterial stiffness are also important factors 
determining FMD induced by reactive hyperemia. Given that vascular changes 
leading to digital ulcers are histopathologically characterized by intimal fibrosis, 
the decrease in vascular compliance may also contribute to the reduction of FMD 
values by reducing NOS activity in SSc. Collectively, the decrease in endothelial 
NO production is a characteristic feature of SSc vasculopathy, which largely 
explains the reduced FMD values in SSc patients (14).  
 
2.2.2. MICROVASCULAR DAMAGE 
 
Microcirculation is a fundamental anatomical component of circulation made 
up of a network of small arterioles, metarterioles, capillaries and venules. From 
the structural point of view, capillaries are considered as unitary structures 
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consisting of an endothelial layer, a basement membrane and numerous 
branching contractile cells on external wall (Rouger’s cells) (20). Microcirculation 
has two main tasks: carrying the blood to tissues and controlling its flow to 
capillaries. The vascular system supplying the skin has a regional heterogeneity 
vascular density, microvascular structure and organization of arterial supply (21). 
At the microvascular level, arterioles and venules form two distinct but 
interconnected systems: first, an upper superficial network in the papillary 
dermis, with a higher microvascular density and the source of nutritional capillary 
loops that extend vertically into the dermal papilla (21) (in the nailfold, the 
capillary orientation changes from vertically to longitudinal inclination and is 
highly accessible to imaging and analysis with nailfold videocapillaroscopy 
(NVC)); second, a lower plexus in the dermal-subcutaneous interface that 
connects with the upper network and branches into lateral systems to supply 
sweat glands and hair follicles (21).  
Glabrous skin contains a rick concentration of arteriovenous anastomoses 
(AVAs) that allow blood to bypass nutritional capillaries loops (21) and are key 
thermoregulatory structures that can rapidly distribute high volume of blood to 
the skin surface, enabling optimal regulation of core temperature (21). AVAs are 
located in both the lower and upper vascular plexuses (21).  
As a consequence of repeated bouts of vasospasm, pathological changes 
occur in microcirculation characterized by decreased microvessel patency and 
blood supply.  One of the earliest pathological events is the evidence of damage 
to endothelial cells, that induces a cascade of consequences to vessels and 
surrounding tissue, including platelet activation, fibrinolytic pathway activation, 
angiogenesis/vasculogenesis stimulation and release of vasoactive mediators 
(22). Vascular smooth muscle cells (vSMCs) proliferate resulting in intimal growth, 
matrix deposition and eventually stenosis or occlusion of vessel lumen (20). 
On histological examination, microvascular changes can be seen in virtually 
all organ systems and include perturbation of endothelial cells, neointimal 
formation, increased numbers of myofibroblasts, pericyte activation, and 
perivascular lymphocyte infiltration. Small arteries and arterioles (50-500 |im in 
diameter) develop a fibrous, concentric intimal lesion that can obliterate the 
vessel lumen. Endothelial cell injury seems to occur at an early stage, with 
evidence of endothelial apoptosis, chronic platelet activation, and subsequent 
vascular thrombosis (23). Characteristic clinical findings include dropout of 
capillaries and distorted capillary structure, swelling of endothelial cells, 
 reduplication of capillary basement membrane , large gaps between endothelial 
cells, vacuolization of endothelial cell cytoplasm, loss of membrane bound 
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storage vesicles in endothelial cells, capillary telangiectasia  and intimal 
proliferation and accumulation of proteoglycans in arterioles and arteries (24). 
Capillaroscopy is the only method for the evaluation of nutritional capillaries 
of the nailfold. The capillaries consist of an arterial and a venous limb and an 
apical loop. Normally nailfold capillaries are hairpin shaped, with parallel, regular 
arrangement; a single capillary loop is localized in a single dermal papilla (25). 
Consistent with this, morphological changes in capillaries are detectable 
before or at disease onset, and enables the early differentiation between PRP and 
SRP using nailfold videocapillaroscopy (NVC). Besides identifying morphological 
patterns specific to various stages of SSc, NVC can also monitor disease severity 
and progression. Koenig et al (26) showed that microvascular changes were 
sequential in a 20-year follow-up study of 586SSc patients. Capillary enlargement 
was followed by capillary loss and then by capillary telangiectasia. This is 
succeeded by morphologic changes in the vessels as well as tissue fibrosis (26). 
In patients with recent-onset RP, these changes may be patchy, unilateral, or 
expressed in a single finger. 
A patient with a PRP meets, among other criteria the following normal 
capillary pattern: capillaries in the distal row of the nailfold have an open hairpin 
shape, are homogeneously sized and regularly arranged in a parallel fashion and 
their number ranges in linear mm from 6 to 14 with a mean of 9 capillaries (27). 
In contrast, capillaroscopic image of an SSc patient with RP is characterized by 
pathognomonic microvessel structural damage consisting of the presence of 
giant capillaries, microhemorrhages, capillary loss and other morphologic 
anomalies such as progressive neoangiogenesis (27).  
The presence of homogeneously and/or irregularly enlarged capillaries 
(circumscribed or homogeneous diameter >50µ) represents one of the earliest 
and most striking features of secondary RP and should be considered as a 
potential marker of microangiopathy. It has been suggested that microvascular 
dilation represents a local autoregulatory response to tissue hypoxia and a 
compensation of the morphofunctional changes in microcirculation such as 
decreased capillary density and hypoperfusion (28). In a recent study, enlarged 
capillaries were found in 100% of SSc patients, and in 56% of undifferentiated 
connective tissue diseases patients (29). As disease progresses architectural 
disarrangement of the nailfold microvascular network is observed. Local 
microhemorrhages are also associated with early vascular damage representing 
the ‘bridge’ between the presence of megacapillaries and the subsequent loss of 
capillaries (30). Loss of capillaries and/or avascular areas. Decreased number of 
loops (<30 over 5 mm in the distal row of the nailfold) with a “desert-like” 
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appearance should be considered highly specific for SRP (29). Progressive loss of 
capillaries has been associated with more extensive skin involvement and with a 
poor prognosis. 
A wide range of morphologic features of capillary neoformation 
(angiogenesis) can be observed in patients with secondary RP. The main 
morphologic hallmark of angiogenesis is the clustering of tortuous capillaries 
with a pronounced shape heterogeneity, including thin or large, meandering, and 
bushy capillaries /ramified capillaries (29) often surrounded by a dropout of 
normal capillary loops.   
 Capillaroscopy has been described as the best predictor tool of transition of 
PRP to SRP (31).  Qualitative, semi-quantitative and quantitative indexes/scores 
have been described. Scoring the capillaroscopic patterns changes during the 
follow-up of SSc patients (32) enables capillaroscopy as a mandatory tool to 
quantify microangiopathy. The usefulness of capillaroscopy in the follow-up of 
SSc patients and the possible prognostic role for the appearance of typical SSc 
vascular and visceral involvement, namely, digital ulcers and mortality, is 
suggested by many authors but still under debate (33). 
 
Qualitative Evaluation Model 
In clinical setting qualitative evaluation is the more accessible and easiest to 
perform. Architectural disorganization, enlarged loops, loss of capillaries, 
angiogenesis, and avascular areas characterize >95% of patients with overt SSc. 
Cutolo et al. (34) described a useful and reproducible qualitative NVC 
“Scleroderma pattern” with 3 different evolutive patterns: early, active and late.  
Early pattern is characterized by the presence of a single or small number of 
giant capillaries and microhemorrhages, no avascular areas and a relatively well 
preserved capillary distribution; in active pattern there are present giant 
capillaries and microhemorrhages, moderate capillary loss (20-30%) and a mild 
disorganized capillary architecture, with rare branches capillaries; Late pattern is 
characterized by near-absence of giant capillaries and microhemorrhages, 
presence of extensive avascular areas (50-70% of capillary loss) and a presence of 
many branched and ramified bushy capillaries (neoangiogenesis) with a complete 
disorganization of capillary array (30, 34). 
 
Semi-Quantitative Evaluation Model 
To allow a longitudinal evaluation of SSc microangiopathy, a semi- 
quantitative analysis of microvascular alterations is required (33). 
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Sulli et al. (35) proposed a semi-quantitative score, Microangiopathy 
Evolution Score (MES). The sum of three scores regarding loss of capillaries, 
disorganization of the microvascular array and capillary ramifications were 
assessed to study the progression of the vascular damage. A rating scale to score 
each capillary abnormality was used (0 = no changes; 1= <33% capillary reduction 
/ changes; 2= 33-66% capillary reduction / changes; 3= > 66% capillary reduction 
/ changes) per linear millimetre (35).  Four consecutive fields (one linear 
millimeter for each one) in the middle of the nailfold, in each 8 fingers were 
studied. The average score values from the eight digits were added together, and 
the final value divided by eight (35). The resulting value represents the evolution 
score of microangiopathy (MES):0-9 (15). We categorized MES scores in 3 
subcategories with the following cut-off values: category 1 – from 0 to 3; category 
2 – from 4 to 6 and category 3 – from 7 to 9, allowing a more detailed analysis 
between microangiopathy and endothelial dysfunction evaluation. 
Smith et al has proposed a simple semi-quantitative NVC evaluation for day-
to-day clinical use as simple prognostic index for digital trophic lesions for daily 
use in SSc. Capillary loss was counted over F32 (8 fingers, 4 fields per finger, 
fingers 2–5 of each hand). The described (semi)-quantitative rating scale (0, no 
changes; 1, <33% capillary reduction vs. normal (9/mm); 2, 33–66% capillary 
reduction; 3, >66% capillary reduction) was adopted to calculate the mean score 
of capillary loss. A mean score value of capillary loss of 1.67 was chosen as the 
cut-off value for the clinical prognostic index for present/future digital trophic 
lesions (36). 
 
Quantitative Evaluation Model 
Sebastini et al. (37) proposed a Capillaroscopic Skin Ulcer Risk Index (CSURI) 
as a predictor risk of the onset on new DU using NVC parameters. The CSURI 
index assessed the total number of capillaries in the distal row (N), maximum 
loop diameter (D), number of megacapillaries (M), and the ratio M: N.  (CSURI = D 
x M: N2). A cut-off of 2.94 had a 73.3% positive predictive value for DU. An 
inverse correlation was found with high N or higher M: N ratio. The strong 
limitation of this index was the obligatory presence of megacapillaries, excluding 
patients with late scleroderma pattern and eventually more severe disease. 
Presumably, capillaroscopy alone is unable to fully explore the complex 
pathophysiology of scleroderma microangiopathy, and other clinical, 
demographic, or serological parameters are essential in the characterization of 
prognostic value of the microvascular damage. Therefore, the evaluation of large 
scleroderma population and more complex predictive model, including 
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capillaroscopy and other clinical/ serological variables, are needed to identify new 
significant associations with SSc organ involvement and prognosis (33). 
 
2.2.3. ANGIOGENESIS  
 
Angiogenesis, the creation of new blood vessels from pre-existing ones, 
mainly depends on the activation, proliferation and migration of ECs, and is 
driven by angiogenic stimuli that also induce proteolytic enzymes cleaving 
extracellular matrix (ECM). The balance between pro-angiogenic and anti-
angiogenic factors tightly regulates angiogenesis (38). This event is highly 
complex and requires a dynamic, temporally and spatially regulated interaction 
between ECs, soluble angiogenic growth factors and ECM molecules. On one 
hand, EC proliferation and new vessel formation is characteristic of several 
diseases such as cancer and macular degeneration, while on the other hand EC 
death is also a typical feature of diseases such as atherosclerosis, allograft 
vasculopathy, heart failure, diabetic retinopathy and SSc (39). 
Endothelial cell damage results in ischemia-reperfusion injury due to the 
ongoing pathological process, which inevitably evolves towards chronic 
underperfusion. Ischemia-reperfusion injury is a complex inflammatory process 
that results from interaction between humoral and cellular components including 
the complement, vasoactive cytokines and the contact activation cascade within 
ischemic vascular beds. Soon after the start of reperfusion, EC dysfunction is 
perpetuated by superoxide radicals mainly produced by damaged ECs and 
neutrophils. Superoxide radicals inhibit the release of NO, prostacyclin and tissue 
plasminogen activator from ECs leading to the impairment of the vascular tone 
control and favoring thrombotic events with consequent chronic tissue hypoxia. A 
characteristic clinical finding is capillary dilation and atrophy noted in the skin by 
nailfold capillary microscopy. Similar attenuation of the microvessels is seen in 
the involved organs. In fact, the pathology suggests significant loss of the 
peripheral vascular network, with a defect in both the vascular repair and in the 
expected increase in vessel growth (angiogenesis, arteriogenesis, 
vasculogenesis); the net result is tissue ischemia, fibrosis, and organ failure (23).  
Although persisting hypoxia should be a major stimulus for angiogenesis, 
sufficient angiogenesis does not occur in SSc patients despite severe tissue 
hypoxia (38, 40). Most likely, this is based on an insufficient response to the 
elevated levels of vascular endothelial growth factor (VEGF) in serum and tissue. 
VEGF controls several steps of angiogenesis, increases the vascular permeability, 
stimulates the migration and proliferation of ECs and induces tube formation 
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(41). Also, an extended exposure to VEGF may have also negative effects by 
fusing immature microvessels in an uncontrolled manner resulting in a chaotic 
vessel network with giant capillaries. Moreover, in experimental settings, isolated 
microvascular EC from SSc patients show an impaired response to VEGF and other 
growth factors (41). 
An explanation for VEGF defective signaling, is that VEGF-A primary 
transcript can be alternatively spliced in its terminal exon, producing two distinct 
mRNA splice variants that are translated to the proangiogenic VEGF165 and 
antiangiogenic VEGF165b isoforms (42). This variant is selectively overexpressed 
at both the mRNA and protein levels in SSc skin. Thus, the increase in VEGF 
expression in SSc patients appears to be mostly due to increased levels of 
VEGF165b and not the pro- angiogenic VEGF165. This switch in SSc from 
proangiogenic to antiangiogenic VEGF isoforms may play a crucial role in 
explaining the insufficient angiogenic response to chronic ischemia (43). These 
two isoforms bind to the tyrosine kinase receptor VEGFR-2 with the same affinity, 
but binding of VEGF165b results in an insufficient tyrosine 
phosphorylation/activation of VEGFR-2 and incomplete or transient downstream 
signaling, which leads to an impaired angiogenic response (42). Manetti et al. 
(42) have recently reported that plasma levels of the VEGF165b, the 
antiangiogenic isoform, correlated with the severity of capillary architectural loss 
and derangement, suggesting that VEGF165b may directly or indirectly 
participate in loss of the microvessels in SSc. 
 Several antiangiogenic or angiostatic mediators have been described as 
being upregulated in SSc, including endostatin, angiostatin, endoglin, platelet 
factor 4, thrombospondin, and IL-4. However, results on angiostatic factors in SSc 
are conflicting or flawed by low patient numbers, poor clinical characterization 
and heterogeneity of the study population (44). 
The role of vasculogenesis in SSc is less clear. Endothelial progenitor cells 
might be recruited for vascular repair during active disease However, conflicting 
results have been published concerning the presence and role of circulating 
endothelial progenitor cells in SSc (39). Avouac et al. (45) demonstrated increased 
circulating endothelial progenitor cell levels in SSc, supporting their mobilization 
from bone marrow. Furthermore, the subset of patients with digital vascular 
lesions and high severity disease score displayed lower endothelial progenitor 
cell counts, suggesting increased homing at this stage (45). On the other hand, 
there is data suggesting that vasculogenesis might be impaired in SSc (39).  
Despite large research, a crucial question persists: why are the damaged 
microvessels not replaced by new capillaries via angiogenesis or vasculogenesis 
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in SSc (46). In this thesis we will discuss the role of angiogenesis in peripheral 
vasculopathy. 
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2.3. VASCULAR BIOMARKERS OF DISEASE ACTIVITY ASSESSMENT 
 
There is a significant amount of evidence from studies of peripheral blood 
in scleroderma that vascular perturbation is present, but still we know very little 
about the role of biomarkers in predicting vascular outcomes (1). In this chapter 
we will review current knowledge of the biomarkers of vascular disease included 
in our research.   
Vascular biological biomarker is a characteristic that is objectively measured 
and evaluated as an indicator of normal biological or pathogenic processes and 
of pharmacologic responses to a therapeutic intervention (2). They may be used 
either as a diagnostic instruments, disease staging tools, monitor of disease 
progress, indicators of disease prognosis or as predictors of new clinical 
outcomes (2).   
Although a popular model to explain the pathogenesis of the underlying 
scleroderma vascular disease is not yet fully proven, it suggests that the 
endothelial cell layer is activated/injured early in the disease process leading to 
endothelial cell dysfunction, over-expression of adhesion molecules, enhanced 
leukocyte activation, proliferation of pericytes, adhesion and activation of 
platelets and an influx of a perivascular infiltrate (3). The downstream effect of 
blood vessel perturbation produces “biomarkers” of vascular damage that reflect 
disease and may predict clinical outcomes (3). Therefore, vascular biomarkers of 
SSc disease activity play a key role in the understanding of pathophysiology of 
disease progression, and should include mediators of angiogenesis, markers of 
tissue hypoxia, endothelial dysfunction and platelet activation (4). Cross-section 
of unselected scleroderma patients measuring the possible biomarkers at one 
point in time, correlation of these measures with clinical data or longitudinal 
measurement of these factors have been reported (1).  
These studies have some limitations as the biological effects of many 
markers are pleiotropic and may change over time, modify in different stages of 
disease, with possible significant intra-patient variation over time, uncertainty of 
the marker’s relationship to vascular disease (relationship to vascular disease 
“activity” versus “damage”) and effects of medications. But despite these 
limitations, circulating factors that reflect ongoing vascular perturbation have the 
potential of serving as intermediate biological endpoints that can not only detect 
and characterize vascular disease activity but also predict ultimate disease 
outcome or treatment response (1). Ideally, a biomarker of vascular disease 
should be present in the preclinical state, involved directly in the pathogenic 
process, and correlate well with future vascular outcomes defined by gold-
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standard testing (5). Validation of these biomarkers, however, require cross-
sectional and cohort studies. 
 
Endothelial dysfunction biomarkers 
 
Endothelin-1 (ET-1) 
The endothelin’s are a family of three vasoactive peptides (ET-1, ET-2 and 
ET-3). The three 21-amino-acid endothelin isoforms bind to two endothelin 
receptors (endothelin receptor subtype A: ET-A and ET-B), with equal affinities for 
ET-B, but with a hierarchy of affinities for the ET-A receptor. ET-1 has the highest 
affinity for ET-A, followed by ET-2 and ET-3. The roles of the ET-A and ET-B 
receptors are becoming less clearly distinguished as the literature expands (6). In 
healthy arteries the production of ET-1 is small and the bioavailability of NO is 
preserved. This means that the balance of effects favors vasorelaxation through 
increased signaling of cyclic GMP. In endothelial dysfunction there is increased 
expression of ET-1 in smooth muscle cells and macrophages. There is also an 
increased expression of ET-B receptors on smooth muscle cells mediating 
vasoconstriction. ET-1 may also decrease endothelial NO synthase (eNOS) 
expression, thereby reducing NO production. Both the ET-A and the ET-B receptor 
on smooth muscle cells may mediate formation of superoxide (O
2
) in endothelial 
dysfunction. Superoxide will decrease the biological activity of NO by forming 
peroxynitrate (ONOO−). Collectively the balance of these effects is shifted towards 
more vasoconstriction, inflammation and oxidative stress in endothelial 
dysfunction (7). 
Endothelin-1 plays a key role in vascular pathologies by exerting various 
deleterious effects including hypertrophy of the vascular smooth muscle cells, 
cellular proliferation and fibrosis, increased vascular permeability, activation of 
leucocytes, and induction of cytokine and adhesion molecule expression (8). It 
can also act in an autocrine manner on the vascular endothelium itself. ET-1 is 
also recognized as a potent mitogen, as there is some evidence that it 
contributes to the vascular remodelling and organ damage. Low oxygen tensions 
typical of ischemic phase of RP, were shown to rapidly increase ET-1 secretion 
from cultured human endothelial cells, 4 to 8 fold above the secretion rates at 
ambient oxygen tension (transcriptional gene-related) (9). 
Endothelin-1 is elevated in the plasma of SSc patients compared to controls, 
and it increases during cold exposure in selected scleroderma patients (10). ET-1 
levels have been reported to be increased in PRP and SRP (9, 11-16) and this 
might be explained by the fact that ET-1 is primarily involved in capillary 
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vasospasm, independently, of its association with underlying connective tissue 
disease (9). Elevated ET-1 is not only a biomarker of vascular disease, but may 
itself be a cause of abnormal vascular reactivity and mediate tissue fibrosis by its 
pro-fibrotic properties via activating TGF-β. Therefore, inhibiting ET-1 activity is 
considered an attractive target in treating scleroderma vascular disease (3).  
 
Asymmetric dimethyarginine (ADMA)  
The free radical nitric oxide (NO) is synthesized from L-arginine by NO 
synthase (NOS) and is a potent endothelium-derived vasodilatory mediator.  There 
are three main isoforms of NOS with a constitutive expression in neuronal NOS 
(nNOS or NOS 1), endothelial NOS (eNOS or NOS 3) and it is possible that an 
inducible NOS expression (iNOS or NOS 2) occurs in response to a variety of 
stimuli, with NO-mediated signaling apparent in the skin (17). However, it is 
considered that NO is a double-edged sword in physiological and pathological 
conditions, both beneficial and detrimental depending on the concentration and 
local environment (18). ADMA can inhibit the NOS resulting in decreased levels of 
NO. When NO overproduction occurs, S-nitrosylation of the ADMA regulating 
enzyme b diminishes the activity of DDAH, leading to an accumulation of ADMA 
(17). High level of NO may result in free-radical damage, and low level of NO may 
correlate with endothelial dysfunction, while the free-radical damage and 
endothelial dysfunction are both present in SSc patients. 
NO is largely oxidized to nitrate (NO
3
−) and nitrite (NO
2
−) and measurements 
of total nitrate and nitrite production, as well as ADMA levels are described as a 
reflection of endothelial dysfunction in many diseases (17). Endothelial 
dysfunction in SSc has been considered to be among the primary events during 
the progression of the disease. Because the etiology of endothelial dysfunction is 
still unclear, free-radical-mediated damage and immunological insults remain the 
attractive proposals to mediate effects. ADMA represents a novel risk factor for 
endothelial dysfunction. 
Doodley et al. (19) have described an increased formation of nitric oxide 
(NO) in patients with PRP or lcSSc, but nitration of proteins and ADMA are a 
particular feature of dcSSc and may reflect abnormal NO regulation and/or 
contribution to endothelial dysfunction in SSc (19). 
Increased serum levels of ADMA in SSc patients have been reported (19-21). 
Conflicting results of ADMA and SSc disease subset may be probably due to 
differences in the degree of inflammatory disorder, disease subset and treatment 
of the patients (19). 
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Angiogenesis biomarkers 
Vascular dysfunction and injury is a hallmark of SSc. Moreover, as the 
disease progress, a marked loss of the microvasculature occurs in several organs. 
The reduction in capillaries leads to a decrease in the supply of oxygen and 
nutrients and thus a hypoxic state. Tissue hypoxia is normally a trigger for 
vasculogenesis and angiogenesis; however, vascular recovery is impaired in SSc, 
and avascular areas are prominent (22). In SSc, several pro-angiogenic mediators 
have been shown to be upregulated, including angiogenic factors such as VEGF, 
interleukin-8 (IL-8/CXCL8), and basic fibroblast growth factor (bFGF) (22). Hence, 
although most studies point to a lack of compensatory blood vessel growth and 
deregulated aberrant angiogenesis in SSc, paradoxically, the balance of pro-
angiogenic factors appears to well exceed the anti-angiogenic mediators.  
Several anti-angiogenic or angiostatic mediators have been reported to be 
upregulated in SSc, including endostatin, platelet factor 4, thrombospondin, and 
IL-4 (23). Although the angiogenic properties of these factors are well-described 
in healthy and other disease settings, their role in SSc angiogenesis is mostly 
lacking (22), conflicting (24) or flawed by low patient numbers, poor clinical 
characterization and heterogeneity of the study population. In addition, the 
functional contribution of angiostatic factors to the disturbed angiogenesis in SSc 
has not been addressed. 
 
Vascular Endotelial Growth Factor (VEGF) 
VEGF is involved in many different steps of angiogenesis, including initial 
vasodilation, endothelial cell permeability, remodeling of the perivascular matrix, 
induction of proliferation and migration of endothelial cells (25) and precursor cells 
(26). It has biological effects extremely dose (24) and time (26) dependent. In SSc 
patients, platelets store and transport high levels of VEGF-A, and when activated in 
contact with injured endothelium, may be a source of circulating VEGF-A (27). 
Bielecki et al. (28) reported that peripheral blood mononuclear cells from SSc 
patients produce high amounts of VEGF-A in the early stage of the disease (28). 
Tissue ischemia normally leads to the expression of angiogenic growth 
factor VEGF, which then initiate angiogenic sprouting by inducing vasodilation, 
proliferation and migration of ECs. This leads to stabilization of a new tubal 
structure and lumina that form new vessels. Interestingly, while both pro- and 
anti-angiogenic factors are overexpressed in SSc, there appears to be an 
imbalance in the ratio of these mediators, favoring inhibition of angiogenesis and 
progressive vascular disease. Surprisingly, several studies have demonstrated 
enhanced expression of the pro-angiogenic factor VEGF-A in both the skin and 
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the circulation of SSc patients (28, 29). The paradox is that VEGF levels, rather 
than being associated with evidence of angiogenesis, actually correlate with 
progressive microvascular loss and disease progression (30). Uncontrolled 
overexpression of VEGF might have deleterious rather than beneficial effects as it 
may result in the formation of irregular vessels with impaired blood flow (26). 
VEGF-A exerts its biological functions by binding to the tyrosine kinase 
receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR) and the co-receptor neuropilin-
1. In particular, the pro-angiogenic effects of VEGF-A are mediated principally by 
the activation of VEGFR-2. In fact, phosphorylation of extracellular signal-
regulated kinase 1/2 (ERK1/2), Akt, and activation of p38 mitogen-activated 
protein kinase (MAPK) by VEGFR-2 is necessary for the promotion of endothelial 
cell proliferation, resistance to apoptosis, migration through extracellular matrix, 
and formation of a vascular lumen. On the contrary, the specific role of VEGFR-1 
in endothelial physiology is less well defined and somewhat controversial (25).  
Manetti et al. (25) showed the first evidence that a switch from pro-
angiogenic to anti-angiogenic VEGF-A isoforms may play a crucial role in the 
defective angiogenic and vascular repair processes that characterizes SSc 
vasculopathy. In this study increase of VEGF-A in SSc patients was the result of a 
significant increase in the anti-angiogenic VEGF165b isoform instead of VEGF165. 
Circulating levels of VEGF165b were raised in SSc, and were both early and 
persistent features of the disease. In addition, this study demonstrated that 
microvascular endothelial cells isolated from SSc skin constitutively expressed 
and released higher levels of VEGF165b than did endothelial cells from healthy 
individuals (29).  
 
Angiogenic Angiostatic 
Vascular endothelial growth factor (VEGF) Endostatin 
Platelet growth factor (PIGF) Angiostatin  
Basic fibroblast growth factor Interferon–inducible protein 10/CXCL10 
Platelet-derived growth factor (PDGF) Soluble endoglin 
Hepatocyte growth factor (HGF) Angiopoietin 2 
Transforming growth factor beta (TGF-β) Kallikrein 3 
Fibroblast growth factor (FGF) Pentraxin 3 
Interleukin-8/CXCL8 Interleukin-4  
Stromal cell–derived factor 1/CXCL12 Thrombospondin 1 (TSP-1) and TSP-2  
Interleukin-6  Platelet factor 4 
CD44 Kallikrein 9, 11, and 12 Monokine induced by interferon-/CXCL9  
Urokinase plasminogen activator receptor Tissue inhibitors of metalloproteinase 
Matrix metalloproteinase 9 (MMP-9) and proMMP-1  
Table 2.3.1: Up-regulated vascular biomarkers in SSc (30, 31) 
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There was an attractive hypothesis that the lack of sufficient angiogenesis in 
SSc could be mediated by a downregulation of the VEGF-A/VEGFR system (32). 
Conversely, several studies have shown that VEGF-A expression is markedly 
increased in different cell types in the skin of patients with SSc (32, 33). 
Moreover, VEGFR-1 and VEGFR-2 were also found o be upregulated on dermal 
microvascular endothelial cells in SSc-affected skin (32). In addition, a number of 
studies have demonstrated that circulating levels of VEGF-A are significantly 
increased in SSc patients throughout different disease stages (5, 26, 34). A 
positive correlation was found between VEGF-A levels and the severity of nailfold 
capillary loss (24) as well as with the extent of skin sclerosis measured by 
Rodman skin thickness score. Kuryliszyn- Moskal et al. addressed the relationship 
between VEGF-A levels and organ systemic involvement in SSc (35) and described 
significant elevated concentrations of VEGF-A in the sera of SSc patients with 
organ systemic damage compared to those without systemic manifestations. 
Although the upregulation of VEGF and other angiogenic factors might be a 
compensatory mechanism for the initial effect of unidentified angiostatic factors, 
the temporal kinetics of its expression appear to be critical in overcoming the 
inhibitory effects of angiostatic factors. In this regard, it has been shown that a 
brief upregulation of VEGF results in instability of newly formed vessels (23) . On 
the other hand, prolonged over-expression of VEGF, as is seen in SSc patients 
throughout various disease stages, also has deleterious effects because the 
vessels fuse in an uncontrolled manner and form a chaotic vessel network that is 
strikingly similar to the disturbed capillary network observed in SSc (23). In 
addition, isolated microvascular endothelial cells from patients exhibit an 
impaired response to VEGF in the Matrigel capillary morphogenesis assay (23) 
indicating that VEGF receptor signaling might be impaired in endothelial cells of 
SSc patients. 
Also, when endothelial cells are exposed to angiogenic stimuli (VEGF), 
plasminogen activation is initiated through the binding of plasminogen and 
urokinase to their receptors. This leads to the formation of plasmin that activates 
pro-metalloproteases which degrades non-collagenous components of the matrix 
and releases peptides that can inhibit continued angiogenesis, these peptides are 
angiostatin and endostatin (36). 
 
Endostatin 
Endostatin is is a newly characterized angiogenesis inhibitor that is an 
endogenously produced, a C-terminal, 20 kDa C-terminal fragment of collagen 
XVIII (37) that inhibits angiogenesis and tumour growth strongly by reducing 
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endothelial cell proliferation and migration (37, 38) potentially by inhibiting 
membrane type 1 matrix metalloproteinase and matrix metalloproteinase 2 (26). 
This action might be related to increased synthesis and proteolysis of type 
XVIII collagen in SSc (38). Endostatin specifically inhibits endothelial proliferation, 
migration and potently inhibits angiogenesis and tumor growth (37, 39). It has 
been reported that endostatin can inhibit VEGF expression in arthritic joints, 
suggesting that endostatin inhibits joint angiogenesis and arthritis progression in 
part by suppressing VEGF production (39). This could be an interesting view to 
explore in SSc patients. Endostatin could participate in the occurrence of ischemic 
manifestations in SSc, as it efficiently inhibits the assembly of human endothelial 
cells into complex vessels (36). 
Moreover, endostatin has been shown to be contained in platelet alpha 
granules, and is released during platelet activation and aggregation. VEGF exerts 
its action on the release of different collagenases, which cleave endostatin from 
collagen XVIII in the endothelial cells. Endostatin exerts its anti-angiogenic effect 
by its interaction with several endothelial cell surface receptors as it competes for 
the receptors of VEGF (36). 
Hebbar et al. (38) and Farouk et al. (36) described increased endostatin 
serum levels in SSc patient while Distler et al (24) described no difference in 
Endostatin levels in SSc patients compared to healthy controls, in dc/ lcSSc,  in  
early /intermediate / late SSc disease stage, in the  three capillaroscopic patterns 
or in patients with DU.  with DU or scars compared to healthy control group. 
 
Endoglin 
Endoglin is a 180 kD homodimeric covalently disulphide-linked 
transmembrane glycosylated protein that acts as a co-receptor for TGF-β 
predominately expressed on cell surface of EC (40). A co-receptor is defined as a 
cell surface protein that is capable of interacting with ligand, but does not 
actively transmits signaling responses (41). 
The vascular effect of TGF-β in angiogenesis results in activation of 
endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) and has a 
critical function in the development of the vascular system, being required for 
efficient VEGF-induced angiogenesis (42). These effects are mainly mediated by 
endoglin (ENG, CD105). ENG plays a role in vascular integrity and endothelium 
functioning whereas soluble ENG (sENG) acts as an anti- angiogenic protein that 
interferes with the binding of TGF- β to its receptor (43). Serum levels of sENG 
have been reported as being increased in SSc patients compared to healthy 
controls (40, 43-45). Wipff et al. found showed association between higher sENG 
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levels and an SSc vascular phenotype that integrates the presence of digital ulcers 
(43). 
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CHAPTER 3 | PATIENTS AND METHODS 
A observational cohort study with a 3-year follow-up was conducted to 
evaluate 109 enrolled patients attending the Multidisciplinary Raynaud Clinics of 
the Clinical Immunology Unit at Centro Hospitalar do Porto in Portugal.  
 
Patients included:  
– Thirty-two patients with primary Raynaud phenomenon.  
– Seventy-seven patients with secondary Raynaud phenomenon.  
– Based on 2013 classification criteria for SSc of American College of 
Rheumatology (1),  all SRP patients had SSc. 
– Systemic sclerosis patients were divided into two subgroups: DU group - 
38 patients with an active ulcer at time of study, with or without a past 
history of DU and naïve-DU group - 39 patients with no DU in the course of 
disease until enrolment. 
– Thirty-four controls  (sex and age matched) healthy non-obese, without 
self-reported cardiovascular risk factors such as  smoking, hypertension, 
diabetes or hyperlipidaemia participated. No control subject was on any 
vasoactive medication. 
 
Exclusion criteria: 
– Patients with factors that could potentially interfere with FMD (smokers, 
diabetic, hypertension, hyperlipidaemia and a past history of myocardial 
infarction).  
– Patients on bosentan were excluded from the study due to possible 
interference with ET-1serum levels. 
– Patients that had ECG and echocardiograph measurements out the normal 
range 
– Previous history of liver or renal disease. 
 
We lost no patients to follow-up.  
 
The institutional review board approved this study (including Ethical for 
Health Committee of Centro Hospitalar do Porto). All subjects and parents of the 
two children signed the informed consent. Data was collected by analysis of 
clinical file data and by clinical interview. 
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Figure 3.1: Evolution of our cohort in the 3-year follow-up. PRP: primary Raynaud phenomenon; 
SRP: secondary Raynaud phenomenon; SSc: systemic sclerosis; DU: digital ulcer. 
 
Definition of digital ulcer 
Ischemic digital fingertip ulcerations were defined as painful area of 2 mm 
or greater in diameter with visible depth and loss of dermis, amenable to healing 
and localized to the fingertip. Digital ulcers caused by conditions other than SSc 
were not considered. 
 
Methods 
At baseline all patients and controls were studied with all the described 
methods in this chapter (Allen test, Flow-mediated dilatation, nailfold 
capillaroscopy, autoantibody and vascular biomarkers detection). 
In the 3-year clinical follow-up sequential NVC were performed to SRP 
patients.  
 
1) Allen test 
Allen test was performed as follows: 1. instructing patient to clench his/her 
fist; 2. applying occlusive pressure to both ulnar and radial arteries by finger 
pressure; 3. confirm palm and finger blanching with the patient´s hand relaxed; 
4. release the occlusive pressure on ulnar artery; 5. Positive test if the hand 
flushes within 5-15 seconds it indicates that the ulnar artery has good blood flow 
and palmar arch is complete; Negative test if the hand does not flush within 5-15 
seconds, it indicates that ulnar circulation is inadequate with an incomplete 
palmar arch. 
 
143 patients 
77 SRP 
(SSc) 
38 
Active  DU 
30 
Recurrent DU 
8 
No new DU 
39 
Naive  DU 
10 
First DU evemt 
29 
Naïve DU 
32 PRP 
34 
controls  
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2) Ultrasound examination and FMD 
Ultrasounds scans were performed using a two-dimensional ultrasonography 
General Electric Logic 7 with a 9 MHz Linear wideband multihertz imaging probe.  
The same operator performed all exams.  
For spectral waveform measurement two cursors were placed on 
sonographic image of braquial artery examined; sample gate cursor and 
alignment angle correct cursor. Three contiguous spectral waveforms were 
recorded for determination of peak systolic velocity (PSV), end diastolic velocity 
(EDV) and Resistive Index (RI). The latter was calculated as (PSV-EDV)/PSV. All 
these parameters were measured for each waveform and obtained as the average 
of three measurements.  
Flow mediated dilatation of the braquial artery in the lower arm was 
evaluated following International Brachial Artery Reactivity Task Force guidelines 
(2) for the ultrasound assessment of brachial artery endothelial-dependent flow-
mediated vasodilatation. Patients and healthy subjects were on overnight fasting 
for twelve hours before the study. The exams were performed in the morning, 
after patients being kept in a quiet temperature controlled room (22-24ºC) for a 
20-minute rest.  Vasoactive drugs were withheld for 10 half-lives. Patients did not 
exercise or ingest substances that could affect the response to ischemia like 
caffeine, vitamin C, tobacco or high-fat foods for 24 hours.  
The braquial artery was scanned in a longitudinal section below the 
antecubital fossa in 2 to 3 cm section. Mean baseline braquial artery diameter 
was calculated as the result of the mean of 3 measurements. A 
sphygmomanometric blood pressure cuff localized above the antecubital fossa 
was inflated 50mmHg above patient’s systolic blood pressure (measured in left 
upper arm) and kept inflated for five minutes. No exam had to be discontinued 
due to pain or discomfort. Before cuff deflation, images were recorded 
continuously from 15s before deflation to 180s after cuff deflation. Ultrasound 
images were analysed for 3 consecutive end diastolic frames (onset of R wave) at 
45 to 60s after cuff deflation. The intraoperator variability was 3.6%. FMD 
measurements were blindly performed with respect to the NVC evaluation. 
FMD was calculated as the percentage of change of the peak diameter in 
response to reactive hyperaemia in (FMD%= (peak diameter – baseline 
diameter/baseline diameter) × 100) (2). 
 
3) Nailfold Videocapillaroscopy  
Nailfold Videocapillaroscopy (NVC) was performed with KK technology 
videocapillaroscopy with a 200x magnification lens. The same operator 
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performed all capillaroscopies, with blind information regarding FMD. In the end 
all images were scored for each patient at baseline and at 3-year follow-up and 
were controlled by a capillaroscopy expert. The inter observer variability was 
2.5%. 
All subjects were in a quiet room with controlled temperature (21-24ºC). 
Nailfold distal row capillaries of 4 fingers, 2nd, 3rd, 4th and 5th of both hands were 
examined. 
Two classifications were used to describe capillaroscopic findings: a 
qualitative classification of scleroderma microangiopathy damaged described by 
Cutolo (3) in 3 patterns early, active and late.  Early pattern was characterized by 
the presence of small number of giant capillaries and microhemorrhages, no 
avascular areas and a relatively well preserved capillary distribution; Active 
pattern was classified according to the presence of numerous giant capillaries 
and microhemorrhages, moderate capillary loss (20-30%) and a mild disorganized 
capillary architecture, with rare branches capillaries; Late pattern is characterized 
by near-absence of giant capillaries and microhemorrhages, presence of 
extensive avascular areas (50-70% of capillary loss) and a presence of many 
branched and ramified bushy capillaries (neoangiogenesis) and a complete 
disorganization of capillary array (3).  
A semi-quantitative score Microangiopathy Evolution Score (MES) was 
adapted from Sulli et al (4).  The sum of three scores regarding loss of capillaries, 
disorganization of the microvascular array and capillary ramifications were 
assessed to study the progression of the vascular damage. A rating scale to score 
each capillary abnormality was used (0 = no changes; 1= <33% capillary reduction 
/ changes; 2= 33-66% capillary reduction / changes; 3= > 66% capillary reduction 
/ changes) per linear millimeter (4).  Four consecutive fields (one linear millimeter 
for each one) in the middle of the nailfold, in each 8 fingers were studied. The 
average score values from the eight digits were added together, and the final 
value divided for eight (4). The resulting value represents the evolution score of 
microangiopathy (MES): 0-9 (5). Following, we categorized MES scores in 3 
subcategories with the following cut-off values: subcategory 1 – from 0 to 3; 
subcategory 2 – from 4 to 6 and subcategory 3 – from 7 to 9, allowing a more 
detailed analysis between microangiopathy and endothelial dysfunction 
evaluation. 
 
4) Autoantibody detection 
Antinuclear antibodies (ANA) were accessed by indirect Immunofluorescence 
on Hep-2 cells (NOVAlite ANA, Inova Diagnostics, Inc., San Diego, CA, USA). 
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Samples with a titer greater than or equal to 1:80 were considered positive. 
Autoantibodies anti-Scl-70, anti-centromere (ACA), anti-Ro52, anti-PM-Scl, anti-
RNA-polymerase, anti-fibrillarin (AFA), and anti-NOR 90 were detected by 
immunoblotting using a Euroline Myositis Profile antibody test syst (Euroimmun, 
Lübeck, Germany). Quantification of anti-U1RNP, antibodies was carried out using 
a Fluoro Enzyme Immuno Assay (EliA™ U1RNP70; Phadia, Uppsala, Sweden)  
 
5) Vascular Biomarkers  
Fasting venous blood samples were collected into a serum tube and a tube 
containing sodium heparin (Vacuette, Greiner-Bio-One, Austria). Serum was allowed 
to clot at room temperature and then separated from cells within 60 minutes and 
stored at -70 ºC until analysis for ADMA, endoglin, endostatin, VEGF-A.  
ET-1 assessment: Plasma was centrifuged immediately in a refrigerated 
centrifuge and stored at -70ºC until analysis for endothelin. Plasma endothelin 
was measured using a RIA assay, (Euro-Diagnostics AG, Sweden). The resulting 
values are reported as pmol/ml.  
ADMA assessment:  Serum was allowed to clot at room temperature and 
then separated from cells within 60 minutes and stored at -70 ºC before analysis 
for ADMA. Serum ADMA was measured using enzyme-linked immunosorbent 
assay, (Immunodiagnostik AG, Germany). The resulting values are reported as 
umol/l.  
VEGF assessment: Serum VEGF-A was measured using enzyme-linked 
immunosorbent assay, (IBL International GMBH, Germany). The resulting values 
were reported as pg/ml. 
Endoglin and Endostatin assessment:  Serum endoglin and endostatin were 
measured using enzyme-linked immunosorbent assay, (Uscn, Life Science Inc., 
Wuhan). The resulting values were reported as ng/ml. 
 
6) Follow-up 
When included in the study cohort, patients were seen on a regular basis of 
3-6 months intervals as indicated by disease severity. Patients were instructed to 
come to the hospital clinics whenever a new digital lesion developed. Final 
observation was in forth trimester of 2014. 
 
7) Outcomes measures 
Primary outcome was the occurrence of at least one or more new ischemic 
fingertip DU in the 3-year follow-up period.  
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In addition we applied survival analysis to new occurrence of DU during the 
study period, regarding endothelium dysfunction (FMD, ET-1 and ADMA) and 
microvascular damage (MES). We also propose a clinical model for day-to-day use 
for prediction of DU in SSc patients. 
 
8) Statistical analysis 
For comparison of normally distributed scale variables, we used unpaired or 
paired two-sided student’s t-test or analysis of variance (Anova). In these cases, 
data were described by mean ± standard deviation (SD) followed by the minimal 
and the maximal values (range).  Normal distribution was tested by Q-Q plots. In 
cases of non-normally distributed variables, we used non-parametric tests: Mann-
Whitney and Kruskal Wallis tests and data were described by median followed by 
the interquartile interval (Q
1
-Q
2
;), where Q
1
 represents the first quartile 
(corresponding to 25% of data) and Q
3
 represents the third quartile 
(corresponding to 75% of data). In Anova test, when the homogeneity of variance 
it is not satisfied, we used the Welch test. For comparison of categorical 
variables, we used Chi-square or Fisher's exact probability test. In cases of 
multiple testing, a Bonferroni correction or a Games-Howell test (for equal 
variances not assumed) was used. Predictors of digital ulcers were evaluated by 
univariate and multivariate logistic regression and summarised as HR and 95%CI. 
We applied survival analysis to determine the probability of freedom from new DU 
during the study period and evaluated the effects of FMD, MES, ET-1, ADMA, 
VEGF, endostatin and endoglin in that probability using the Kaplan-Meier method 
and the Cox regression multivariate analysis. A receiver operating characteristic 
(ROC) curve analysis was performed to obtain the predictive accuracy of FMD, 
MES score, ET-1, ADMA, VEGF, endostatin, endoglin and 2 risk clinical score 
model with regards to new ulcer development. We considered p values <0.05 as 
significant. Data were analysed using the SPSS software (v.22.0, SPSS, Chicago, 
IL). 
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CHAPTER 4 | RESULTS 
The results of our investigational study are presented in 6 sections following 
STROBE Statement recommendations (Strengthening the Reporting of 
Observational Studies in Epidemiology) (1).  
 
Section 1. Peripheral vasculopathy in Raynaud phenomenon: vascular 
disease biomarkers 
The aim of this study was to assess the differences between primary RP 
(PRP) and secondary RP (SRP) regarding macrovascular disease parameters, 
endothelial dysfunction and angiogenesis biomarkers. 
Section 2. Microvascular damage, endothelial dysfunction and ischemic 
peripheral vasculopathy in secondary Raynaud phenomenon 
In this study we evaluated endothelial dysfunction and microvascular 
damage in secondary Raynaud Phenomenon (SRP) patients as predictors of 
ischemic fingertip digital ulcers (DU) in a 3-year clinical follow-up.   
Section 3. Digital ulcers in Systemic Sclerosis: role of flow-mediated 
dilatation and capillaroscopy as risk assessment tools 
The objective was to evaluate macrovascular disease and microvascular 
damage as risk factors for digital ulcers in SRP SSc-associated patients.  
Section 4. Impaired angiogenesis as a feature of digital ulcers in systemic 
sclerosis  
We investigated if angiogenic biomarkers (vascular endothelial growth 
factor (VEGF), endoglin and endostatin) are related to microvascular damage and 
determined their prediction value for new digital ulcer episode.  
Section 5. Predictive value of vascular disease biomarkers for digital ulcers 
in systemic sclerosis patients 
In this publication we analysed the role of endothelial dysfunction and 
angiogenesis vascular biomarkers as risk factors and their predictive value for 
digital ulcers in systemic sclerosis patients. 
Section 6. Endothelial dysfunction and nailfold videocapillaroscopy pattern 
as predictors of digital ulcers in systemic sclerosis: a cohort study and review of 
the literature 
Our aim was to investigate the diagnostic and predictive value for DU the 
full set of parameters investigated in our work (endothelial dysfunction 
biomarkers (flow-mediated dilatation (FMD), serum levels of Endothelin-1 (ET-1) 
and ADMA), angiogenic/angiostatic biomarkers (vascular endothelial growth 
factor (VEGF), endoglin and endostatin) and nailfold videocapillaroscopy (NVC).  
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4.1 PERIPHERAL VASCULOPATHY IN RAYNAUD PHENOMENON: 
VASCULAR DISEASE BIOMARKERS 
 
ABSTRACT 
 
BACKGROUND: 
Introduction: Raynaud's phenomenon (RP) is a well-defined clinical 
syndrome. Systemic sclerosis (SSc) is the most frequent associated disease to RP 
(96%). The aim of this study was to assess the differences between primary RP 
(PRP) and secondary RP (SRP) regarding macrovascular disease parameters, 
endothelial dysfunction and angiogenesis biomarkers.  
MATERIALS AND METHODS: 
Flow-mediated dilatation (FMD), endothelin-1 (ET-1), asymmetric 
dimethylarginine (ADMA) vascular endothelial growth factor (VEGF), endoglin and 
endostatin were analysed in a cohort study of 32 PRP patients and 77 SRP all with 
SSc. 38 of the SRP SSc-associated patients had severe digital ulcer (DU).   
RESULTS: 
Patients with PRP had significantly longer history of RP compared to SRP SSc-
sssociated patients (p = 0.028).  
FMD was significantly lower in SRP patients 10.85±11.0% (p<0.001), more 
evidenced in SRP SSc-associated DU patients 5.34±7.49 (p<0.001). ET-1 plasma 
levels were significantly increased in both PRP 7.53 (0.16-11.73) and SRP patients 
11.85 (7.42-17.23) (p<0.001). Significant increased serum levels of ADMA 0.52 
(0.45-0.63) umol/L (p<0.001) and endoglin 3.01(1.46-7.02) mg/ml (p<0.001) 
were found in the SRP SSc-associated group with DU. VEGF was significantly 
decreased in the DU group 245.06 (158.68-347.33) pg/ml compared to other 
(p<0.001).  No significant differences were found between groups regarding 
endostatin (p=0.118).   
Comparing PRP and SRP SSc-associated patients without DU no  statistically 
significant difference regarding  FMD, ET-1, ADMA, VEGF, plasma levels were 
observed. 
CONCLUSION  
Overproduction of ET-1 and VEGF is present in PRP patients. Macrovascular 
disease and an impaired response to shear stress are more characteristic of SRP 
with a grater expression in patients with peripheral ischemic lesions.  
Keywords: Raynaud disease, endothelial dysfunction, digital ulcers, 
angiogenesis. 
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INTRODUCTION 
Raynaud's Phenomenon (RP) was first described by Maurice Raynaud in 1862 
and is defined as bouts of reversible vasospastic ischemia of the extremities (1, 
2).  Episodic color changes of the fingers classically turn into white (ischemia), 
then blue (cyanosis) and red (reperfusion). In a recent Delphi exercise round, 12 
invited experts agreed recently in three-step outline for a newly proposed 
diagnostic method. Consensus was achieved in that at least biphasic color 
changes are required to make the diagnosis of RP. They also agreed that 
white/pallor and blue/cyanosis were the two most important colors and that 
patients must report cold temperatures as one of the triggers for their RP attacks 
(3). 
Primary RP (PRP), also known as Raynaud's disease, is a functional vascular 
disorder that occurs isolated as an exaggerated response to cold and emotional 
stress, not progressing to irreversible tissue injury (3, 4). The requests for 
definition of PRP defined in Delphi exercise round were: (i) normal capillaroscopy 
(ii) negative physical examination for findings suggestive of secondary causes 
(e.g. ulcerations, tissue necrosis or gangrene, sclerodactily, calcinosis, or skin 
fibrosis); (iii) no history of existing connective tissue disease and (iv) negative or 
low titer ANA (3, 5). 
Secondary RP (SRP), also known as Raynaud's Syndrome, appears in 
response to those triggers too, however, it occurs in the setting of underlying 
structural vascular disease and is often associated with digital ulceration, scarring 
or gangrene (6). Recent advances in the diagnosis of RP has have recognized that 
abnormalities in nailfold capillary pattern and specific autoantibodies are 
independent risk factors for connective tissue disease(4). Autoreactive antibodies 
specifically ANA, anti-centromere and anti-SCL 70 antibodies are helpful as 
diagnostic for secondary RP.  
PRP is a common condition, which has a prevalence of 3-5% in the general 
population (2). The onset age is below 40 years and there could be a history of 
PRP in family but the entire clinical course is benign (6). By contrast, SRP is a 
much rarer condition, but frequent in the patients with connective diseases such 
as Systemic Sclerosis (SSc) (90%), systemic lupus erythematous (30%), rheumatoid 
arthritis (20%), Sjögren’s syndrome and polymiositis.  
Endothelial dysfunction and free-radical damage are primary events 
throughout the course of the RP disease, which result in vascular obliteration and 
diminished blood flow to the organs involved (7) and are prominent features of 
RP and ischemic peripheral digital ulcers. There are several serological 
biomarkers that reflect the vasculopathy of the disease, such as vasoconstrictor 
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ET-1(8), the controversial vasodilator nitric oxide(NO) (8) and the inhibitor of 
endothelial NO synthase(eNOS) ADMA.  
Endothelial cell damage results in ischemia-reperfusion injury due to the 
ongoing pathological process, which inevitably evolves towards chronic 
underperfusion. A characteristic clinical finding is capillary dilation and atrophy 
diagnosed by nailfold capillary microscopy. Thse findings suggest significant loss 
of the peripheral vascular network with a defect in both the vascular repair and in 
the expected increase in vessel growth (angiogenesis, arteriogenesis, 
vasculogenesis); the net result is tissue ischemia, fibrosis, and organ failure (9).  
The aim of the current study was to evaluate macrovascular disease 
parameters, endothelial dysfunction and angiogenic vascular biomarkers in a 
cohort of RP patients, in an attempt to define the boundaries between PRP and 
SRP allowing early identification of PRP patients who are at risk of developing an 
underling secondary disease.  
 
Materials and Methods 
An observational cohort study was conducted to evaluate 109 RP patients 
(32 PRP and 77 SRP) attending our Multidisciplinary Raynaud Clinics of the Clinical 
Immunology Unit at Centro Hospitalar do Porto in Portugal. We excluded from our 
study all patients with risk factors that could potentially interfere with flow-
mediated dilatation (FMD): smokers, diabetics, with hyperlipidaemia, and with 
past history of myocardial infarction, as well as patients on bosentan treatment, 
due to possible interference with endothelin-1 levels (ET-1).  
Controls and PRP patients were followed for 3-years to ensure no underlying 
secondary disease. All 77 SRP included patients had SSc based on 2013 
classification criteria for SSc of American College of Rheumatology (10). A 
washout of the vasodilator drugs was done before inclusion in the study. Thirty-
four healthy, sex/age matched, non-obese, without self-reported cardiovascular 
risk factors controls were invited to participate. No control subject was on any 
vasoactive medication.  
SRP SSc-associated patients were divided into two groups: DU group, that 
included 38 patients having an active ischemic ulcer at inclusion (34 women; mean 
age 52.7 ± 14.8 years; range 14-75); and a 39 patients group with no history of DU 
until enrolment (38 women; mean age 53.2 ± 10.3 years; range 30-79).  
The institutional ethical review board of Centro Hospitalar do Porto 
approved this study. All subjects signed informed consent before inclusion in the 
study. Data were collected by analysis of clinical file data and by clinical 
interview. 
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2.1 Methods 
2.1.1. Allen test 
Allen test was performed as follows: 1. instruct patient to clench his/her 
fist; 2. apply occlusive pressure to both ulnar and radial arteries by finger 
pressure; 3. confirm palm and finger blanching with the patient´s hand relaxed; 
4. release the occlusive pressure on ulnar artery; 5. Positive test: If the hand 
flushes within 5-15 seconds, this indicates that the ulnar artery has good blood 
flow and palmar arch is complete; Negative test: If the hand does not flush within 
5-15 seconds, this indicates that ulnar circulation is inadequate with an 
incomplete palmar arch. 
 
2.1.2. Flow-mediated dilatation (FMD) 
Ultrasounds scans were performed using a two-dimensional ultrasonography 
General Electric Logic 7 with a 9 MHz Linear wideband multihertz imaging probe. 
Ultrasound images were recorded and analysed for 3 consecutive end diastolic 
frames (onset of R wave) at 45 to 60s after cuff deflation. The inter-operator 
variability was 3.6%.  
Flow mediated dilatation of the brachial artery in the lower arm was 
evaluated following International Brachial Artery Reactivity Task Force Guidelines 
(11) for the ultrasound assessment of brachial artery endothelial-dependent flow-
mediated vasodilatation. Patients and controls (healthy subjects) were on 
overnight fasting for twelve hours before the ultrasound study was performed. 
The exams were performed in the morning, with patients being kept in a quiet 
temperature controlled room (22-24ºC) for a preliminary 20-minute rest.  
Vasoactive drugs were withheld for 10 half-lives. It was assured that patients did 
not exercise or ingest substances that could affect the response to ischemia like 
caffeine, vitamin C, tobacco or high-fat foods for 24 hours.  
FMD was calculated as the percentage of change of the peak diameter in 
response to reactive hyperaemia in (FMD%= (peak diameter – baseline 
diameter/baseline diameter) × 100) (11). 
 
2.1.3. Vascular Biomarkers  
Venous blood samples from fasting individuals were collected into a serum 
tube, and another tube containing sodium heparin (Vacuette, Greiner-Bio-One, 
Austria). Serum was allowed to clot at room temperature and then separated from 
cells within 60 minutes, and stored at -70 ºC until analysis for asymmetric 
dimethylarginine (ADMA), endoglin, endostatin, vascular endothelial growth 
factor (VEGF-A).  
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ET-1 assessment: Plasma was centrifuged immediately in a refrigerated 
centrifuge and stored at -70ºC until analysis for endothelin. Plasma endothelin 
was measured using a RIA assay, (Euro-Diagnostics AG, Sweden). The resulting 
values are reported as pmol/ml.  
ADMA assessment:  Serum was allowed to clot at room temperature and 
then separated from cells within 60 minutes and stored at -70 ºC before analysis 
for ADMA. Serum ADMA was measured using enzyme-linked immunosorbent 
assay, (Immunodiagnostik AG, Germany). The resulting values are reported as 
umol/l.  
VEGF assessment: Serum VEGF-A was measured using enzyme-linked 
immunosorbent assay, (IBL International GMBH, Germany). The resulting values 
were reported as pg/ml. 
Endoglin and Endostatin assessment:  Serum endoglin and endostatin were 
measured using enzyme-linked immunosorbent assay, (Uscn, Life Science Inc., 
Wuhan). The resulting values were reported as ng/ml. 
 
2.2.4 Statistical analysis 
For comparison of normally distributed scale variables, we used unpaired 
two-sided Student’s t-test or analysis of variance (Anova). In these cases, data 
were described by mean ± standard deviation (SD) followed by the minimal and 
the maximal values (range).  Normal distribution was tested by Q-Q plots. In 
cases of non-normally distributed variables, we used non-parametric tests: Mann-
Whitney and Kruskal Wallis tests and data were described by median followed by 
the interquartile interval (Q
1
-Q
3
;), where Q
1
 represents the first quartile 
(corresponding to 25% of data) and Q
3
 represents the third quartile 
(corresponding to 75% of data). In Anova test, when the homogeneity of variance 
was not satisfied, we used the Welch test. For comparison of categorical 
variables, we used Chi-square or Fisher's exact probability test. A receiver 
operating characteristic (ROC) curve analysis was performed to obtain the 
predictive accuracy of FMD, MES score, ET-1, ADMA, VEGF, endostatin and 
endoglin. We considered p values <0.05 as significant. Data were analysed using 
the SPSS software (v.22.0, SPSS, Chicago, IL). 
 
RESULTS 
The demographic and clinical characteristics of the 143 subjects are 
described in Table 4.1.1 and 4.1.2. No major differences were observed between 
SSc patients, PRP patients and control group regarding age, gender, mean arterial 
pressure and total cholesterol.  
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Disease duration was significantly longer in PRP patients (median value: 15 
years) compared to SRP SSc patients (median value: 10 years) (p = 0.028). All PRP 
patients and controls had negative ANA and normal capillaroscopy.  
 
 
 
SRP- SSc associated 
Variables PRP 
DU naive-DU 
Control p-value 
Subjects, n 32 38 39 34 NA 
Age (years), mean ± SD  49.9 ± 12.5 52.7 ± 14.8 53.2 ± 10.3 
47.1 ± 
10.96 
0.137a 
Gender 
Women, n (%) 
25 (78.1) 34 (89.5) 38 (97.4) 29 (85.3) 0.067b 
Disease duration (years), median (Q
1
-
Q
3
) 
15 10 10 NA 0.028*,c 
Mean arterial pressure (mmHg), 
mean ± SD  
87.6 ± 5.6 
 
87.9 ± 6.04 
 
88.3 ± 6.4 
 
86.7 ± 6.8 
 
0.75a 
Total cholesterol (mg/dl), mean ± SD  188.8 ± 8.8 191.3 ± 9.0 187.1 ± 12.1 190.6 ± 7.6 0.242a 
Allen test, positive (%) 2 (6.3%) 27 (71.1) 7 (17.9) 0 (0) <0.001* 
Table 4.1.1: The demographic and clinical characteristics of the 143 subjects.  RP: Raynaud 
phenomenon; PRP: primary SRP: secondary RP; SSc: systemic sclerosis; DU: digital ulcer; NA: non 
applicable; SD: standard deviation; Q: quartile.  a : Chi-Square test. b : Fisher’s Exact test.  c : Mann-
Whitney test. *: Statistical significance for a level of 5%. 
Variables SSc DU SSc naïve DU p-value 
Subjects, n 38 39  
Disease subset   0.001*,a 
Limited, n (%) 26 (68.4) 38 (97.4)  
Diffuse, n (%) 12 (31.6) 1 (2.6)  
Onset of 1st ulcer (years), Median (Q
1
-Q
2
)  5 (3-13.25) NA NA 
Telangiectasias, Positive, n(%) 38 (100) 27 (69.2) <0.001*,a 
Allen Test, Positive, n (%) 27 (71.1) 7 (17.9) <0.001*,a 
Autoantibodies    
ACA, Positive, n (%) 22 (57.9) 27 (69.2) 0.301 
Scl-70, Positive, n (%) 12 (31.6) 6 (15,4) 0.093a 
Anti-PM. Scl ,Positive, n(%) 2 (5.3) 5 (12.8) 0.431b 
Anti-RO 52, Positive, n (%) 20 (52.6) 12 (30.8) 0.052a 
Anti-NOR, Positive, n (%) 0 (0) 3 (7.7) 0.240b 
Anti-fibrilarin, Positive, n (%) 0 1 (2.6) 1.000b 
Anti U1 RNP,  Positive, n(%) 2 (5.3) 2 (5.1) 1.000b 
NVC Pattern    
Early, n (%) 0 (0) 13 (33.3) 
Active, n (%) 11 (28.9) 22 (56.4) 
Late, n (%) 27 (71.1) 4 (10.3) 
< 0.001a 
Table 4.1.2: Comparison between SRP SSc-DU and SSc naïve DU groups. SSc: systemic sclerosis; DU: 
digital ulcer; dcSSc: diffuse systemic sclerosis subset lcSSc: limited systemic sclerosis subset; SRP: 
secondary Raynaud phenomenon; ACA: autoantibody anti-centromere; NVC: nailfold 
videocapillarosocopy; MES: microangiopathy evolution score; NA: no applicable.  a : Chi-Square test. b : 
Fisher’s Exact test.  *: statistical significance for a level of 5% 
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Macrovascular disease 
Macrovascular disease was evaluated by clinical and hemodynamic 
parameters. Only 6.3% of PRP patients had a positive Allen test. However it was 
positive in 71% of SRP SSc-associated patients with DU whilst only 18% in patients 
without DU (p < 0.001).  
Macrovascular ultrasound examination showed no difference in braquial 
artery diameter between groups (p=0.620). Primary RP (p<0.001), SRP naive-DU 
(p=0.001) and SRP DU (p=0.002) had significantly decreased basal state PSV 
compared to control group. No differences were found between SRP patients with 
and without DU (p=0.989). Table 4.1.3. 
Flow-mediated dilatation at 60 seconds after deflation was significantly 
lower in SRP patients (p<0.001). Patients with DU had significantly reduced FMD% 
(p<0.001) when compared to all other groups. No statistical differences were 
found between PRP and control groups (p=0.999) and between PRP and SRP SSc-
associated naive-DU (p=0.07). Figure 1. No correlation was found between FMD 
and disease duration (R = 0.41).  
After 5 minutes braquial artery occlusion, PRP and SRP had significant 
differences regarding EDV (p<0.001) and RI (p=0.007).  PSV and EDV were 
significantly decreased in SRP group SSc-associated DU group (p<0.001). Table 
4.1.3.  
 
Vascular disease biomarkers Table.4.1.3 and 4.1.4; Figure 4.1.1  
Endothelin-1 
ET-1 plasma levels were found to be significantly higher (p<0.001) in 
patients with both PRP and SRP SSc-associated compared with controls. A 
statistically significant difference for ET-1 plasma levels was observed between 
patients with PRP and SRP SSc-associated patients (p<0.001). 
Among patients with SSc, ET-1 plasma levels were significantly higher (p 
<0.001) in patients with DU. No statistically significant difference for ET-1 plasma 
levels was observed between the PRP and SRP SSc patients without DU.  
 
ADMA 
ADMA serum levels were significantly higher in the SRP SSc-associated DU 
group (p<0.001). No significant differences were found between SRP SSc naive-DU 
and PRP (p=0.757) and between PRP and controls (p=0.204). 
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VEGF 
Significant differences were found in VEGF between PRP and SRP patients 
(p<0.001) and between PRP and control group patients (p<0.001). Lower plasma 
levels of VEGF were found in patients with fingertip digital ulcers (p<0.001).  We 
found no difference when PRP was compared to SRP SSc naive-DU group 
(p=0.099). 
 
Endoglin 
Angiostatic serum endoglin levels were increased in SRP patients with active 
DU (p<0.001) and no significant difference was found between other groups.  
 
Endostatin 
No significant differences were found between groups (p=0.118). 
Comparing SRP with PRP no significant difference was found (p=0.302). 
Variables 
PRP 
(n=32) 
SRP – SSc 
(n=77) 
Control 
(n=40) 
p-value 
 
FMD %, mean ± SD 17.96 ± 12.78 10.85±11.0 20.17 ± 8.86 <0.001*,b 
PSV 60 sec after cuff 
deflation (cm/s), mean ± 
SD  
177.69±26.69 165.35 ±53 199.77±32.93 <0.001*,b 
EDV 60 sec after cuff 
deflation (cm/s), mean ± 
SD  
92.95 ± 35.05 
 
67.28 ±24.37 
93.70 ± 20.01 
 
<0.001*,b 
RI, mean ± SD  0.47 ± 0.23 0.51± 0.18 0.43 ± 0.08 =0.034,b 
ET-1 pmol/ml, Median (Q
1
-
Q
3
) 
7.53 (0.16-11.73) 11.85 (7.42-17.23) 2.48 (0.00-5.60) <0.001*,a 
ADMA, umol/I, Median (Q
1
-
Q
3
) 
0.40 (0.37-0.49) 0.49 (0.41-0.54) 0.38 (0.32-0.43) <0.001*,a 
Endoglin ng/ml, Median 
(Q
1
-Q
3
) 
0.52 (0.28-0.88) 2.17 (1.27 -4.21) 0.28  (0.15-0.71) <0.001*,a 
Endostatin ng/ml, Median 
(Q
1
-Q
3
) 
0.90  (0.38-1.43) 0.51 (0.19-1.24) 0.565 (0.35-0.77) 0.268a 
VEGF pg/ml, Median (Q
1
-Q
3
) 438.50 (269.26854.00) 290 (166.71-361.78) 
178.03  (101.27-
222.10) 
<0.001*,a 
Table 4.1.3: Comparison of variables investigated between SRP, PRP and controls at baseline.  SSc: 
systemic sclerosis; DU: digital ulcer; SRP: secondary Raynaud phenomenon, ET-1: endothelin-1; ADMA:  
asymmetric dimethylarginine; VEGF: vascular endothelial growth factor. FMD: flow mediated 
dilatation; Q; quartile; SD: standard deviation; a : Kruskal Wallis; *  b:Anova test: Statistical significance 
for a level of 5%. 
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The AU-ROC (CI
95%
) of the macrovascular parameters and vascular 
biomarkers investigated associated to SRP were: FMD (AUC: 0.737 95%CI: 0.655-
0.819); post-occlusion PSV  (AUC: 0.681 95%CI: 0.593-0.768); post-occlusion EDV  
(AUC: 0.766 95%CI: 0.689-0.844); RI (AUC: 0.634 95%CI: 0.544-0.725), ET-1 (AUC: 
0.826 95%CI: 0.758-0.895); ADMA (AUC: 0.754 95%CI: 0.675-0.832); VEGF (AUC: 
0.508 95%CI: 0.410-0.606); endoglin (AUC: 0.914 95%CI: 0.870-0.959) and 
endostatin (AUC: 0.591 95%CI: 0.463-0.720).  
 
SRP- SS 
Variables PRP 
DU Non-DU 
Control p-value 
Baseline artery (mm), mean ± 
SD  
3.51 ± 0.69 3.34 ± 0.51 
 
3.44 ± 0.52 
 
3.37 ± 0.55 
 
0.620a 
Absolute difference (mm), 
mean ± SD  
0.57 ± 0.29 
 
0.17 ± 0.23 
 
0.52 ± 0.29 
 
0.65 ± 0.23 
 
<0.001*,a 
 
FMD (%), mean ± SD  
17.96 ± 12.78 
 
5.34 ± 7.49 
 
16.21 ± 11.31 
 
20.17 ± 8.86 <0.001*,a 
 
Baseline PSV (cm/s), mean ± 
SD  
65.77 ± 11.23 
 
76.65 ± 19.72 
 
75.26 ± 18.91 
 
94.99 ± 21.57 
 
<0.001*,a 
PSV 60 sec after cuff deflation 
(cm/s), mean ± SD  
177.69±26.69 
 
148.78±34.10 
 
181.51 ± 38.10 
 
199.77±32.93 
 
<0.001*,a 
EDV 60 sec after cuff deflation 
(cm/s), mean ± SD  
92.95 ± 35.05 
 
58.03 ± 16.89 
 
78.43 ± 24.37 
 
93.70 ± 20.01 
 
<0.001*,a 
RI, mean ± SD  
0.47 ± 0.23 
 
0.68 ± 0.23 
 
0.57 ± 0.09 
 
0.43 ± 0.08 
 
0.024*,a 
ET-1 pmol/ml, median (Q
1
-Q
3
) 
7.53 (0.16-11.73) 16.13 (10.97-
21.17) 
8.8 (5.89-12.68) 2.48 (0.00-5.60) <0.001b,* 
ADMA umol/L, median (Q
1
-Q
3
) 0.40 (0.37-0.49) 0.52 (0.45-0.63) 0.45 (0.41-0.51) 0.38 (0.32-0.43) <0.001b,* 
Endoglin ng/ml, median (Q
1
-
Q
3
) 
0.52 (0.28-0.88) 3.01 (1.46-7.02) 1.88 (0.84-3.28) 0.28 (0.15-0.71) <0.001b,* 
Endostatin ng/ml, median (Q
1
-
Q
3
) 
0.90 (0.38-1.43) 0.70 (0.26-1.73) 0.43 (0.16-0.80) 0.565 (0.35-
0.77) 
0.118b 
VEGF pg/ml, median (Q
1
-Q
3
) 
438.50 
(269.26-854.00) 
245.06 
(158.68-347.33) 
422.47 
(269.26-847.97) 
178.03 
(101.27-222.10) 
<0.001b,* 
 Table 4.1.4: Comparison between PRP, SRP (with and without digital ulcers) and controls. 
PRP: primary Raynaud phenomenon; SRP: secondary Raynaud phenomenon; SSc: systemic 
sclerosis; DU: digital ulcer; FMD: flow mediated dilatation; PSV: peak systolic velocity; EDV: 
end diastolic velocity; RI: resistive index. ET-1: endothelin-1; ADMA: asymmetric 
dimethylarginine; VEGF: vascular endothelial growth factor. FMD: flow mediated dilatation; 
Q; quartile; a: Anova test; b : Kruskal Wallis; * statistical significance for a level of 5% 
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Figure 4.1.1: Graphic representation of variables investigated. FMD (p<0.001), ET-1 
(p<0.001), ADMA (p<0.001), VEGF (p<0.001), Endoglin (p<0.001) and Endostatin p=0.266. ADMA:  
asymmetric dimethylarginine; VEGF: vascular endothelial growth factor FMD: flow mediated 
dilatation 
 
DISCUSSION 
We report here on the clinical and laboratory data regarding a large group of 
patients with diagnosis Raynaud’s phenomenon. This is an observational cohort 
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study of 109 RP patients that were divided into two subpopulations PRP and SRP, 
the latter in 2 groups (with or without previous ischemic peripheral lesions). 
Clearly, our findings suggest that endothelial dysfunction suggested by 
increased serum levels of ET-1 as well a pro-angiogenic state due to increased 
serum levels of VEGF are already present in PRP and when comparing these 
patients with SRP SSc- associated without DU no major difference were found 
regarding the vascular biomarkers investigated. Thus, a new and useful 
information coming out of this investigation is that severe obliterative peripheral 
vasculopathy is present only in SRP patients with DU as expressed by the 
increased peripheral resistance, low FMD response to shear stress, decreased PSV 
and EDV and high RI mostly consequent of the EC injury with endothelial 
dysfunction associated to an impaired angiogenesis.  
RP occurs when the balance of vascular tone is disturbed, favoring 
vasoconstriction. This endothelial activation and/or damage leads to reduce 
efficacy of vasodilators and/or overproduction of vasoconstrictors (4). Doubts 
persist whether there is overproduction of endothelium vasoconstrictor 
endothelin­1 (ET-1), underproduction of vasodilators such as nitric oxide (NO) and 
prostacyclin, or whether they are impaired in RP (4). Further complicating the role 
of NO, patients with SRP and SSc, have increased the plasma levels of an 
endogenous inhibitor of endothelial NOS—asymmetric dimethyl arginine— 
(ADMA) leading to reduced NO production (12).  
As a response to increase in shear stress, several vasodilators are released 
such as NO, prostaglandins and endothelium-derived hyperpolarizing factor (13). 
This response is commonly known as flow-mediated dilatation (FMD), and has 
been largely used for endothelium-dependent dysfunction assessment. NO is 
probably the major mediator of vasodilation and reduced NO bioavailability has 
been broadly accepted as a marker of endothelium dysfunction (14).  
In our cohort increased serum levels of ET-1 were present in PRP and SRP 
but only SRP SSc-associated patients with DU had significantly increased plasma 
levels of an endogenous inhibitor of endothelial NOS – ADMA. This favors early 
endothelial dysfunction with overproduction of vasoconstrictors (ET-1) even in 
PRP but only in severe SRP with peripheral vasculopathy is there an impaired 
inhibition of endothelial NOS. Furthermore endothelial dependent FMD was 
impaired in SRP, whilst PRP and control groups had similar response to shear 
stress. 
Controversial results have been published regarding endothelial dysfunction 
assessment in SRP SSc patients. A systematic review and meta-analysis (15) 
analyzed FMD assessment in SSc patients demonstrating that most of the studies 
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(71%) assessing the FMD% found significantly lower brachial artery FMD% in SSc 
patients compared to controls. The lack of compensatory increase in blood flow 
to the ischemic stimulus may be due to endothelial dysfunction, reduced 
compliance, impaired distensability or increased arterial stiffness (16-18). 
Positive Allen test has been associated to RP and SSc (19). Occlusion of ulnar 
artery in SSc patients as a predictor of DU has been reported (20) probably due to 
lack of compensatory flow of radial/ulnar artery and incomplete palmar arch.  In 
this study patients with DU had more positive Allen tests compared to other 
groups favouring macrovascular disease in these patients.   
Endothelial cell damage results in ischemia-reperfusion injury due to the 
ongoing pathological process, which inevitably evolves towards chronic 
underperfusion. Chronic hypoxia due to reduced blood flow is not compensated 
by efficient angiogenesis; even though elevated angiogenic biomarkers VEGF in 
SSc patients may be an attempt to induce neoangiogenesis and capillary 
neoformation. Yet, increased serum levels of angiostatic markers, such as 
endoglin, angiostatin or endostatin, may counteract this activity (12). 
SRP SSc-associated with DU patients expressed lower VEGF and increased 
angiostatic endoglin serum levels suggesting impaired vascular remodelling in 
response to the chronic ischemia. No significant differences were found when PRP 
and SRP SSc-associated patients with no peripheral lesions were compared.   
In conclusion endothelial dysfunction and a pro-angiogenic stimulus are 
already present in patients with PRP. Macrovascular disease, increased peripheral 
resistance due to structural lesions and an impaired response to shear stress are 
characteristic of SRP, particularly in patients with peripheral ischemic lesions. SRP 
SSc-associated patients with DU overproduce endothelial dysfunction (ET-1 and 
ADMA) and angiostatic (endoglin) vascular biomarkers. 
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4.2 MICROVASCULAR DAMAGE, ENDOTHELIAL DYSFUNCTION 
AND ISCHEMIC PERIPHERAL VASCULOPATHY IN SECONDARY 
RAYNAUD PHENOMENON 
 
ABSTRACT 
Objective: To evaluate endothelial dysfunction and microvascular damage in 
secondary Raynaud Phenomenon (SRP) Systemic sclerosis (SSc) associated 
patients as possible predictors of ischemic fingertip digital ulcers (DU) in a 3-year 
clinical follow-up.   
Methods: Flow-mediated dilatation (FMD), nailfold videocapillaroscopy 
(NVC), endothelin-1 (ET-1) and asymmetric dimethylarginine (ADMA) were 
analysed in a 3-year observational cohort study of 77 SRP with systemic sclerosis. 
Primary outcome was the occurrence of a new DU.  
Results: Risk factors for DU at baseline were low FMD% (p<0.001), NVC 
pattern (p<0.001), high microangiopathy evolution score (MES) (p<0.001), 
increasedET-1 (p<0.001) and ADMA serum levels (p=0.001). Median time to the 
occurrence of a new DU was 4.50 (1.25-16.25) months. History of at least one DU 
before enrolment (p<0.001), autoantibody anti-scleroderma-70 (p=0.012), NVC 
late pattern (p<0.001), high MES score (p<0.001), low FMD% (p<0.001) and 
increased ET-1 serum levels (p<0.001) were identified as risk factors for the 
occurrence of at least one new DU episode in follow-up.  
By univariate Cox regression analysis, FMD>9.41% (HR: 0.37 95%CI: 0.14-
0.99) and ET-1 >11.85 pmol/L (HR: 3.81 95%CI: 1.41-10.26) and NVC (HR: 2.29 
95%CI: 0.97-5.38) were predictors of DU recurrence, whereas for first DU event in 
naïve DU patients at baseline late NVC pattern (HR: 12.66 95%CI: 2.06-77.89) and 
MES score (HR: 1.693 95%CI: 1.257–2.279) were independent predictors. 
Conclusion: This study identified endothelium dysfunction biomarkers (FMD 
and ET-1) and severe microvascular damage in NVC as strong predictors of new 
DU in SSc patients.  
 
Keywords: 
Systemic Sclerosis, digital ulcers, flow-mediated dilatation, capillaroscopy, 
Allen test, ET-1, ADMA, microangiopathy evolution score. 
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INTRODUCTION 
Intimal hyperplasia, endothelial dysfunction and occlusive vasculopathy are 
ubiquitous features of systemic sclerosis (SSc) (1). 
 Endothelial cells (ECs) are the primary targets in systemic sclerosis (SSc). 
Underlying its pathogenesis is the interaction of ECs with other cells of the innate 
and adaptive immune system, platelets, coagulation factors, smooth muscle cells 
and fibroblasts (2).  
Manifestations of vasculopathy in SSc patients are frequent. Raynaud 
phenomenon is frequently the first symptom and may precede other clinical 
manifestations of organ involvement by years. An estimated 30- 50% of all 
patients with SSc will experience a DU at some stage in their disease course (3-7). 
Prevalence rates reported vary between studies ranging from 8% to 31% (3, 8, 9). 
Differences in reported DU frequencies reflect not only the difficulties in defining 
them but also inconsistencies between studies as to which types are considered 
(6). Digital ulcers develop in an average of 30% pear year in patients with SSc (10, 
11). These are a true burden, as a source of pain, have frequently severe 
complications such as infection, tissue loss and amputation, lead to severe hand 
impairment with a high impact in quality of life. Telangiectasia is a clinical marker 
of widespread aberrant microvascular disease (10) and are frequently seen in SSc 
patients due to the dilatation of the postcapillary venules located in the papillary 
and superficial reticular dermis (12). 
As a response to the increase in shear stress, several vasodilators are 
released such as nitric oxide (NO), prostaglandins and endothelium-derived 
hyperpolarizing factor. This response is commonly known as flow-mediated 
dilatation (FMD) and has been largely used for endothelium dysfunction 
assessment and as functional bioassay of NO bioavailability (13).  
Endothelin-1 (ET-1) has been identified as a key player of endothelial 
dysfunction in connective tissue diseases. It has been reported to be over-
expressed in biological fluids, tissue sections and in multiple organs that are 
affected by SSc, notably blood vessels, lung, kidney and skin (14). Increased 
expression of ET-1 and increased receptor binding sites are found in pre-sclerotic 
and early diffuse skin lesions in SSc patients (15). 
It has been suggested that decreased NO may contribute to endothelial 
dysfunction (16). Recently, asymmetric dimethylarginine (ADMA), an endogenous 
inhibitor of endothelial NO-synthase, has emerged as a promising biomarker of 
endothelial dysfunction in cardiovascular diseases (17). 
Microvasculopathy with alterations in morphology and function can easily be 
detected in the nailfold bed with capillaroscopy (18). Structural changes such as 
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giant capillaries, microhemorrhages, avascular areas and neo-angiogenic 
capillaries are important markers of disease progression and are present in more 
than 90% of SSc patients (19). Scoring the capillaroscopic patterns changes during 
the follow-up of SSc patients (20) enables capillaroscopy as a mandatory tool to 
quantify microangiopathy. 
In this study, we hypothesized that endothelial dysfunction assessment 
(FMD, ET-1 and ADMA) and microvascular damage (NVC) in SSc patients could 
predict new ischemic fingertip DU in a 3-year clinical follow-up.  Our primary 
outcome was the occurrence of a new DU in the 3-year follow-up.  
 
PATIENTS AND METHODS 
Patients  
We describe a prospective observational study with 3-year follow-up of 77 
SRP patients (72 women; mean age 52.95 ± 12.6 years; range 14-79 years) that 
attended the multidisciplinary Raynaud Clinics of the Clinical Immunology Unit at 
Centro Hospitalar do Porto in Portugal from October 2011 to December 2014. We 
excluded patients with factors that could potentially interfere with FMD (smokers, 
hypertension, hyperlipidaemia and a past history of myocardial infarction) and 
patients on bosentan.  
All patients fulfilled 2013 classification criteria for SSc of American College 
of Rheumatology (21) and had ECG and echocardiographic measurements within 
normal range.  According to Leroy classification (22), 13 patients (16.9%) had 
diffuse SSc (dcSSc) and 64 (83.1%) had limited SSc (lcSSc).  
Secondary RP SSc patients were divided into two groups: DU group, that 
included 38 patients having an active ulcer at the beginning of our follow-up 
study, with or without a past history of DU, (34 women; mean age 52.7 ± 14.8 
years; range 14-75 years); and DU naïve group with no history of DU, that 
included 39 patients with no history of DU in the course of disease until 
enrolment (38 women; mean age 53.2 ± 10.3 years; range 30-79 years).  Onset of 
disease was defined at the time of first RP episode.  
The local institutional Health and Ethical Committee approved this study and 
all subjects signed informed consent before the study. Data was collected by 
analysis of clinical file data and by clinical interview. 
 
Allen test 
Allen test was performed as follows: 1. instructing patient to clench his/her 
fist; 2. applying occlusive pressure to both ulnar and radial arteries by finger 
pressure; 3. Confirm palm and finger blanching with the patient´s hand relaxed; 
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4. release the occlusive pressure on ulnar artery; 5. Positive test: If the hand 
flushes within 5-15 seconds it indicates that the ulnar artery has good blood flow 
and palmar arch is complete; Negative test: If the hand does not flush within 5-15 
seconds, it indicates that ulnar circulation is inadequate with an incomplete 
palmar arch. 
 
Flow-mediated dilatation 
Ultrasounds scans were performed using a two-dimensional ultrasonography 
General Electric Logic 7 with a 9 MHz Linear wideband multihertz imaging probe.  
The same operator performed all exams.  Before cuff deflation, images were 
recorded continuously from 15s before deflation to 180s after cuff deflation. 
Ultrasound images were analysed offline manually for 3 consecutive end diastolic 
frames (onset of R wave) at 45 to 60s after cuff deflation and averaging the 
arterial diameter along 10 mm segments from 3 consecutive end-diastolic 
frames. Ultrasound images were analyzed offline manually, averaging the arterial 
diameter during respective experimental stages along a 10-mm segment. The 
inter-operator variability was 3.6%. FMD measurements were blindly performed 
with respect to the NVC evaluation. 
Flow mediated dilatation of the braquial artery in the lower arm was 
evaluated following International Brachial Artery Reactivity Task Force guidelines 
(23) for the ultrasound assessment of brachial artery endothelial-dependent flow-
mediated vasodilatation. Patients and healthy subjects were on overnight fasting 
for twelve hours before the study. The exams were performed in the morning, 
after patients being kept in a quiet temperature controlled room (22-24ºC) for a 
20-minute rest.  Vasoactive drugs were withheld for 10 half-lives. Patients did not 
exercise or ingest substances that could affect the response to ischemia like 
caffeine, vitamin C or high-fat foods for 24 hours.  
The braquial artery was scanned in a longitudinal section below the 
antecubital fossa in 2 to 3 cm section and the ultrasound probe was positioned 
using a mechanical probe stabilizer. 
A sphygmomanometric blood pressure cuff localized above the antecubital 
fossa was inflated 50mmHg above patients systolic blood pressure (measured in 
left upper arm) and kept inflated for five minutes. No exam had to be 
discontinued due to pain or discomfort.  
FMD was calculated as the percentage of change of the peak diameter in 
response to reactive hyperaemia in (FMD%= (peak diameter – baseline 
diameter/baseline diameter) × 100) (23). 
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Nailfold Videocapillaroscopy   
Nailfold videocapillaroscopy (NVC) was performed with KK technology 
videocapillaroscopy with an x200 magnification lens. The same operator 
performed all capillaroscopies, with blind information regarding FMD. Images 
were recorded and kept anonyms in a KK image analysis software. In the end all 
images were scored for each patient at baseline and at 3-year follow-up and were 
controlled by a capillaroscopy expert. The inter observer variability was 2.5%. 
All subjects were in a quiet room with controlled temperature (21-24ºC). 
Nailfold distal row capillaries of 4 fingers, 2nd, 3rd, 4th and 5th of both hands were 
examined. 
Two classifications were used to describe capillaroscopic findings: a 
qualitative classification described by Cutolo in 3 patterns early, active and late 
(12). As SSc is recognized to be a progressive, obliterative microvascular disease, 
the borders between the consecutive NVC patterns are delineated, in between 
others, by gradually more severe capillary loss (24). A semi-quantitative score 
microangiopathy evolution score (MES) was adapted from Sulli et al (25). The sum 
of three scores regarding loss of capillaries, disorganization of the microvascular 
array and capillary ramifications were assessed to study the progression of the 
vascular damage. 
 
Autoantibody detection 
Antinuclear antibodies (ANA) were accessed by indirect Immunofluorescence 
on Hep-2 cells (NOVAlite ANA, Inova Diagnostics, Inc., San Diego, CA, USA). 
Autoantibodies anti-Scl-70, anti-centromere (ACA) was detected by 
immunoblotting using a Euroline Myositis Profile antibody test system 
(Euroimmun, Lübeck, Germany).  
 
Biomarkers: ET-1 and ADMA 
Fasting venous blood samples were collected into a serum tube and a 
tubecontaining sodium heparin (Vacuette, Greiner-Bio-One, Austria).  
ET-1 assessment: Plasma was centrifuged immediately in a refrigerated 
centrifuge and stored at -70ºC until analysis for endothelin. Plasma endothelin 
was measured using a RIA assay, (Euro-Diagnostics AG, Sweden). The resulting 
values are reported as pmol/ml.  
ADMA assessment:  Serum was allowed to clot at room temperature and 
then separated from cells within 60 minutes and stored at -70 ºC before analysis 
for ADMA. Serum ADMA was measured using enzyme-linked immunosorbent 
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assay, (Immunodiagnostik AG, Germany). The resulting values are reported as 
umol/l.  
 
Follow-up 
Ischemic digital fingertip ulcerations were defined as painful area of 2 mm 
or greater in diameter with visible depth and loss of dermis, amenable to healing 
and localized to the fingertip. Digital ulcers caused by conditions other than SSc 
were not considered. Patients were instructed to come to clinics whenever a new 
digital tropic lesion occurred. If no DU developed, patients were seen on a regular 
basis at 3-6 months intervals as indicated by disease severity. Final observation 
was in last trimester of 2014.   
 
Outcomes measures 
Primary outcome was the occurrence of one or more new ischemic DU in the 
3-year follow-up period.  We applied survival analysis to new DU occurrence 
during the 3-year clinical follow-up, regarding endothelium dysfunction (FMD, ET-
1 and ADMA) and microvascular damage (MES).  
 
Statistical analysis 
For comparison of normally distributed scale variables, we used unpaired 
two-sided student’s t-test or analysis of variance (Anova). In these cases, data 
were described by mean ± standard deviation (SD). Normal distribution was 
tested by Q-Q plots. In cases of non-normally distributed variables, we used non-
parametric tests: Mann-Whitney and Kruskal Wallis tests and data were described 
by median followed by the interquartile interval (Q
1
-Q
3
), where Q
1
 represents the 
first quartile (corresponding to 25% of data) and Q
3
 represents the third quartile 
(corresponding to 75% of data). In Anova test, when the homogeneity of variance 
is not satisfied, we used the Welch test. For comparison of categorical variables, 
we used Chi-square or Fisher's exact probability test. Predictors of digital ulcers 
were evaluated by univariate and multivariate logistic regression and summarised 
as OR and 95%CI. We applied survival analysis to determine the probability of 
freedom from new DU during the study period and evaluated the effects of FMD, 
MES, ET-1 and ADMA in that probability using the Kaplan-Meier method and the 
Cox regression. Values of p≤0.05 were considered as significant. Receiver-
operating characteristic (ROC) analysis was performed for the selection of the 
optimal cut-off value of the FMD, MES, ET-1 and ADMA serum levels for the 
prediction of new DU. Data were analysed using the SPSS software (v.22.0, SPSS, 
Chicago, IL). 
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The association between baseline characteristics and the DU reoccurrence or 
new DU event was first analysed in univariate Cox regression followed by 
multivariate Cox regression including all variables with p<0.2 in univariate 
analysis. 
 
RESULTS 
A: Baseline characteristics 
The demographic and clinical baseline characteristics of the 77 SSc patients 
are described in Table 1. Diffuse subset SSc patients had significantly more active 
DU at enrolment (31.6%, p<0.001). Sclerodactily (55.3%, p < 0.001), telangiectasia 
(100%, p < 0.001), digital pitting scars (84.2%, p = 0.001) and calcinosis (47.4%, p 
< 0.001) were also significantly associated to the presence of active DU. 
Endothelial dysfunction biomarkers (decreased FMD% (p<0.001) and enhanced 
increased serum levels of ET-1 (p<0.001) and ADMA (p=0.001)) as well as 
microvascular damage evidenced by worse NVC patterns (p<0.001), and higher 
MES score (p<0.001) were also significantly associated with the presence of active 
DU. Naïve DU patients exhibited more puffy hands (87.2%, p = 0.008).  
 
B. Primary outcome: occurrence of a DU event in 3-year follow-up (Table 
4.2.2) 
In the 3-year follow-up, 40 (51.95%) patients developed new ischaemic 
digital ulcers (Table 4.2.2). Diffuse subset disease had proportionally more DU in 
follow-up (76.9%) compared to limited SSc (46.9%, p=0.048). No differences 
regarding disease duration were found between groups (p=0.101). Median time 
to the occurrence of a new DU was 4.50 (1.25-16.25) months. History of at least 
one DU before enrolment (p<0.001), autoantibody anti-scleroderma-70 (p=0.012), 
presence of telangiectasia (p=0.042), NVC late pattern (p<0.001), high MES score 
(p<0.001), low FMD% (p<0.001), positive Allen test (p<0.001) and increased ET-1 
serum levels (p<0.001) were identified as risk factors for the occurrence of at 
least one new DU episode in follow-up. The occurrence of at least one new DU 
episode in follow-up. 
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Variables DU (n=38) Naïve DU (n=39) p-value 
Age (years), mean ± SD (min-max) 52.7 ± 14.8 (14-75) 53.2 ± 10.3 (30-79) 0.137a 
Gender, Women, n (%) 34 (89.5) 38 (97.4) 0.067b 
Disease duration (years), median (Q
1
-Q
3
) 10 (5-23) 10 (7-20) 0.028c,* 
Mean arterial pressure (mmHg), mean ± 
SD (min-max) 
87.9 ± 6.04 (79-102) 88.3 ± 6.4 (77-103) 0.75a Total cholesterol (mg/dl), ean ± SD 
(min-max) 
191.3 ± 9.0 (169-216) 187.1 ± 12.1 (156-202) 0.242a 
Disease subset   0.001a, * 
Limited, n (%) 26 (68.4) 38 (97.4)  
Diffuse, n (%) 12 (31.6) 1 (2.6)  
Disease duration, Median (Q
1
-Q
3
) 10.00 (5.00-23.00 10.00 (7.00-20.00) 0.602c 
Onset of 1st ulcer (years), Median (Q
1
-Q
3
)  5 (3-13.25) NA NA 
Puffy hands, Presence, n(%) 23 (60.5) 34 (87.2) 0.008a,* 
Sclerodactily, Presence, n (%) 21 (55.3) 5 (12.8) <0.001a,* 
Telangiectasia, Presence, n (%) 38 (100) 27 (69.2) <0.001a,* 
Digital Pitting scars, Presence n (%) 32 (84.2) 19 (48.7) 0.001a,* 
Calcinosis, Presence, n (%) 18 (47.4) 3 (7.7) <0.001a,* 
Hand / arm contractures, Presence, n (%) 19 (50) 3 (7.7) <0.001a,* 
Allen Test, Positive, n (%) 27 (71.1) 7 (17.9) <0.001a,* 
Autoantibodies    
        ACA, Positive, n (%) 22 (57.9) 27 (69.2) 0.301a 
        Anti-scleroderma-70, Positive, n (%) 12 (31.6) 6 (15,4) 0.093a 
FMD (%), Median (Q
1
-Q
3
) 5.3 (2.88-7.80) 16.21 (12.55-19.88) <0.001c,* 
ET-1  (pmol/mi), Median (Q
1
-Q
3
) 16.13 (10.97-21.17) 8.8 (5.89-12.68) <0.001c,* 
ADMA(umol/i), Median (Q
1
-Q
3
) 0.52 (0.45-0.63) 0.45 (0.41-0.51) 0.001c,* 
NVC Pattern    
Early, n(%) 0 (0) 13 (33.3) 
Active, n(%) 11 (28.9) 22 (56.4) 
Late, n(%) 27 (71.1) 4 (10.3) 
< 0.001a,* 
MES score, Median (Q
1
-Q
3
) 5.00 (2.75-6.00) 1.00 (1.00-2.00) <0.001c,* 
Table 4.2.1: Comparison between DU and naïve-DU groups at baseline.  SSc: systemic sclerosis; DU: 
digital ulcer; dcSSc: diffuse systemic sclerosis subset; lcSSc: limited systemic sclerosis subset; ACA: 
autoantibody anti-centromere; NVC: nailfold Videocapillaroscopy; MES: microangiopathy evolution 
score; FMD: flow-mediated dilatation; ET-1: endothelin-1; ADMA:  asymmetric dimethylarginine.; NA: 
non applicable;  SD: standard deviation; Q: quartile. a: Chi-Square test. b: Fisher’s Exact test. c: Mann-
Whitney test. *: Statistical significance for a level of 5%. 
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ROC analysis was performed in order to define positive diagnostic value of 
the different parameters studied as potential risk factors for DU events, reflected 
by an area under the curve: ET-1 (AUC: 0.758 95%CI: 0.649-0.866); FMD (AUC: 
0.754 95%CI: 0.643-0.864) and for NVC scleroderma pattern (AUC: 0.846 95%CI: 
0.760-0.932).  
 
B.1 Recurrence of digital ulcers  
Thirty (79%) of the 38 SSc patients with active DU at baseline had DU 
recurrence (Supplementary Table 1). By univariate Cox regression analysis, 
FMD<9.41% (HR: 0.37 95%CI: 0.14-0.99) and ET-1 >11.85 pmol/L (HR: 3.81 
95%CI: 1.41-10.26) and NVC (HR: 2.29 95%CI: 0.97-5.38) were predictors of DU 
Variables 
 New DU in follow-up 
(n=40) 
No- DU in follow-up 
(n=37) 
p-value 
dcSSc/lcSSc   0.048a,* 
    Limited, n(%) 30 (75.0) 34 (91.9)  
    Diffuse, n(%) 10 (25.0) 3 (8.1)  
Disease duration,  Median (Q
1
-Q
3
) 9.50 (4.25-20.00) 13.00 (7.50-22.00) 0.101d 
History of DU, n(%) 30 (75.0) 8 (21.6) <0.001a, 
Time to new DU occurrence, Median 
(Q
1
-Q
3
) 
4.50 (1.25-16.25) NA NA 
Telangiectasias,  Presence, n(%) 37 (92.5) 28 (75.7) 0.042a,* 
Allen Test, Positive, n(%)    
Autoantibodies    
          ACA , Positive, n(%) 27 (67.5) 22 (59.5) 0.464a 
Anti-scleroderma-70 Positive, n(%) 14 (35.0) 4 (10.8) 0.012a,* 
NVC Pattern baseline 
Early, n(%) 2 (5.0) 11 (29.7) 
Active, n(%) 12 (30.0) 21 (56.8) 
Late, n(%) 26(65.0) 5 (13.5) 
<0.001a,* 
MES score baseline, Mean ± SD 4.55±1.986 1.89±1.646 <0.001c,* 
FMD (%), Mean ± SD 6.42±7.45 15.64±12.26 <0.001c,* 
ET1 (pmol/ml),  Median (Q
1
-Q
3
) 15.05  (11.12-20.27) 7.63 (5.98-12.74) <0.001d,* 
ADMA (umol/l),  Mean ± SD 0.498±0.112 0.48±0.078 0.419c 
Table 4.2.2: Primary outcome: new digital ulcer occurrence in the 3-year follow-up. DU: digital 
ulcer; dcSSc: diffuse systemic sclerosis; lcSSc: limited systemic sclerosis; ACA: anti-centromere 
autoantibody; NVC: nailfold Videocapillaroscopy; MES: microangiopathy evolution score; FMD: flow-
mediated dilatation; ET-1: endothelin-1; ADMA:  asymmetric dimethylarginine. a: Chi-Square test; b: 
Fisher’s Exact test; c: Student’s t test; d: Mann-Whitney test; *: Statistical significance for a level of 
5%. 
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recurrence (Table 4.2.3). Kaplan Meyer analyses of freedom from the DU 
recurrence showed that the median values of FMD (p=0.035), ET-1 (p=0.004) and 
qualitative scleroderma NVC (p=0.047) were significantly associated with the 
recurrence of DU (Figure 4.2.1: A-C).  
 
B.2 First DU event in 3-year follow-up 
In univariate analysis predictive factors for the first DU event in naïve DU 
patients at baseline only late NVC pattern (HR: 12.66 95%CI: 2.06-77.89) and MES 
score (HR: 1.69 95%CI: 1.26–2.28) were independent predictors of first DU event 
(Table 4.2.4). 
Kaplan Meyer analyses of freedom from first DU event strengthen the 
results of Cox analysis with NVC qualitative scleroderma pattern (p<0.001) and 
MES score (p<0.001) being significantly associated with the occurrence of the first 
DU in follow-up. (Figure 4.2.2: A-B).  
 
C. Clinical model for prediction of new DU 
We considered as potential predictors of DU the following variables: MES 
score, FMD, ET-1, ADMA, presence of telangiectasia, NVC pattern (as markers of 
endothelial dysfunction and microvascular damage), Allen test (macrovascular 
disease) and disease subset. Univariate analysis identified as risk factors for new 
DU higher MES score, increased serum levels of ET-1, positive Allen Test, 
telangiectasia, late capillaroscopic pattern and dcSSc. Higher FMD % values were 
found to be protective from new DU.  
Univariate Cox regression 
Baseline characteristics 
p-value HR (95% CI) 
Age  0.324 0.99 (0.97-1.01) 
Male gender 0.155 2.17 (0.75-6.33) 
Disease duration  0.235 0.98 (0.93-1.02) 
Diffuse cutaneous subset 0.418 1.37 (0.64-2.93) 
Positive Allen Test  0.471 1.37 (0.59-3.20) 
Positive Anti-scleroderma-70 0.339 1.44 (0.68-3.04) 
Positive Anti-centromere 0.518 0.79(0.38-1.63) 
FMD > 9.41% 0.047 0.37 (0.14-0.99) 
ET-1 > 11.85 pmol/L 0.008 3.81 (1.41-10.26) 
ADMA > 0.49 µmol/L 0.897 0.95 (0.46-1.97) 
Late NVC Pattern baseline 0.050 2.29 (0.97-5.38) 
MES score 0.064 2.49(0.95-6.56) 
Vasodilator therapy 0.462 0.58 (0.14-2.47) 
Table 4.2.3: Univariate Cox Regression evaluating the predictive value for digital ulcer recurrence.  
FMD: flow-mediated dilatation; ET-1: endothelin1; ADMA:  asymmetric dimethylarginine; VEGF: 
vascular endothelial growth factor; NVC: nailfold Videocapillaroscopy; NA: non applicable.  
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When all these variables are included in a enter logistic regression, only MES 
score (2<MES≤6, HR 428.44, 95% CI 4.36 to 4.21E4), FMD (5.7%<FMD≤9.5% HR 
0.005, 95% CI 0.00 to 0.59) and positive Allen test (HR 71.64 95% CI 2.75 to 
1.87E3) remained significantly associated with DU. We then analysed the 
combined effect of these 3 variables in an attempt to build a clinical model for 
prediction of DU. With this aim, we created a score reflecting the sum of these 
risk variables present for each patient (MES>2, FMD≤5.7% and positive Allen test). 
When considering the 3 variables, all patients with 2 or more risk factors had DU. 
when considering only simple day-to-day office tools (MES and Allen test) patients 
with 1 risk factor had 75 % new DU risk and all patients with the 2 variables had 
new DU. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1: (A-C): Kaplan-Meier analyses of freedom from digital ulcer recurrence in 36 
months follow-up of 38 SSc patients with active ulcer at baseline. Curves are shown for: A – 
patients who had FMD levels ≤ 9.5% or > than 9.5% (p=0.001); B - patients who had ET-1 serum 
levels   ≤ 11.9 pmol/ml or > than 11.9 pmol/ml (p<0.001); C – NVC patterns (p=0.047). SSc: 
systemic sclerosis; NVC: nailfold videocapillaroscopy; FMD: flow-mediated dilatation; ET-1: 
endothelin-1. 
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DU at Baseline Naïve DU at Baseline 
Follow-up 3 years Follow-up 3 years 
Variables 
New DU 
 (n=30) 
Non-new DU 
 (n=8) 
p-value First DU  
(n=10) 
Naïve DU 
(n=29) 
p-value 
p-value 
 
Age (years),  
mean ± SD  
50.67±15.64 60.13±7.94 0.027d, * 53.10±11.04 53.28±10.27 0.964d 0.141a 
Gender 
Women, n (%) 
26 (86.7) 8 (100) 0.560b 10 (100) 28 (96.6) 1.000b 0.368b 
Disease duration 
(years), 
Median (Q
1
-Q
3
) 
7.00  
(4.00-20.75) 
20.50  
(13.00-24.50) 
0.050e, * 
15.00  
(5.25-20.75) 
10.00 
 (7.00-20.00) 
0.974e 0.160c 
dcSSc/lcSSc   1.000b   1.000b 0.005b,* 
Limited, n (%) 20 (66.7) 6 (75.0)  10 (100) 28 (96.6)   
Diffuse, n (%) 10 (33.3) 2 (25.0)  0 (0) 1 (3.4)   
Sclerodactily 
Presence, n (%) 
17 (56.7) 4 (50.0) 1.000b 0 (0) 5 (17.2) 0.302b <0.001b,* 
Puffy hands 
Presence, n (%) 
18(60.0%) 5(62.5) 1.000b 10(100) 24(82.8) 0.302b 0.030b,* 
Telangiectasia 
Presence, n (%) 
30 (100) 8 (100) NA 7 (70.0) 20 (69.0) 1.000b 0.001b,* 
Digital Pitting scars 
Presence, n (%) 
24 (80.0) 8 (100.0) 0.309b 4 (40.0) 15 (51.7) 0.716b 0.005b, * 
Digital amputation 
Presence, n (%) 
8 (26.7) 2 (25.0) 1.000b 0 (0) 0 (0) NA 0.004b,* 
Calcinosis 
Presence, n (%) 
15 (50.0) 3 (37.5) 0.697b 1 (10.0) 2 (6.9) 1.000b 0.001b,* 
Hand / arm 
contractures 
Presence, n (%) 
15 (50.0) 4 (50.0) 1.000b 1 (10.0) 2 (6.9) 1.000b <0.001b,* 
Allen Test  
Positive, n (%) 
23 (76.7) 4 (50.0) 0.195b 3 (30.0) 4 (13.8) 0.344b <0.001b,* 
Autoantibodies        
ACA 
       Positive, n (%) 
17 (56.7) 5 (62.5) 1.000b 10 (100) 17 (58.6) 0.017b,* 0.051b 
     Anti-scleroderma-70    
       Positive, n (%) 
11 (36.7) 1 (12.5) 0.393b 3 (30.0) 3 (10.3) 0.163b 0.080b 
FMD 
Mean ± SD / median 
(Q
1
-Q
3
) 
3.96±6.06 10.55±10.26 0.025d,* 
11.49 
(9.41-19.86) 
13.52 
(8.36-21.83) 
0.700e 
 
<0.001c,* 
ET-1 
Median (Q
1
-Q
3
) 
17.24 
(12.89 -23.72) 
7.62  
(6.31-14.39) 
0.002e,* 
10.34 
(7.14-12.95) 
8.06 
(5.78-12.74) 
0.421e <0.001c,* 
ADMA 
Median (Q
1
-Q
3
) 
0.51 
(0.44-0.63) 
0.56 
(0.48-0.62) 
0.654e 
0.41 
(0.35-0.51) 
0.45 
(0.41-0.50) 
0.233e 0.006c,* 
NVC Pattern baseline   0.195b   0.060b <0.001b,* 
Early, n (%) 0(0) 0 (0)  2 (20) 11 (37.9)   
Active, n (%) 7(23.3) 4 (50.0)  5 (50.0) 17 (58.6)   
Late, n (%) 23(76.7) 4 (50.0)  3 (30.0) 1 (3.4)   
MES score baseline 
Median (Q
1
-Q
3
) 
5.50 
(4.50-6.0) 
3.50 
(2.00-5.75) 
 
0.070e 
2.50 
(1.00-5.25) 
1.00 
(1.00-2.00) 
 
0.010e,* 
 
<0.001c,* 
Table 4.2.4. Supplementary Table 1: Three-year follow-up of 77 SSc patients according to inclusion 
at baseline. DU: digital ulcer; dcSSc: diffuse systemic sclerosis; lcSSc: limited systemic sclerosis; ACA: 
anti-centromere autoantibody; NVC: nailfold Videocapillaroscopy; MES: microangiopathy evolution 
score; FMD: flow-mediated dilatation; ET-1: endothelin-1; ADMA:  asymmetric dimethylarginine.  
a:Anova test. b: Fisher’s Exact test. c: Kruskal-Wallis test.  d: Student’s t test.  e: Mann-Whitney test *: 
statistical significance for a level of 5%. 
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Figure 4.2.2: (A-B): Kaplan-Meier analyses of freedom from first digital ulcer event in 36 months 
follow-up of 39 naïve DU SSc patients at baseline. Curves are shown for: A – patients who had MES 
score ≤ 2 or > than 2 (p=0.001); B – NVC patterns (p=0.001). SSc: systemic sclerosis; NVC: nailfold 
videocapillaroscopy; MES: microangiopathy evolution score. 
 
DISCUSSION 
Several reports have identified different risk factors associated to DU. 
Different disease subsets cohorts, variable disease duration, sample size, risk 
factors analysed might contribute to different results reported. In a recent review, 
dcSSc, early onset of RP, early first non-RP symptom, high Rodman’s skin score 
and anti-scleroderma-70 positive autoantibodies were considered strong 
predictors of DU (18). 
Univariate Cox regression 
Baseline characteristics 
p-value HR (95% CI) 
Age  0.879 0.99 (0.94-1.06) 
Disease duration  0.821 0.99 (0.92-1.07) 
Telangiectasia 0.969 0.97 (0.25-3.77) 
Positive Allen Test  0.270 2.14 (0.55-8.29) 
Positive Anti-scleroderma-70 0.112 3.01 (0.77-11.71) 
FMD > 9.41% 0.523 1.66 (0.35-7.82) 
ET-1 > 11.85 pmol/L 0-708 0.74 (0.16-3.50) 
ADMA > 0.49 µmol/L 0.721 1.28 (0.33-4.95) 
Late NVC Pattern baseline   
Active pattern 0.661 1.44 (0.28-7.44) 
Late pattern 0.006 12.66 (2.06-77.89) 
MES score 0.001 1.69 (1.26 – 2.28) 
Vasodilator therapy 0.326 2.82 (0.36-22.23) 
Table 4.2.5: Univariate Cox Regression evaluating the predictive value for first digital ulcer event. 
FMD: flow-mediated dilatation; ET-1: endothelin1; ADMA: asymmetric dimethylarginine; VEGF: 
vascular endothelial growth factor; NVC: nailfold Videocapillaroscopy; NA: non applicable.  
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In our study DU incidence was similar to placebo group of RAPIDS-1 study 
(26) (55.8%/61%) respectively. Diffuse subset, positive Allen test, presence of 
telangiectasia, late NVC pattern, high MES score, positive anti-scleroderma 70 
autoantibody and impaired FMD were associated to the presence of new DU. 
Additionally past history of DU was identified as a risk factor for new DU. These 
factors favour microvascular damage and simultaneously macrovascular disease 
as potential contributors for the impaired vascular response to ischemic bouts of 
Raynaud phenomenon. The present study suggests that a positive Allen test and 
NVC findings are as a simple and easy office tests, valuable in early identification 
of patients at risk for DU. Further studies are needed to validate this model as a 
screening tool. Further investigation with pressure measurement of digits is 
needed and palmar and digital arteries ultrasound evaluation and cutaneous 
blood flow was measured using laser Doppler flowmetry. 
Controversial results have been published regarding endothelial dysfunction 
assessment in SSc patients. In respect to FMD, there are studies favouring 
reduction of FMD in SSc compared to control groups (27-31) no reduction of FMD 
(32) and similar FMD (33, 34). These studies were not designed to analyse 
relationship of FMD and DU. Even though not always available, FMD may be in the 
near future a screening prognostic tool for vasculopathy in SSc patients. In our 
study patients with DU had a reduced vasodilatation response to the increased 
shear stress. Values of FMD greater than 9.5% were found to be protective from 
DU, suggesting that impaired FMD might be an alert trigger for peripheral 
vasculopathy. 
Three recent studies reported increased serum ET-1 levels in patients with 
DU (18, 35-37) and one (38) describes no association between ET-1 serum levels 
and DU. Regarding ADMA, conflicting results of ADMA and SSc also have been 
described.  Increased levels have been reported by Doodley et al (39) in dcSSc 
and by Blaise et al (17) in SSc reflecting abnormal NO regulation and/or 
contribution to endothelial dysfunction in SSc.  
Our results have identified high serum levels of ET- as independent 
predictor of the development of a new DU episode in patients with or without a 
past history of DU. Additionally when freedom from digital ulcer was analysed, 
ET-1 serum levels > than 11.9 pmol/ml was found to be a risk for new DU in the 
3-year follow-up. These findings are consistent with previous reports that suggest 
that ET-1 plays a major role in vascular dysfunction and vascular disease, through 
vasoconstrictive effects and as an important mediator in vessel remodelling, 
which ultimately results in major changes in cellular and tissue architecture (40). 
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Our patients with SSc have increased serum levels of ADMA. These results 
are in line with previous reports (39, 41).  Although its an independent risk factor 
for DU it had no predictable value for new DU. Systemic sclerosis serum 
significantly reduces NO synthase activity, paralleled by decreases in intracellular 
cGMP and NO production in the cell medium, suggesting the presence of a factor 
that inhibits NOS (42). Nitric oxide has vasodilation effects on vessels and inhibits 
the thrombogenicity and the proliferation of vascular muscle cells, and is 
important for the regulation of blood flow and the maintenance of normal 
vascular wall structure (42). 
As a research tool, qualitative and semi-quantitative capillaroscopic scoring 
has an indisputable value, but it has not yet found its way into day-to-day clinical 
practice (43). Several scores have been described. Smith et al (43) proposed as 
prognostic index for digital trophic lesions, Sulli et al reported a semi-quantitative 
microvascular injury surveillance score, MES, that paralleled the evolution of 
microangiopathy in SSc, although there is no reference to its association to DU 
(25). Sebastini et al suggested the Capillaroscopic Skin Ulcer Risk Index (CSURI) as 
a predictor risk of the onset on new DU (44). 
In the present study capillaroscopy has great value in identifing high-risk 
patients for new DU events. Late capillaroscopy pattern was an independent 
predictor for DU recurrence and for the first DU episode in the 3-year follow-up. 
Qualitative and semi-quantitative assessments demonstrated that late NVC 
pattern (12) and disorganization of microvascular array with loss of capillaries, 
and angiogenesis were risk factors for DU occurrence. Additionally in 3-year 
freedom from DU analysis, MES score >2 was associated to a higher incidence of 
new DU. Late scleroderma pattern evidenced increased serum level of endothelial 
dysfunction biomarkers favouring the hypothesis that increased ET-1 
concentrations may contribute to the pathogenesis of both RP and progressive 
microvascular/fibrotic damage in SSc (36). 
Predictive clinical scores or models would be of great value for daily clinical 
practice (45). We propose a simple day-to-day clinical model for early 
identification of patients at high risk for DU. As FMD is not always accessible and 
reproducible, we suggest a simple clinical model for clinical practice: A 2-risk 
factor score (Allen test and MES) that identified SSc patients with 1 factor as 
having a 75% risk of new DU while all patients with both factors had new DU 
episodes. It would be interesting to validate this score in large sample studies, 
allowing the application of this simple day-to-day clinical tool. 
Our study has some limitations, such as small patient sample limited by 
number of patients with active DU at time of enrolment. Small number of dcSSc 
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patients might have interfered in risk factors. Additional studies with larger 
cohorts are needed to validate the score and predictive risk factors enabling 
further understanding of the progression of vascular damage and endothelium 
dysfunction in the aetiology of DU.  
 
CONCLUSIONS 
Our study identified flow-mediated dilatation, microangiopathy score and 
Allen test as risk factors for DU. Additionally endothelium dysfunction 
biomarkers, FMD and ET-1 and severe microvascular damage in NVC as strong 
predictors of new DU in SSc patients. Further studies are needed to validate these 
data and identify patients who are candidate for early preventive target therapy. 
 
Key messages: 
1. Elevated serum ET-1 concentrations and impaired endothelial dependent 
flow-mediated dilatation are associated with an increased risk of 
developing new digital ulcers. 
2. Scleroderma patients with late videocapillaroscopic pattern show an 
increased risk to have an active ulcer disease and more a severe 
microvascular damage is predictor for new digital ulcer episodes. 
3. Allen test and Nailfold Videocapillaroscopy are simple clinical prognostic 
tools for digital ulcers. 
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4.3 DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: ROLE OF FLOW-
MEDIATED DILATATION AND CAPILLAROSCOPY AS RISK 
ASSESSMENT TOOLS 
 
ABSTRACT 
Aim: The aim of this study was to evaluate macrovascular endothelial 
dysfunction and microvascular damage as clinical markers of peripheral 
microangiopathy in patients with Raynaud’s phenomenon (RP). 
Patients and methods: Seventy-seven secondary RP with systemic sclerosis, 
32 primary RP and 34 healthy controls were included in our study. Secondary RP 
patients were divided into two subgroups: 39 with digital ulcers (DU) and 38 
without digital ulcers (non-DU). 
Results: Patients with DU had significantly lower flow-mediated dilatation 
values (5.34 ± 7.49%) compared to non-DU patients (16.21 ± 11.31%), primary RP 
(17.96 ± 12.78%) and controls (20.17 ± 8.86%), p<0.001, favouring macrovascular 
endothelium dysfunction. 
Regarding microvascular damage, DU group had predominately 
capillaroscopic late pattern (71.1%) whereas non-DU patients had active pattern 
(56.4%). Microangiopathy evolution score was significantly higher in DU group 
compared to non-DU group (4.79±1.82 vs. 1.79±1.56, p < 0.001). Flow-mediated 
dilation was significantly lower in late pattern (6.13±7.09%) compared to active 
(12.58±10.66%) and early pattern (17.72±14.90%), p= 0.016 and p= 0.044 
respectively.  
Conclusions: Low flow-mediated dilatation and microvascular damage in 
capillaroscopy are early clinical markers of DU risk in RP patients. 
Keywords: Raynaud phenomenon, systemic sclerosis, digital ulcer, 
endothelial dysfunction, flow-mediated dilatation, capillaroscopy. 
 
Highlights 
1. Patients with systemic sclerosis and severe vasculopathy have: 
a. lower endothelial dependent flow-mediated dilatation. 
b. higher capillary dropout and impaired angiogenesis in capillaroscopy. 
c. increased microangiopathy evolution score 
2. FMD and NVC are important tools in early identification of patients at 
risk of developing DU. 
CHAPTER 4 | RESULTS 
108 | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
INTRODUCTION 
Raynaud phenomenon (RP) is the earliest clinical presentation of some 
connective tissue disease and in systemic sclerosis (SSc), is for most authors, 
considered the first clinical manifestation of disease. Although microvessel 
involvement has largely been described, it is important to highlight that 
macrovascular disease my also affect more than half of the SSc patients [1].  
Endothelium is a dynamic endocrine organ that plays a critical role in 
vascular homeostasis by secreting substances that regulate vascular tone, 
platelet activity and coagulation factors. It participates in vascular inflammation, 
cell migration and proliferation [2]. An increased apoptotic state is involved in 
endothelium denudation and dysfunction [2], leading to impaired vascular tone, 
pro-inflammation and pro-thrombotic state [2], increased expression of adhesion 
molecules and oxidative stress [3]. Structural integrity of endothelium is 
fundamental for a normal function. An impaired release and bioavailability of 
endothelium derived relaxing factor nitric oxide (NO) is observed in endothelial 
dysfunction [2]. NO is probably the major mediator of vasodilation and reduced 
NO bioavailability has been broadly accepted as a marker of endothelium 
dysfunction. [4] 
Endothelial dependent flow-mediated dilatation (FMD) measurement is a 
functional bioassay of a NO bioavailability [4], a combination of the endothelium 
NO production and destruction by reactive oxygen species [5]. FMD is simple, 
safe, cheap, non-invasive, sensitive, reproducible method, and has been largely 
used for endothelium dysfunction assessment.  
Microvasculopathy with alterations in morphology and function can easily be 
detected at the nailfold bed with nailfold Videocapillaroscopy (NVC). 
Capillaroscopy is a valuable, accessible, non-invasive, easy, safe and cheap tool 
with important diagnostic and prognostic value in patients with SSc. Qualitative, 
semi-quantitative and quantitative indexes/scores may be performed. 
Capillaroscopy has been described as the best predictor tool of transition of 
primary to secondary RP [6]. Structural changes are present in more than 90% of 
SSc patients [7]. Structural morphological and functional changes in capillaries 
allows differentiation between PRP and SRP identification of different Scleroderma 
evolution patterns with a close monitoring of disease evolution. 
In clinical setting qualitative evaluation is the most accessible and easy to 
perform an enables diagnosis of different stages of disease activity and 
progression. Architectural disorganization as a result of microvascular injury 
includes giant capillaries, microhemorrhages, capillary loss and avascular areas 
and morphological changes with branched/ramified/bushy capillaries suggesting 
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angiogenesis. Cutolo et al. described an useful and reproducible qualitative NVC 
“Scleroderma patterns” with 3 different evolutive patterns: early, active and late 
[8].  Several studies have been done in an attempt to identify NVC changes and 
correlation to organ disease, in order to identify a possible predictive role of NVC.  
The aim of this study was to evaluate and compare macrovascular 
endothelial dysfunction and microvascular damage as potential clinical markers 
of peripheral microangiopathy in patients with Raynaud’s phenomenon. 
Additionally we determined the relationship of these clinical markers with severity 
of vasculopathy, namely the presence of digital ulcers. 
 
PATIENTS AND METHODS 
Patients  
All hundred and nine enrolled patients, 97 women; mean age 50.9 ± 12.4 
years; range 14-79, attended the Multidisciplinary Raynaud Clinics of the Clinical 
Immunology Unit at Centro Hospitalar do Porto in Portugal.  
Thirty two patients had primary Raynaud phenomenon (PRP), 25 women; mean 
age 49.9 ± 12.5 years; range 22-73, with negative autoantibodies (ANA), no digital 
ulcers and had a bi or triphasic colour change of fingers when exposed to cold.  
 Seventy-seven patients had secondary Raynaud phenomenon (SRP), 72 women; 
mean age 52.95 ± 12.6 years; range 14-79, and based on 2013 classification criteria 
for SSc of American College of Rheumatology [9], all SRP patients had SSc. According 
to Leroy [10] classification, 13 (16.9%) had diffuse SSc (dcSSc) and 64 (83.1%) had 
limited SSc (lcSSc). SSc patients were divided into two subgroups: DU group - 38 
patients with an active ulcer at time of study (painful area of 2 mm or greater in 
diameter with visible depth and loss of dermis, amenable to healing and localized to 
the fingertip), with or without a past history of DU, (34 women; mean age 52.7 ± 
14.8 years; range 14-75) and non-DU group - 39 patients with no DU in the course of 
disease (38 women; mean age 53.2 ± 10.3 years; range 30-79). Onset of disease was 
defined at time of first episode of RP.  
A group of 34 (sex, age matched) healthy non-obese, without self-reported 
cardiovascular risk factors: smoking, hypertension, diabetes or hyperlipidaemia 
were invited to participate as controls (29 women; mean age 47.1 ± 10.96 years; 
range 23-66). No control subject was on any vasoactive medication. 
The study was done in the winter months from November to February. Pre-
menstrual women were assessed in day 1 to 7 in the menstrual cycle.  Three 
patients with factors that could potentially interfere with FMD were excluded at 
the beginning of the study (smoking, diabetes, hypertension, hyperlipidaemia 
and a history of myocardial infarction). All subjects studied had ECG and 
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echocardiographic measurements within normal range. Allen test was performed 
in all subjects for macrovascular impairment screening. 
This study was approved by the Local institutional Ethical Committee and all 
subjects signed informed consent before the study.  
 
Allen test 
Allen test was performed as follows: 1. instructing patient to clench his/her 
fist; 2. Applying occlusive pressure to both ulnar and radial arteries by finger 
pressure; 3. Confirm palm and finger blanching with the patient´s hand relaxed; 
4. Release the occlusive pressure on ulnar artery; 5. Positive test: If the hand 
flushes within 5-15 seconds it indicates that the ulnar artery has good blood flow 
and palmar arch is complete; Negative test: If the hand does not flush within 5-15 
seconds, it indicates that ulnar circulation is inadequate with an incomplete 
palmar arch. 
 
Ultrasound examination and FMD 
Ultrasounds scans were performed using a two-dimensional ultrasonography 
General Electric Logic 7 with a 9 MHz Linear wideband multihertz imaging probe.  
All exams were performed by the same operator and recorded in the image 
analysis software.  
For spectral waveform measurement two cursors were placed on 
sonographic image of braquial artery examined; sample gate cursor and 
alignment angle correct cursor. Three contiguous spectral waveforms were 
recorded for determination of peak systolic velocity (PSV), end diastolic velocity 
(EDV) and Resistive Index (IR). The latter was calculated as (PSV-EDV)/PSV. All 
these parameters were measured for each waveform and obtained as the average 
of three measurements in each waveform.  
Flow mediated dilatation of the braquial artery in the lower arm was 
evaluated following International Brachial Artery Reactivity Task Force guidelines 
[11] for the ultrasound assessment of brachial artery endothelial-dependent flow-
mediated vasodilatation. Patients and healthy subjects were on overnight fasting 
for twelve hours before the study. The exams were performed in the morning, 
after patients being kept in a quiet temperature controlled room (22-24ºC) for a 
20 minute rest. Vasoactive drugs were withheld for 10 half-lives. Patients did not 
exercise or ingest substances that could affect the response to ischemia like 
caffeine, vitamin C, tobacco or high-fat foods for 24 hours.  
The braquial artery was scanned in a longitudinal section below the 
antecubital fossa in 2 to 3 cm section. Mean baseline braquial artery diameter 
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was calculated as the result of the mean of 3 baseline measurements. A 
sphygmomanometric blood pressure cuff localized above the antecubital fossa 
was inflated 50mmHg above patients systolic blood pressure (measured in left 
upper arm) and kept inflated for five minutes. No exam had to be discontinued 
due to pain or discomfort. Before cuff deflation, images were recorded 
continuously from 15s before deflation to 180s after cuff deflation. Ultrasound 
images were analysed for 3 consecutive end diastolic frames (onset of R wave) at 
45 to 60s after cuff deflation. The intraoperator variability was 3.6%. FMD 
measurements were blindly performed with respect to the NVC evaluation. 
FMD was calculated as the percentage of change of the peak diameter in 
response to reactive hyperaemia in (FMD%= (peak diameter – baseline 
diameter/baseline diameter) × 100) [11]. 
 
Nailfold Videocapillaroscopy  
Nailfold videocapillaroscopy (NVC) was performed with KK technology 
videocapillaroscopy with a 200x magnification lens. The same operator 
performed all capillaroscopies, with blind information regarding FMD. Images 
were recorded and kept anonyms in a KK image analysis software. The inter 
observer variability was 2.5%. 
All subjects were in a quiet room with controlled temperature (21-24ºC). 
Nailfold distal row capillaries of 4 fingers, 2nd, 3rd, 4th and 5th of both hands were 
examined. 
Two classifications were used to describe capillaroscopic findings: a 
qualitative classification of scleroderma microangiopathy damaged described by 
Cutolo [12] in 3 patterns early, active and late.  Early pattern was characterized by 
the presence of small number of giant capillaries and microhemorrhages, no 
avascular areas and a relatively well preserved capillary distribution; Active 
pattern was classified according to the presence of numerous giant capillaries 
and microhemorrhages, moderate capillary loss (20-30%) and a mild disorganized 
capillary architecture, with rare branches capillaries; Late pattern is characterized 
by near-absence of giant capillaries and microhemorrhages, presence of 
extensive avascular areas (50-70% of capillary loss) and a presence of many 
branched and ramified bushy capillaries (neoangiogenesis) and a complete 
disorganization of capillary array [12].  
A semi-quantitative score Microangiopathy Evolution Score (MES) was 
adapted from Sulli et al [13].  The sum of three scores regarding loss of 
capillaries, disorganization of the microvascular array and capillary ramifications 
were assessed to study the progression of the vascular damage. A rating scale to 
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score each capillary abnormality was used (0 = no changes; 1= <33% capillary 
reduction / changes; 2= 33-66% capillary reduction / changes; 3=> 66% capillary 
reduction / changes) per linear millimeter [13]. The average score values from the 
eight digits were added together, and the final value divided for eight [13]. The 
resulting value represents the evolution score of microangiopathy (MES): 0-9 [14]. 
Following, we categorized MES scores in 3 subcategories with the following cut-
off values: subcategory 1 – from 0 to 3; subcategory 2 – from 4 to 6 and 
subcategory 3 – from 7 to 9, allowing a more detailed analysis between 
microangiopathy and endothelial dysfunction evaluation. 
 
Autoantibody detection 
Antinuclear antibodies (ANA) were accessed by indirect Immunofluorescence 
on Hep-2 cells (NOVAlite ANA, Inova Diagnostics, Inc., San Diego, CA, USA). 
Samples with a titer greater than or equal to 1:80 were considered positive. 
Autoantibodies anti-Scl-70, anti-centromere (ACA), anti-Ro52, anti-PM-Scl, anti-
RNA-polymerase, anti-fibrillarin (AFA), and anti-NOR 90 were detected by 
immunoblotting using a Euroline Myositis Profile antibody test syst (Euroimmun, 
Lübeck, Germany). Quantification of anti-U1RNP, antibodies was carried out using 
a Fluoro Enzyme Immuno Assay (EliA™ U1RNP70; Phadia, Uppsala, Sweden)  
 
Statistical analysis 
For comparison of normally distributed scale variables, we used unpaired or 
paired two-sided student’s t-test or analysis of variance (Anova). In these cases, 
data were described by mean ± standard deviation (SD) followed by the minimal 
and the maximal values (range).  Normal distribution was tested by Q-Q plots. In 
cases of non-normally distributed variables, we used non-parametric tests: Mann-
Whitney and Kruskal Wallis tests and data were described by median followed by 
the interquartile interval (Q
1
-Q
2
;), where Q
1
 represents the first quartile 
(corresponding to 25% of data) and Q
3
 represents the third quartile 
(corresponding to 75% of data). In Anova test, when the homogeneity of variance 
it is not satisfied, we used the Welch test. For comparison of categorical 
variables, we used Chi-square or Fisher's exact probability test. In cases of 
multiple testing, a Bonferroni correction or a Games-Howell test (for equal 
variances not assumed) was used. We considered p values <0.05 as significant. 
Data were analysed using the SPSS software (v.22.0,SPSS,Chicago,IL). 
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RESULTS 
Clinical assessment 
The demographic and clinical characteristics of the 143 subjects are 
described in Table 4.3.1. No major differences were observed between SSc 
patients, PRP patients and control group regarding age, gender, mean arterial 
pressure and total cholesterol.  
 
 
Disease duration was significantly different between groups (p = 0.028). 
Patients with PRP had significantly longer history of RP (median value: 15 years) 
compared to SSc patients (median value: 10 years). The DU group had a median 
of 5 years of DU history.  
The characteristics of the SSc patients with or without ischemic digital ulcer 
are summarized in Table 4.3.2.  
Allen test was positive in 71% of patients with DU and in 18% in SSc non-DU 
patients (p < 0.001). Patients with SSc-DU had significantly more sclerodactily 
(55.3%, p < 0.001), telangictasia (100%, p < 0.001), digital pitting scars (84.2%, p 
= 0.001) and calcinosis (47.4%, p < 0.001). Patients without DU had significantly 
more puffy hands (87.2%, p = 0.008).  
 
SRPSS 
Variables PRP 
DU Non-DU 
Control p-value 
Subjects, n 32 38 39 34 NA 
Age (years),  
mean ± SD (min-max) 
49.9 ± 12.5 
(22-73) 
52.7 ± 14.8 
(14-75) 
53.2 ± 10.3 
(30-79) 
47.1 ± 10.96 
(23-66) 
0.137a 
 
Gender 
Women, n(%) 
25 (78.1) 34 (89.5) 38 (97.4) 29 (85.3) 0.067b 
Disease duration (years), 
median (Q
1
-Q
3
) 
15 
(11.25-30) 
10 
(5-23) 
10 
(7-20) 
NA 0.028*,c 
Mean arterial pressure 
(mmHg), 
mean ± SD (min-max) 
87.6 ± 5.6 
(76-102) 
87.9 ± 6.04 
(79-102) 
88.3 ± 6.4 
(77-103) 
86.7 ± 6.8 
(70-101) 
0.75a 
Total cholesterol (mg/dl), 
mean ± SD (min-max) 
188.8 ± 8.8 
(169-201) 
191.3 ± 9.0 
(169-216) 
187.1 ± 12.1 
(156-202) 
190.6 ± 7.6 
(170-201) 
0.242a 
Table 4.3.1: Demographic and clinical data of subjects included. PRP: primary Raynaud phenomenon; 
SRP: secondary Raynaud phenomenon; SSc: systemic sclerosis; NA: no applicable. a:Anova test. b: 
Fisher’s Exact test. c: Kruskal-Wallis test. *: Statistical significance for a level of 5%. 
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Autoantibodies 
There were no significant differences between SSc-DU and SSc non-DU 
patients regarding to ACA (p = 0.301), anti-Scl-70 (p = 0.093), AFA (p = 1.000), 
anti-PM-Scl (p = 0.431), anti-NOR 90(p = 0.240), and anti-RNA-polymerase 
Variables SRPSS-DU SRPSS non-DU p-value 
Subjects, n 38 39  
dcSSc/lcSSc   0.001*,a 
Limitada, n(%) 26 (68.4) 38 (97.4)  
Difusa, n(%) 12 (31.6) 1 (2.6)  
Onset of 1st ulcer (years) 
Median (Q
1
-Q
2
) 
5 (3-13.25) NA NA 
Puffy hands 
Positive, n(%) 
23 (60.5) 34 (87.2) 0.008*,a 
Sclerodactily 
Positive, n(%) 
21 (55.3) 5 (12.8) <0.001*,a 
Telangiectasia’s 
Positive, n(%) 
38 (100) 27 (69.2) <0.001*,a 
Digital Pitting scars 
Positive, n(%) 
32 (84.2) 19 (48.7) 0.001*,a 
Periungeal haemorrhages 
Positive, n(%) 
29 (76.3) 24 (61.5) 0.162a 
Digital amputation 
Positive, n(%) 
10 (26.3) 0 (0) 0.001*,b 
Calcinosis 
Positive, n(%) 
18 (47.4) 3 (7.7) <0.001*,a 
Hand / arm contractures 
Positive, n(%) 
19 (50) 3 (7.7) <0.001*,a 
Allen Test  
Positive, n(%) 
27 (71.1) 7 (17.9) <0.001*,a 
Autoantibodies    
ACA  
Positive, n(%) 
22 (57.9) 27 (69.2) 0.301 
Scl-70   
Positive, n(%) 
12 (31.6) 6 (15,4) 0.093a 
Anti-PM. Scl    
Positive, n(%) 
2 (5.3) 5 (12.8) 0.431b 
Anti-RO 52   
Positive, n(%) 
20 (52.6) 12 (30.8) 0.052a 
Anti-NOR   
Positive, n(%) 
0 (0) 3 (7.7) 0.240b 
Anti-fibrilarin   
Positive, n(%) 
0 1 (2.6) 1.000b 
Anti U1 RNP  
Positive, n(%) 
2 (5.3) 2 (5.1) 1.000b 
NVC Pattern    
Early, n(%) 0 (0) 13 (33.3) 
Active, n(%) 11 (28.9) 22 (56.4) 
Late, n(%) 27 (71.1) 4 (10.3) 
Normal, n(%) 0 (0) 0 (0) 
< 0.001a 
 
MES 
from 0 to 3 
from 4 to 6 
from 7 to 9 
 
11 (28.9) 
21 (55.3) 
6 (15.8) 
 
35(89.7) 
4 (10.3) 
0 (0) 
 
<0.001*,b 
Table 4.3.2: Comparison between SSc-DU and SSc non-DU groups. Limited systemic sclerosis subset;  
SRP: secondary  Raynaud phenomenon; ACA: autoantibody anti-centromere; NVC: nailfold 
videocapillarosocopy; MES: microangiopathy evolution score;NA: no applicable.  a : Chi- Square test. 
b : Fisher’s Exact test.  *: Statistical significance for a level of 5%. 
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(p=1.000). Although without statistical significance, anti-Ro52 showed a higher 
clinical prevalence in the SSc- DU group (52.6%) comparatively with the SSc non-
DU group (30.8%) (p = 0.052). 
 
Videocapillaroscopy 
All SSc patients had scleroderma pattern at NVC examination. Significantly 
differences were found between SSc DU group and SSc non-DU group regarding 
qualitative evaluation (p < 0.001): late pattern was the most frequent pattern in 
DU patients (71.1%) whereas early and active patterns were the most 
representative patterns in non-DU patients (33.3% and 56.4%, respectively). 
Significant differences of qualitative evaluation were found relatively to disease 
subset (p = 0.010). Patients with diffuse disease had predominately late pattern 
(76.9%) while limited disease had more active pattern (46.9%). Concerning semi-
quantitative MES score significantly differences were observed: MES score was 
higher in DU group compared to non-DU group (4.79±1.82 vs. 1.79±1.56, p < 
0.001). Relatively to MES subcategories, we found significantly differences (p < 
0.001): subcategory 2 is the most frequent in SSc-DU patients (55.3%) while 
subcategory 1 is the most representative in SSc non-DU group (89.7%). 
 
Macrovascular ultrasound examination and FMD 
Ultrasound patterns and FMD are described in Table 4.3.3.  
Flow-mediated dilatation at 60 seconds after deflation was significantly 
lower in patients with DU (mean 5.34±7.49%; range -9.22 - 21.67) when 
compared to SSc non-DU (mean 16.21±11.31%; range -4.60 - 48.27; p < 0.001), 
primary RP (mean 17.96±12.78%; range 2.04 - 63.21; p < 0.001) and control 
(mean 20.17±8.86%; range 7.66 - 44.81; p < 0.001). No statistical differences 
were found between SSc non-DU, PRP and control groups. When comparing the 
values of FMD in limited (n = 64) and diffuse (n = 13) SSc subjects, no statistical 
differences were founded (mean 11.91±11.35% vs. 5.63±7.45%, p = 0.06). No 
linear regression was found between FMD and disease duration (p = 0.542). 
Baseline artery diameter was similar between groups (p=0.620). Absolute 
difference between mean baseline and post occlusive hyperemia dilatation at 60 
seconds showed significant differences between SSc DU patients and all the other 
groups (p<0.001), see Table 4.3.3. 
Primary RP (p< 0.001), SSc non-DU (p = 0.001) and control group  (p = 
0.002) had significantly decreased basal state PSV compared to SS DU group 
(mean 94.99±21.57cm/s; range 44.6-125.3). No differences were found between 
patients with and without DU (p = 0.989). After 5 minutes braquial artery 
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occlusion PSV and EDV were significantly reduced in SSc naïve DU patients (PSV: 
mean 151.51 ± 38.10cm/s; EDV: mean 58.03±16.89cm/s) and in PRP (PSV: 
p=0.003; EDV: p < 0.001) and in controls (PSV and EDV: p < 0.001) compared to  
SSc DU (PSV and EDV: p<0.001) and controls (PSV and EDV: p < 0.001). Resistance 
Index (RI) had significant differences between groups (p = 0.024). 
 
 
FMD and NVC 
Regarding qualitative NVC patterns statistically differences of FMD were 
found between groups (p=0.005, Figure 4.3.1). FMD was significantly lower in the 
late pattern (mean 6.13±7.09%; range -9.22 - 21.67) compared to active pattern 
(mean 12.58±1.07%; range -8.49 - 40.04, p = 0.016) and early pattern (mean 
17.72±1.49%; range -4.60 - 48.27, p = 0.044). No differences found between 
active and early patterns (p = 0.506).  
 
SRPSS 
Variables1 PRP 
DU Non-DU 
Control p-value 
Baseline artery (mm) 
mean ± SD (min-max) 
3.51 ± 0.69 
(1.48-4.51) 
3.34 ± 0.51 
(1.95-4.72) 
3.44 ± 0.52 
(2.31-4.17) 
3.37 ± 0.55 
(2.31-4.69) 
0.620a 
Absolute difference (mm) 
mean ± SD (min-max) 
0.57 ± 0.29 
(0.08-1.08) 
0.17 ± 0.23 
(-0.31-0.60) 
0.52 ± 0.29 
(-0.17-1.24) 
0.65 ± 0.23 
(0.28-1.09) 
<0.001*,a 
 
FMD(%) 
mean ± SD (min-max) 
17.96 ± 12.78 
(2.04-63.21) 
5.34 ± 7.49 
 (-9.22-21.67) 
16.21 ± 11.31 
 (-4.60-48.27) 
20.17 ± 8.86 
(7.66-44.81) 
<0.001*,a 
 
Baseline PSV (cm/s) 
mean ± SD (min-max) 
65.77 ± 11.23 
(49.10-94.80) 
176.65 ± 19.72 
(39.80-213.90) 
75.26 ± 18.91 
(37.10-113.50) 
64.99 ± 21.57 
(44.60-125.3) 
<0.001*,a 
PSV 60 sec after cuff 
deflation(cm/s) 
mean ± SD (min-max) 
77.69±26.69 
(16.9-122,0) 
158.78±34.10 
(51.7-207.8) 
111.51 ± 38.10 
(45.4-168.5) 
39.77±12.93 
12.7-112.8) 
<0.001*,a 
EDV  sec after cuff 
deflation(cm/s) 
mean ± SD (min-max) 
29.95 ± 15.05 
(11.8-29.3) 
56.70 ± 20.01 
(40.5-131.9) 
48.43 ± 24.37 
(23.9-131.4) 
18.03 ± 16.89 
(14.6-31.3) 
<0.001*,a 
RI 
mean ± SD (min-max) 
0.47 ± 0.23 
(0.38-0.94) 
0.78 ± 0.23 
(0.60-0.95) 
0.57 ± 0.09 
(0.29-0.82) 
0.53 ± 0.08 
(0.33-0.70) 
0.024*,a 
Table 4.3.3: Macrovascular ultrasound and Flow mediated dilation in study population. PRP: primary 
Raynaud phenomenon; SRP: secondary Raynaud phenomenon; SSc: systemic sclerosis; DU: digital 
ulcer; FMD: flow mediated dilatation; PSV: peak systolic velocity; EDV: end diastolic velocity; RI: 
resistive index. a:Anova test. *: Statistical significance for a level of 5%. 
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FMD and MES 
Flow-mediated dilatation was statistically different in MES subcategories 
(p=0.006, Figure 4.3.2): lower in the subcategory 3 (mean 4.37±5.55% range -
1.49 - 12.98) compared to subcategory 1 (mean 14.03±1.21% range -8.49 - 
48.27) and subcategory 2 (mean 6.55±7.44%; range -9.22; 21.67).  
 
DISCUSSION 
Vascular dysfunction is a key element of SSc pathogenesis [14]. Functional 
and structural changes involve microvessels, digital arteries and small elastic 
conduit arteries, such as radial and braquial artery. Vascular changes in SSc can 
be classified in two subgroups: destructive vasculopathy with progressive loss of 
capillaries early in disease course and proliferative obliterative vasculopathy 
characterized by proliferation of vascular cells, with luminal narrowing due to 
intimal hyperplasia and intimal fibrosis [15]. Although microvessel involvement 
has largely been described, macrovascular disease may affect more than half of 
the SSc patients [1] but there are few studies regarding small elastic conduits 
such as brachial, ulnar and radial arteries [16-18].  
Comparing results of FMD across studies is troublesome. The absolute 
mean FMD varies among studies between -1,9 to 19,2% [19]. These differences 
may be due to different study populations, risk profiles and measurement 
procedures or non-compliance to FMD recommendations and guidelines. 
Celemajer et al (1992) [20] described a non-invasive technique to measure 
endothelial function and defined guidelines and recommendations [4 11 21]. 
Controversial results have been published regarding FMD in SSc patients. 
Favouring reduction of FMD and non endothelial dependent nitroglycerine 
mediated dilatation (NMD) [22-24], only reduction of FMD [14 15], reduction of 
FMD and preserved NMD[25] and similar FMD and NMD [26 27].  
In SSc patients, ultrasonography of digital arteries show small artery lumen, 
reduced pulsation, thickened artery walls, low vessel compliance [18] and 
increased RI [16].  Vessel fibrosis and calcification reduce vascular compliance, 
and affect NO signalling by limiting vascular stretch due to arterial stiffness [15]. 
Different disease profile and mostly disease duration may reflect different 
responses to shear stress stimulus. 
We assessed endothelial-dependent macrovascular functional impairment in 
PRP and SRP patients. Baseline artery diameter was similar between groups.  FMD 
and absolute difference in baseline diameter/post-ischemic artery diameter were 
significantly lower in patients with SSc patients with active DU. (Figure 4.3.1). 
Patients without DU still had a preserved response to shear stress as no 
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significant differences were found when compared to PRP and control group. Late 
pattern had significantly reduced FMD. Our SSc patients were mostly lcSSc just as 
other reports with similar values of FMD in SSc patients [26 27]. Lekakis et al [22] 
,and Cypiene et al [23] patients have demonstrated that dcSSC patients have 
lower FMD value. In our study, most of dcSSc patients had DU, and no significant 
difference was found when comparing lcSSc and dcSSc patients regarding FMD. 
More investigation with larger series of patients is needed to analyse FMD in SSc 
disease subset.  
Basal PSV was decreased in RP patients compared to control group.  Post-
occlusive PSV and EDV were significantly reduced in SSc DU patients while RI was 
considerably increased in SSc DU patient group. We found no relationship of PSV, 
EDV and RI with progression of microvascular damage in NVC. The lack of 
compensatory increase in blood flow to the ischemic stimulus may be due to 
endothelial dysfunction, reduced compliance, impaired distensability or increased 
arterial stiffness [28-30]. Increased arterial stiffness has been related to vascular 
fibrosis leading to decreased elastic proprieties of large conduit arteries [31] and 
to diffuse inflammation involving arterioles and elastic arteries [26]. An increase 
in peripheral resistance due to microvascular damage might also contribute to 
impaired FMD. 
In accordance to Takahashi et al [15] our study suggests that FMD might be 
a useful marker of severity of obliterative vasculopathy in SSc patients with DU, as 
shown by the lower FMD value, decreased PSV and EDV and higher RI. 
Few studies evaluating endothelial dysfunction and microangiopathy as 
clinical markers for increased risk for DU have been reported. In our study, the 
main highlights were: 1) DU SSc patients had more avascular area, 
disorganization of capillary array and neoangiogenesis capillaries than the non-
DU group; 2) high number of giant capillaries and haemorrhages with moderate 
capillary drop-off was the most frequent pattern in the non-DU group; 3) no 
patients with DU had early scleroderma pattern; 4) MES had lower scores in non-
DU group (89.7% had scores<3) while in the DU group severe alterations in 
capillary morphology and distribution were present; 5)  patients with late pattern 
had significantly lower FMD in accordance with Le et al [32] and Rollando et al 
[14]. Our findings point to a trend towards association between macrovascular 
endothelial dysfunctions disease and damage of microvascular structure in 
patients with DU. In agreement with Le et al [32], micro and macrovascular 
function might still be partially preserved in early phase of vascular disease. 
Positive Allen has been associated to RP and scleroderma [33]. Occlusion of 
ulnar artery in SSc patients as predictive of DU has been reported [34] probably 
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due to lack of compensatory flow of radial/ulnar artery and incomplete palmar 
arch.  In our study patients with DU had high prevalence of positive Allen test 
compared to other groups suggesting macrovascular disease in these patients 
This simple test might be a useful tool in evaluation of patients with increased 
risk for DU. 
We failed to identify association of ACA and anti-Scl70 with DU. A trend 
towards association of positive Anti-Ro52/TRIM21 and DU was verified. These 
antibodies can be detected across a number of autoimmune diseases with 
significant prevalence, but it clinical relevance remains controversial. They are 
often detected in patients with scleroderma but are not diagnostically specific [35 
36]. They may be overlapped with other main scleroderma related antibodies, like 
anti-centromere, anti-topoisomerase I, anti-RNA polymerase III, or anti-Pm/Scl 
antibodies and there is some evidence of its association with interstitial lung 
disease, and overlap syndrome [37]. More studies of larger patients SSc with DU 
cohorts are needed to identify possible autoantibodies as a possible risk for DU.  
 
CONCLUSIONS 
In our study, findings favour FMD and NVC as important tools in early 
identification of patients at risk of developing DU. Lower values of FMD, late NVC 
scleroderma pattern and worsening of capillaroscopic scleroderma pattern are 
red flags towards DU occurrence. 
More studies, mainly longitudinal, are needed to investigate these vascular 
markers as long-term risk predictors, possible role in evaluation of disease 
evolution and markers for target therapy.  
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Figure 4.3.1: I. Silva. Comparison of FMD in different qualitative capillaroscopy patterns in patients 
with SRP non-DU and DU patients. FMD: flow mediated dilation; SRP: Secondary Raynaud 
Phenomenon patients; DU: digital ulcers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2: I. Silva FMD and MES sub-categories in SSc patients with and without digital ulcers. 
MES Sub-category 1 (n= 46); Sub-category 2 (n= 25) and Sub-category 3 (n=6). FMD: flow mediated 
dilation; MES:Microangiopathy evolution score; SSc Systemic sclerosis. 
RESULTS | CHAPTER 4 
 PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | 121 
REFERENCES 
1. Ho M, Veale D, Eastmond C, et al. Macrovascular disease and systemic sclerosis. Annals of the rheumatic 
diseases 2000;59(1):39-43  
2. Kasprzak JD, Klosinska M, Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacological 
reports : PR 2006;58 Suppl:33-40  
3. Barac A, Campia U, Panza JA. Methods for evaluating endothelial function in humans. Hypertension 
2007;49(4):748-60 doi: 10.1161/01.HYP.0000259601.38807.a6[published Online First: Epub Date]|. 
4. Harris RA, Nishiyama SK, Wray DW, et al. Ultrasound assessment of flow-mediated dilation. Hypertension 
2010;55(5):1075-85 doi: 10.1161/hypertensionaha. 110.150821[published Online First: Epub Date]|. 
5. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: implications 
for the assessment of endothelial function. The Journal of physiology 2005;568(Pt 2):357-69 doi: 
10.1113/jphysiol.2005.089755[published Online First: Epub Date]|. 
6. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and 
predictors of transition to secondary diseases. Archives of internal medicine 1998;158(6):595-600  
7. Cutolo M, Smith V. State of the art on nailfold capillaroscopy: a reliable diagnostic tool and putative 
biomarker in rheumatology? Rheumatology (Oxford, England) 2013;52(11):1933-40 doi: 
10.1093/rheumatology/ket153[published Online First: Epub Date]|. 
8. Cutolo M, Sulli A, Pizzorni C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in 
systemic sclerosis. The Journal of rheumatology 2000;27(1):155-60  
9. Hudson M, Fritzler MJ. Diagnostic criteria of systemic sclerosis. Journal of autoimmunity 2014 doi: 
10.1016/j.jaut.2013.11.004[published Online First: Epub Date]|. 
10. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and 
pathogenesis. The Journal of rheumatology 1988;15(2):202-5  
11. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-
dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery 
Reactivity Task Force. J Am Coll Cardiol 2002;39(2):257-65  
12. Cutolo M, Pizzorni C, Secchi ME, et al. Capillaroscopy. Best practice & research Clinical rheumatology 
2008;22(6):1093-108 doi: 10.1016/j.berh.2008.09.001[published Online First: Epub Date]|. 
13. Sulli A, Secchi ME, Pizzorni C, et al. Scoring the nailfold microvascular changes during the capillaroscopic 
analysis in systemic sclerosis patients. Annals of the rheumatic diseases 2008;67(6):885-7 doi: 
10.1136/ard.2007.079756[published Online First: Epub Date]|. 
14. Rollando D, Bezante GP, Sulli A, et al. Brachial artery endothelial-dependent flow-mediated dilation identifies 
early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular 
impairment. The Journal of rheumatology 2010;37(6):1168-73 doi: 10.3899/jrheum.091116[published 
Online First: Epub Date]|. 
15. Takahashi T, Asano Y, Amiya E, et al. Clinical correlation of brachial artery flow-mediated dilation in patients 
with systemic sclerosis. Modern rheumatology / the Japan Rheumatism Association 2014;24(1):106-11 doi: 
10.3109/14397595.2013.854064[published Online First: Epub Date]|. 
16. Rosato E, Gigante A, Barbano B, et al. In systemic sclerosis macrovascular damage of hands digital arteries 
correlates with microvascular damage. Microvascular research 2011;82(3):410-5 doi: 
10.1016/j.mvr.2011.07.009[published Online First: Epub Date]|. 
17. Hasegawa M, Nagai Y, Tamura A, et al. Arteriographic evaluation of vascular changes of the extremities in 
patients with systemic sclerosis. The British journal of dermatology 2006;155(6):1159-64 doi: 
10.1111/j.1365-2133.2006.07475.x[published Online First: Epub Date]|. 
18. Schmidt WA, Wernicke D, Kiefer E, et al. Colour duplex sonography of finger arteries in vasculitis and in 
systemic sclerosis. Annals of the rheumatic diseases 2006;65(2):265-7 doi: 
10.1136/ard.2005.039149[published Online First: Epub Date]|. 
19. Bots ML, Westerink J, Rabelink TJ, et al. Assessment of flow-mediated vasodilatation (FMD) of the brachial 
artery: effects of technical aspects of the FMD measurement on the FMD response. European heart journal 
2005;26(4):363-8 doi: 10.1093/eurheartj/ehi017[published Online First: Epub Date]|. 
20. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children 
and adults at risk of atherosclerosis. Lancet 1992;340(8828):1111-5  
21. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: a methodological 
and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300(1):H2-12 doi: 
10.1152/ajpheart.00471.2010[published Online First: Epub Date]|. 
22. Lekakis J PC, Mavrikakis M, Stamatelopoulos S. . Effect of long-term estrogen therapy on brachial arterial 
endo- thelium-dependent vasodilation in women with RaynaudO"s phenomenon secondary to systemic 
sclerosis. Am J Cardio 1998;82:1555–57  
23. Cypiene A, Laucevicius A, Venalis A, et al. The impact of systemic sclerosis on arterial wall stiffness 
parameters and endothelial function. Clinical rheumatology 2008;27(12):1517-22 doi: 10.1007/s10067-008-
0958-1[published Online First: Epub Date]|. 
CHAPTER 4 | RESULTS 
122 | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
24. Rossi P, Granel B, Marziale D, et al. Endothelial function and hemodynamics in systemic sclerosis. Clin 
Physiol Funct Imaging 2010;30(6):453-9 doi: 10.1111/j.1475-097X.2010.00965.x[published Online First: 
Epub Date]|. 
25. Szucs G, Timar O, Szekanecz Z, et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--
relevance for prevention of vascular complications. Rheumatology (Oxford, England) 2007;46(5):759-62 doi: 
10.1093/rheumatology/kel426[published Online First: Epub Date]|. 
26. Andersen GN, Mincheva-Nilsson L, Kazzam E, et al. Assessment of vascular function in systemic sclerosis: 
indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide 
production. Arthritis Rheum 2002;46(5):1324-32 doi: 10.1002/art.10191[published Online First: Epub 
Date]|. 
27. Roustit M, Simmons GH, Baguet JP, et al. Discrepancy between simultaneous digital skin microvascular and 
brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. The Journal of rheumatology 
2008;35(8):1576-83  
28. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. 
Circulation 2005;112(21):3337-47 doi: 10.1161/circulationaha.104.507996[published Online First: Epub 
Date]|. 
29. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nature clinical 
practice Rheumatology 2006;2(2):99-106 doi: 10.1038/ncprheum0092[published Online First: Epub Date]|. 
30. Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic 
sclerosis. Annals of the rheumatic diseases 1995;54(10):853-5  
31. Piccione MC, Bagnato G, Zito C, et al. Early identification of vascular damage in patients with systemic 
sclerosis. Angiology 2011;62(4):338-43 doi: 10.1177/0003319710387918[published Online First: Epub 
Date]|. 
32. Le JH, Cho KI. Association between endothelial function and microvascular changes in patients with 
secondary Raynaud's phenomenon. Clinical rheumatology 2014 doi: 10.1007/s10067-014-2553-y[published 
Online First: Epub Date]|. 
33. Pistorius MA, de Faucal P, Planchon B, et al. [Importance of the Allen test in the diagnosis of distal 
arteriopathy in Raynaud's phenomenon. Prospective study on a continuous series of 576 patients]. Journal 
des maladies vasculaires 1994;19(1):17-21  
34. Frerix M, Stegbauer J, Dragun D, et al. Ulnar artery occlusion is predictive of digital ulcers in SSc: a duplex 
sonography study. Rheumatology (Oxford, England) 2012;51(4):735-42 doi: 
10.1093/rheumatology/ker414[published Online First: Epub Date]|. 
35. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmunity 
reviews 2009;8(7):632-7 doi: 10.1016/j.autrev.2009.02.010[published Online First: Epub Date]|. 
36. Hervier B, Rimbert M, Colonna F, et al. Clinical significance of anti-Ro/SSA-52 kDa antibodies: a retrospective 
monocentric study. Rheumatology (Oxford, England) 2009;48(8):964-7 doi: 
10.1093/rheumatology/kep145[published Online First: Epub Date]|. 
37. Hudson M, Pope J, Mahler M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. 
Arthritis research & therapy 2012;14(2):R50 doi: 10.1186/ar3763[published Online First: Epub Date]|. 
 
RESULTS | CHAPTER 4 
 PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | 123 
CHAPTER 4 | RESULTS 
124 | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
Manuscript accepted in Clinical Rheumathology 
 
Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis  
 
Ivone Silva1*, Cristiana Almeida2, Andreia Teixeira3, José Oliveira4, Isabel Almeida5, 
Rui Almeida6, Carlos Vasconcelos7 
 
1. Angiology and Vascular Surgery Service and Clinical Immunology Unit, Centro 
Hospitalar do Porto, Portugal  
2. Internal Medicine – Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal  
3. Health Information and Decision Sciences Department – Universidade do Porto; 
CINTESIS – Center for Research in Health Technologies and Information 
Systems  
4. Clinical Pathology Department, Clinical Chemistry, Centro Hospitalar do Porto, 
Portugal  
5. Clinical Immunology Unit, Centro Hospitalar do Porto, Portugal  
6. Angiology and Vascular Surgery Service, Centro Hospitalar do Porto, Portugal  
7. Clinical Immunology Unit, Centro Hospitalar do Porto; Instituto de Ciências 
Biomédicas Abel Salazar, University of Porto; Multidisciplinar Unit of biomedical 
investigation, Porto, Portugal  
 
RESULTS | CHAPTER 4 
 PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | 125 
4.4 IMPAIRED ANGIOGENESIS AS A FEATURE OF DIGITAL ULCERS 
IN SYSTEMIC SCLEROSIS 
 
ABSTRACT 
Introduction: Impaired angiogenesis in systemic sclerosis has a major role 
in tissue injury pathogenesis. Our objective was to determine whether angiogenic 
biomarkers (vascular endothelial growth factor [VEGF], endoglin, and endostatin) 
are related to microvascular damage and to determine their predictive value for 
new digital ulcers (DU. The main outcome of the study was the occurrence of a 
new digital ulcer during 3-year follow-up. 
Methods: This prospective longitudinal study was performed between 
October 2011 and December 2014. Seventy-seven patients definitely diagnosed 
with systemic sclerosis where divided into two groups: those with active DU at 
baseline and those with no DU until enrollment. Patients were matched by sex 
and age with healthy controls. Serum levels of VEGF, endoglin, and endostatin 
were measured at enrollment, and several nailfold videocapillaroscopies were 
performed during the 3-year follow-up. 
Results: Serum levels of VEGF were lower (245.06: 158.68-347.33;p<0.001) 
and those of endoglin were higher (3.013: 1.463-7.023;p<0.001) in patients with 
active DU than those with no DU history (339.49: 202.00-730.93/ 1.879:  0.840-
3.280), and they were higher than those found in controls (178.030: 101.267-
222.102)/0.277:0.154-0.713) respectively. No differences in endostatin levels 
were found between groups (p=0.450). Endoglin was the only biomarker 
significantly different (p=0.031) between patients with diffuse versus limited 
systemic sclerosis and between early, active, and late patterns (p=0.020). VEGF 
was identified as an independent predictor for the development of new DU. 
Conclusion: Our study confirmed the relationship between angiogenic 
vascular biomarkers and the occurrence of DU. Endoglin and VEGF serum levels 
are potential risk factors, and VEGF has a predictive value for the occurrence of 
new DU. 
Keywords: systemic sclerosis, digital ulcers, VEGF, endoglin, endostatin, 
capillaroscopy. 
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INTRODUCTION 
Microvascular alterations are key features of systemic sclerosis (SSc). 
Disease outcome depends on extent and severity of vasculopathy, and frequently 
the earliest clinical symptoms are related to the peripheral vascular system (1). 
Raynaud phenomenon (RP) is the earliest clinical finding of SSc, and for 
many it is considered the first manifestation of disease. Initially RP has only 
functional implications, but repeated bouts lead to structural abnormalities and 
digital ischemia, which may progress to digital ulceration or, in extreme cases, to 
digital critical ischemia (2). 
Digital ulcers are a true burden for patients because they are very painful, 
heal slowly, carry high risks of infection, and are extremely disabling, leading to 
severe impairment of simple daily activities. In adults, 40% to 50% (3, 4) of 
patients experience at least one ulcer in the course of disease and of these, 31% 
to 71% will have recurrent ulcers (5). 
Endothelial cell (EC) injury results in disorganization of the EC layer favoring 
an early disorganized capillary architecture with loss of capillaries (1). In early 
disease stages enlarged, giant, meandering, ramified, and bushy capillaries occur 
in part as a result of EC injury and subsequent vascular remodelling (6). With 
disease progression, capillary loss might result from an uncompensated 
endothelial repair through angiogenesis and vasculogenesis, leading to reduced 
peripheral blood flow with consequent tissue hypoxia and formation of new blood 
vessels from the pre-existing microvasculature (6-8). 
Microvascular structural changes are easily assessed using nailfold 
videocapillaroscopy (NVC), a simple, non-invasive, inexpensive, and accessible 
tool. Capillaroscopic patterns are dynamic and probably reflect disease evolution 
and severity. Several qualitative, semi-quantitative, and quantitative indices have 
been proposed as predictors of organ involvement and, in particular, digital 
ulcers (DUs) (2). 
Angiogenesis, the creation of new blood vessels from pre-existing ones, 
depends primarily on the activation, proliferation, and migration of ECs and is 
driven by angiogenic stimuli that also induce proteolytic enzymes that cleave the 
extracellular matrix (9). It is tightly regulated by the balance between pro-
angiogenic and anti-angiogenic factors (8). This event is highly complex and 
requires a dynamic, temporal, and spatially regulated interaction between ECs, 
soluble angiogenic growth factors, and extracellular matrix molecules (9). 
Several studies have reported impaired angiogenesis in SSc, suggesting 
immune reactions to viral or environmental factors, reperfusion injury, or to anti-
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endothelial antibodies (10). Alternatively, it might be a consequence of an 
imbalance between angiogenic factors and angiostatic factors. 
Angiogenesis biomarkers have been extensively studied in SSc patients and 
investigated as possible putative biomarkers of organ involvement. Vascular 
endothelial growth factor (VEGF) is the most widely researched and understood 
angiogenic mediator; it is a potent angiogenic factor that stimulates migration, 
proliferation, and survival of ECs and endothelial pre-cursor cells (11). 
Distler et al. (8) found increased levels of VEGF in SSc patients without 
fingertip ulcers, suggesting it has a protective effect. Farouk et al. (12) also 
demonstrated a significantly higher serum VEGF level in patients in the early 
phases of SSc without digital ischemic manifestations when compared to those 
with ischemic manifestations. Avouac et al. (1) reported increased levels of VEGF 
in late phases of the disease, suggesting that its upregulation might be an 
insufficient compensatory mechanism to stimulate angiogenesis and an inverse 
correlation between capillary density and VEGF. 
Endoglin (CD105 or ENG) is a co-receptor for TGF-β predominantly 
expressed on cell surfaces of ECs. In SSc patients, this angiostatic biomarker has 
been measured and correlated primarily with pulmonary arterial hypertension. 
Wipff et al. (13) analyzed serum levels of sENG in SSc patients and found that they 
were higher in those with SSc with a vascular phenotype that integrates the 
presence of DUs. 
Endostatin is a C-terminal 20-kDa fragment of the basement protein 
collagen type XVIII that strongly inhibits angiogenesis and tumour growth by 
reducing EC proliferation and migration (14). Hebbar et al. (15) demonstrated 
greater endostatin serum levels in SSc patients than in healthy controls and 
greater mean endostatin concentrations in SSc patients with cutaneous ulcers or 
scars than in those without cutaneous ulcerations. Farouk et al. (12) found 
significantly higher levels of serum endostatin in the late stages of SSc in patients 
with ischemic manifestations. Distler et al. (8) found no association between 
endostatin levels and fingertip ulcers, but did find an association between 
endostatin levels and the presence of giant capillaries. 
We hypothesize that angiogenic biomarkers (VEGF, endoglin, and 
endostatin) reflecting disturbances of angiogenesis are related to microvascular 
damage objectified in NVC. Decreased angiogenic factors and/or increased 
angiostatic factors may be associated with the presence and development of new 
ischemic fingertip DUs during a 3-year follow-up of SSc patients. In this study, our 
primary outcome was the occurrence of a new DU during the 3-year follow-up. 
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PATIENTS AND METHODS 
Patients 
A prospective, longitudinal observational study was carried out between 
October 2011 and December 2014. Seventy-seven SSc patients (72 women; mean 
age 52.95 ± 12.6 years; range, 14-79) attending the Multidisciplinary Raynaud 
Clinics of the Clinical Immunology Unit at Centro Hospitalar do Porto in Portugal 
were followed. All patients fulfilled the 2013 classification criteria for SSc of 
American College of Rheumatology (16). According to the Leroy classification 
(17), 13 (16.9%) had diffuse SSc (dcSSc), and 64 (83.1%) had limited SSc (lcSSc). A 
group of 34 (sex and age matched) healthy controls were invited (29 women; 
mean age 47.1 ± 10.96 years; range, 23-66). They were non-obese and without 
self-reported cardiovascular risk factors (smoking, hypertension, diabetes, or 
hyperlipidaemia). No control was on vasoactive medications. Three patients died 
during the study period and were excluded. 
At enrolment, patients were divided into two groups. The DU group 
comprised 38 patients with an active ulcer at baseline, with or without a past 
history of DUs, (34 women; mean age 52.7 ± 14.8 years; range, 14-75). The 
naïve-DU group comprised 39 patients with no DU in the course of disease until 
inclusion (38 women; mean age 53.2 ± 10.3 years; range, 30-79). Onset of 
disease was defined as the first episode of RP. All patients were on vasodilators, 
either the calcium channel blocker nifedipine or the angiotensin II receptor 
antagonist losartan, and a washout of these drugs was done before inclusion in 
the study. 
This study was approved by the institutional review board (including Ethical 
for Health Committee of Centro Hospitalar do Porto). All patients signed informed 
consents before inclusion in the study. Data were collected by analysis of clinical 
file data and by clinical interview. 
 
Nailfold videocapillaroscopy 
Nailfold videocapillaroscopy was performed using a KK technology 
videocapillaroscope with a 200x magnification lens. The same operator 
performed all exams. 
With the patient in a quiet room at a controlled temperature (21ºC to 24ºC), 
the nailfold distal row capillaries of 8 fingers (2nd, 3rd, 4th, and 5th of both hands) 
were examined. 
Capillaroscopic findings were described according to the qualitative 
classification of scleroderma microangiopathy damage as proposed by Cutolo 
(18): early, active, or late pattern. The early pattern was characterized by the 
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presence of a small number of giant capillaries and microhemorrhages, no 
avascular areas, and a relatively well preserved capillary distribution. The active 
pattern was characterized by the presence of numerous giant capillaries and 
microhemorrhages, moderate capillary loss (20%-30%), and a mildly disorganized 
capillary architecture with few branched capillaries. The late pattern was 
characterized by a near-absence of giant capillaries and microhemorrhages, 
presence of extensive avascular areas (50%-70% capillary loss), presence of many 
branched and ramified bushy capillaries (neoangiogenesis), and a complete 
disorganization of the capillary array (18). 
 
Biomarkers 
Fasting venous blood samples were collected at enrollment into a serum 
tube and a tube containing sodium heparin (Vacuette; Greiner-Bio-One, Austria). 
Serum was allowed to clot at room temperature and then separated from the cells 
within 60 minutes and stored at -70ºC until analysis for endoglin, endostatin, and 
VEGF-A. 
VEGF assessment: Serum VEGF-A was measured using an enzyme-linked 
immunosorbent assay, (IBL International GMBH, Germany). The resulting values 
were reported in pg/mL. 
Endoglin and endostatin assessment: Serum endoglin and endostatin were 
measured using enzyme-linked immunosorbent assay, (Uscn; Life Science Inc., 
Wuhan). The resulting values were reported in ng/mL. 
 
Follow-up 
Ischemic digital fingertip ulcerations in the Stage 3 peripheral vascular 
category according to the Medsger Disease Severity scale (19) were considered to 
be DUs. 
When included in the study cohort, patients were seen on a regular basis at 
3 to 6 months intervals, as indicated by disease severity. The final observation 
was made in the fourth quarter of 2014. 
 
Outcome measures 
Our main objectives were to analyze the roles of angiogenic and angiostatic 
factors, to determine their associations with active ulcers at enrollment, and to 
establish whether they are predictors of developing new DUs during the 3-year 
follow-up period. 
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Statistical analysis 
For comparisons of normally distributed scale variables, we used unpaired 
or paired two-sided Student t tests or analysis of variance (ANOVA). In these 
cases, data were described using mean ± standard deviation. Normal distribution 
was tested using Q-Q plots. In cases of non-normally distributed variables, we 
used the non-parametric Mann-Whitney and Kruskal-Wallis tests, and data were 
described using median and interquartile interval (Q
1
-Q
3
), where Q
1
 represents the 
first quartile (corresponding to 25% of data) and Q
3
 represents the third quartile 
(corresponding to 75% of data). When using ANOVA, if homogeneity of variance 
was not satisfied, we used the Welch test. For comparing categorical variables, we 
used chi-square or Fisher exact probability tests. Predictors of digital ulcers were 
evaluated using univariate and multivariate logistic regression. We applied 
survival analysis to determine the probability of freedom from new DUs during 
the study period and evaluated the effects of VEGF, endoglin, and endostatin in 
that probability using the Kaplan-Meier method and the Cox regression. When p ≤ 
0.05, significance was recognized. Data were analysed using SPSS software 
(v.22.0, SPSS, Chicago, IL). 
 
RESULTS 
Study population 
Demographic and clinical characteristics are described in Table 4.4.1. 
Significant differences in the disease subset (p < 0.001) and capillaroscopic 
patterns (p < 0.001) were found between the DU and naïve-DU groups. The 
former predominantly showed the late pattern while the early and active patterns 
were more frequent in the latter. No differences were found in age, sex, disease 
duration (RP onset), or presence of auto-antibodies. 
The DU group had lower VEGF serum levels 245.06 (158.68-347.33) pg/ml(p 
< 0.001) and higher endoglin serum levels 3.013 (1.463-7.023) ng/ml (p < 0.001) 
compared to naïve-DU group 339.49(202.00-730.93)pg/ml/ 1.879(0.840-
3.280ng/ml). See Table 4.4.2. In contrast, patients with active DUs had higher 
serum levels of VEGF and endoglin when compared to the control group 
178.030(101.267-222.102)pg/ml/0.277(0.154-0.713ng/ml) respectively (p < 
0.001). No significant differences were found in endostatin levels between the 
groups (p = 0.450). See Fig. 4.4.1. 
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Variables DU (n=38) naïve-DU (n=39) p-value 
Age (years), mean ± SD (min-
max) 
52.7 ± 14.8 (14-75) 53.2 ± 10.3(30-79) 0.845d 
Gender women n(%) 34 (89.5) 38 (97.4) 0.2b 
dcSSc/lcSSc   0.001a,* 
Limited, n(%) 26 (68.4) 38 (97.4)  
Diffuse, n(%) 12 (31.6) 1 (2.6)  
Disease duration (years), 
Median (Q
1
-Q
3
) 
10.00 (5.00-23.00) 10.00 (7.00-20.00) 0.602c  
Onset of 1st ulcer (years), 
Median (Q
1
-Q
3
) 
5 (3-13.25) NA NA 
Autoantibodies    
ACA Positive, n(%) 22 (57.9) 27 (69.2) 0.301 a 
Anti-scleroderma-70 
Positive, n(%) 
12 (31.6) 6 (15,4) 0.093a 
Endoglin  ng/ml,  Median 
(Q
1
-Q
3
) 
3.013, (1.463-7.023) 1.879 , (0.84-3.28) 0.017c,* 
Endostatin  ng/ml, Median 
(Q
1
-Q
3
) 
0.695, (0.26-1.73) 0.429,  (0.16-0.8) 0.129c  
VEGF  pg/ml ,  Median (Q
1
-
Q
3
) 
245.06, (158.68-347.33) 339.49, (202.00-730.93) 0.009c,* 
NVC Pattern    
Early, n(%) 0 (0) 13 (33.3) < 0.001a,* 
Active, n(%) 11 (28.9) 22 (56.4)  
Late, n(%) 27 (71.1) 4 (10.3)  
Table 4.4.1: Comparison between DU and naïve-DU groups at enrolment. SSc: systemic sclerosis; DU: 
digital ulcer; dcSSc: diffuse systemic sclerosis subset; lcSSc: limited systemic sclerosis subset; ACA: 
autoantibody anti-centromere; NVC: nailfold Videocapillaroscopy; VEGF: vascular endothelial growth 
factor.  NA: non applicable; SD: standard deviation; Q: quartile.  a : Chi-Square test. b : Fisher’s Exact 
test.  c : Mann-Whitney test. d :  Student’s t test.  *: Statistical significance for a level of 5%. 
 Control naïve-DU group DU group p 
Endoglin ng/ml, 
Median (Q
1
-Q
3
) 
0.277, 0.154-0.713 1.879, 0.840-3.280 3.012, 1.462-7.022 <0.001a* 
Endostatin ng/ml, 
Median (Q
1
-Q
3
) 
0.565, 0.350-0.770 0.429, 0.160-0.770 0.695, 0.260-1.727 =0.450 
VEGF pg/ml, Median 
(Q
1
-Q
3
) 
178.030, 101.267-222.102 339.49202.00-730.93,  
245.060, 158.675-
347.327 
<0.001a* 
Table 4.4.2: Comparison of pro-angiogenic VEGF and angiostatic endostatin and endoglin between 
groups at enrollment.  DU: digital ulcer VEGF: vascular endothelial growth factor. Q: quartile. a : Mann-
Whitney test. *: Statistical significance for a level of 5%. 
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Figure 4.4.1: Serum levels of vascular endothelial growth factor (VEGF), endostatin and endoglin in 
77 SSc patients with and without digital ulcers (DU) compared to 34 healthy controls. Serum levels 
of Endoglin were increased in patients with DU  3.012(1.462-7.022) compared to controls 
0.277(0.154-0.713) and patients without DU 1.879(0.840-3.280) p<0.001. VEGF serum levels were 
increased in patients without DU 339.49 (202.00-730.93) p<0.001 suggesting that VEGF increased 
levels are protective for new DU development. No significative difference between groups regarding 
endostatin p=0.450. 
 
No significant differences were found between those classified with dcSSc 
and lcSSc in terms of VEGF (344,50: 267.54- 379.56/ 269.26: 192,74- 453,82 
pg/ml; p = 0.492) or endostatin (0.46: 0.28.1.70 / 0.53: 0.17- 1.07ng/ml; p = 
0.355). Endoglin serum levels were higher among those with dcSSc (3.21: 2.20-
17.51/ 2.06: 1.06- 3.96 ng/ml; p = 0.031). 
Endoglin levels were significantly different between those with early, active, 
or late pattern NVC (p = 0.020), but VEGF and endostatin levels were not (p = 
0.318 and p = 0.074, respectively). 
p<0.001 
p<0.001 
p=0.450 
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Using univariate logistic regression, baseline VEGF (p = 0.007) and endoglin 
(p = 0.028) were identified as risk factors for digital ulcers. Multivariate 
regression analysis confirmed both as independent risk factors for DU (p = 0.006 
and p = 0.028, respectively). 
 
Occurrence of a new DU during the 3-year follow-up 
In the 3-year clinical follow-up, 40 (51.95%) patients developed new 
ischaemic digital ulcers (Table 4.4.3). Those with dcSSc had significantly more 
new DUs (76.92%) than those with lcSSc (46.88%), p = 0.048. No differences in 
disease duration were found (p = 0.101). Median time to the occurrence of a new 
DU was 4.50 months (range, 1.25-16.25). 
 
 
 
Variables  DU (n=40) naïve-DU (n=37) p-value 
dcSSc/lcSSc    0.048a,* 
     Limited, n(%) 30 (75.0) 34 (91.9)  
 Diffuse, n(%) 10 (25.0) 3 (8.1)  
Disease duration  9.50 13.00 0.101d 
Median (Q
1
-Q
3
)  (4.25-20.00) (7.50-22.00)  
History of DU, n(%)  30(75.0) 8(21.6) <0.001a,* 
Time to new DU occurrence  4.50 NA NA 
Median (Q
1
-Q
3
)  (1.25-16.25)   
Autoantibodies     
ACA    0.464a 
 Positive, n(%) 26 (65.0) 22 (59.5)  
Anti-scleroderma-70     0.012a,* 
 Positive, n(%) 14 (35.0) 4 (10.8)  
NVC Pattern baseline     
 Early, n(%) 2 (5.0) 11 (29.7) 
 Active, n(%) 12 (30.0) 21 (56.8) 
 Late, n(%) 26(65.0) 5 (13.5) 
<0.001a,* 
Endoglin  2.57  2.14  0.153d 
Median (Q
1
-Q
3
)  (1.39-4.73) (1.03-3.33)  
Endostatin  0.695  0.429 0.142d 
Median (Q
1
-Q
3
)  (0.273-1.755) (0.16-0.77)  
VEGF  279.94  335.17  0.018d,* 
Median (Q
1
-Q
3
)  (142.37-360.29) (207.53-717.01)  
Table 4.4.3: Primary outcome: new digital ulcer occurrence during the 3-year follow-up. DU: digital 
ulcer; dcSSc: diffuse systemic sclerosis; lcSSc: limited systemic sclerosis; ACA: anti-centromere 
autoantibody; NVC: nailfold Videocapillaroscopy; VEGF: vascular endothelial growth factor.  a : Chi-
Square test; b : Fisher’s Exact test; c: Student’s t test;  d: Mann-Whitney test; *: Statistical significance 
for a level of 5%. 
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Using univariate analysis, VEGF was the only predictive risk factor identified 
for the occurrence of at least one new DU during the three-year follow-up (p = 
0.018). The Kaplan-Meyer analysis of freedom of DU for VEGF, endostatin, and 
endoglin is shown in Figs. 4.4.2 A-C. Those with low VEGF serum levels (< 422.47 
pg/mL) had significantly more DUs (p = 0.028) in the 3-year follow-up period. 
While not significant, a trend toward increased serum levels of endoglin 
(>4.215ng/mL) was associated with a new DU (p = 0.053). No predictive value 
was found for endostatin (p = 0.130). Multivariate Cox analysis confirmed low 
VEGF as an independent predictor for the development of new DUs (p = 0.002). 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.2 (A-C): Kaplan-Meier analyses of freedom from new digital ulcers in 36 months follow-
up of 77 systemic sclerosis patients. Curves are shown for: A - patients who had Endoglin serum 
levels ≥ 4.215 ng/ml or < than 4.215 ng/ml (p=0.05); B - patients who had Endostatin serum levels   
≤ 1.246 ng/ml or > than 1.246 ng/ml (p=0.130); C - patients who had VEGF serum levels   ≤ 422.47 
pg/ml or > than 422.47 pg/ml (p=0.028). 
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The VEGF (p = 0.024) and endoglin (p = 0.020) levels were significantly 
different between those with early or active patterns and those with late pattern 
NVCs. No difference was found in endostatin levels (p = 0.151). See Fig. 4.4.3. 
Only VEGF levels were significantly different (p = 0.027) between the DU and 
naïve-DU groups 267(134.570-357.302 vs 415.230(207.525-863.165) in terms of 
developing a new DU during the follow-up period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.2 (A-C): Kaplan-Meier analyses of freedom from new digital ulcers in 36 months follow-
up of 77 systemic sclerosis patients. Curves are shown for: A - patients who had Endoglin serum 
levels ≥ 4.215 ng/ml or < than 4.215 ng/ml (p=0.05); B - patients who had Endostatin serum levels   
≤ 1.246 ng/ml or > than 1.246 ng/ml (p=0.130); C - patients who had VEGF serum levels   ≤ 422.47 
pg/ml or > than 422.47 pg/ml (p=0.028). 
 
Analysing angiogenic and angiostatic serum baseline levels biomarkers and 
the progression of the capillaroscopy pattern during 3-year follow-up VEGF 
CHAPTER 4 | RESULTS 
136 | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
(p=0.024) and endoglin (p=0.020) had significant differences when comparing 
early/active to late pattern in NVC. No difference was found respecting endostatin 
(p=0.151) Figure 4.4.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.3: Serum levels of vascular endothelial growth factor (VEGF), endoglin and endostatin 
according to progression of nailfold capillaroscopic pattern in 3-year follow-up. VEGF (p=0.024) and 
endoglin (p=0.020) had significant differences when comparing early/active with late pattern in 
NVC. No differences were found relative to endostatin (p=0.151). 
 
When comparing patients with/without DU at enrolment with reference to a 
new DU development in the 3-year follow-up, only VEGF showed significant 
differences (p=0.027) in patients with an active ulcer at baseline 267 (134.570-
357.302 compared to patients with no DU until inclusion 415.230 (207.525-
863.165). 
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DISCUSSION 
Disparities seen in the results of various studies are likely the result of 
different SSc patient populations, disease stages, or clinical presentations as well 
as diverse organ involvement, non-uniform DU classification, and a small number 
of SSc patients in most clinical and investigational research cohorts. Furthermore, 
most of the studies were not designed to find predictable risk factors for DU on 
their own, but information and lessons may be learned from these publications. 
Our study shows that circulating levels of VEGF are increased in SSc patients 
with early or active NVC patterns and without DUs, suggesting it has a protective 
role against digital ulcers. Reduced VEGF levels in late NVC patterns suggest that 
ineffective angiogenesis may contribute to the avascular areas observed in this 
pattern, largely responsible for the ischemic territory underlying digital ulcers. 
This insufficient angiogenesis in the late pattern also might be related to 
increased levels of angiostatic factors, which are reportedly increased in the late 
stages of SSc (20). Another explanation is that a prolonged, uncontrolled, and 
chronic overexpression of VEGF in SSc may have a deleterious effect on the 
vascular network, resulting in a chaotic vascular morphology with reduced blood 
flow in the newly-formed vessels (1, 20). Our study was not designed to analyze 
any association between VEGF and capillary morphology, but our results 
confirmed those found by Distler et al. (8) and Farouk et al. (12), finding 
significantly higher serum VEGF levels in the early phases of the disease when 
digital ischemic manifestations are lacking. In contrast, Avouac et al. (1) reported 
increased levels of VEGF in the late pattern as well, suggesting that this 
upregulation might be an insufficient compensatory mechanism to stimulate 
angiogenesis and an inverse correlation between capillary density and VEGF level. 
We found similar levels of endoglin as that reported by Wipff et al. (13). 
Greater serum levels in patients with the SSc vascular phenotype were associated 
with the presence of digital ulcers. High levels of sENG in the sera of SSc patients 
highlight a possible contribution of this antiangiogenic protein in tSSc vascular 
disturbances. Greater serum levels of endoglin in the subset with dcSSc are 
expected, given the important profibrotic role of endoglin in SSc fibroblasts (21, 
22). 
Conflicting results have been reported regarding endostatin in SSc patients. 
Our results confirm those of Distler et al. (8), finding no association between 
endostatin levels and DU, yet this contrasts with results reported by Hebbar et al. 
(15) and Farouk et al. (12), who reported associations between endostatin and the 
presence of DU. Additionally, we identified greater endostatin serum levels in SSc 
patients than in the healthy controls, as did Hebbar et al. (15). Endostatin plays 
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an important role in microvascular changes and balance in SSc patients, and its 
actions are more probably mediated by several other angiostatic factors that 
remain to be identified. Larger observational studies are required to define the 
relathionships between angiostatic biomarkers, DUs, and other clinical 
manifestatins of vasculopathy in SSc patients. 
Limitations of this study are its small patient sample, all recruited from the 
same centre, and the number of patients with active DU at the time of enrollment. 
Additional longitudinal studies with larger cohorts are needed to validate 
predictive risk factors, thus enabling a better understanding of the progression of 
vascular damage and angiogenesis in the aetiology of DU. It would be interesting 
to study angiopoietins and VEGF-A isoforms and analyze their predictive roles. 
Angiopoietins are known to be involved in the development, remodelling, and 
stability of blood vessels (23). Altered expressions of Angiopoietin 1 (Ang-1), 
Angiopoietin 2 (Ang-2) (23), and Angiopoetin-like Protein 3 (ANGPTL3) (24) have 
been studied as biomarkers of SSc-related microangiopathy. Manetti et al. (25) 
described proangiogenic VEGF165 and antiangiogenic VEGF165b isoforms, 
finding the first evidence of a switch from proangiogenic to antiangiogenic VEGF-
A isoforms and their crucial roles in the defective angiogenic and vascular repair 
processes that characterize SSc. 
 
CONCLUSION 
Our study confirms the relationship between some angiogenic vascular 
biomarkers and the occurrence of DU and determines which of them could be 
predictors of these disabling complications of the disease. In SSc patients, 
reduced levels of VEGF, after an initial increase in the early stages of disease, 
independently predict development of new DUs. We identified a trend toward 
high serum endoglin levels as a predictor of DUs. Increased endoglin is present in 
dcSSc and the late NVC scleroderma pattern. We found that endostatin is not an 
independent risk factor for active DUs nor a predictor of the occurrence of new 
DUs. The molecular analysis of the vascular mediators associated with SSc, 
particularly with peripheral microangiopathy, may identify new therapeutic 
targets that lead to the prevention of further vascular injury or the improvement 
of SSc disease. 
 
Acknowledgments 
This study was partially supported by an investigational Grant from Centro 
Hospitalar do Porto. The authors thank Clinical Pathology Department for their 
valuable technical assistance. 
RESULTS | CHAPTER 4 
 PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | 139 
Conflict of interests:  
Ivone Silva: none 
Cristiana Almeida: none 
Andreia Teixeira: none 
José Oliveira: none 
Isabel Almeida: none 
Rui Almeida: none 
Carlos Vasconcelos: none 
 
REFERENCES  
1. Avouac J, Vallucci M, Smith V, Senet P, Ruiz B, Sulli A, et al. Correlations between angiogenic factors and 
capillaroscopic patterns in systemic sclerosis. Arthritis research & therapy. 2013;15(2):R55. 
2. Silva I, Almeida J, Vasconcelos C. A PRISMA-driven systematic review for predictive risk factors of digital 
ulcers in systemic sclerosis patients. Autoimmunity reviews. 2015;14(2):140-52. 
3. Herrick AL. Management of Raynaud's phenomenon and digital ischemia. Current rheumatology reports. 
2013;15(1):303. 
4. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: 
demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine. 
2002;81(2):139-53. 
5. Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S, et al. Digital ulcers in scleroderma: staging, 
characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford, England). 
2010;49(7):1374-82. 
6. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Current 
rheumatology reports. 2012;14(1):56-63. 
7. Lambova SN, Muller-Ladner U. Capillaroscopic pattern in systemic sclerosis - an association with dynamics of 
processes of angio- and vasculogenesis. Microvascular research. 2010;80(3):534-9. 
8. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al. Angiogenic and angiostatic 
factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the 
earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis research. 
2002;4(6):R11. 
9. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M. Mechanisms of vascular damage in SSc--implications for 
vascular treatment strategies. Rheumatology (Oxford, England). 2008;47 Suppl 5:v18-20. 
10. Serrati S, Chilla A, Laurenzana A, Margheri F, Giannoni E, Magnelli L, et al. Systemic sclerosis endothelial 
cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor 
(CCN2)/transforming growth factor beta-dependent mesenchymal-to-mesenchymal transition. Arthritis 
Rheum. 2013;65(1):258-69. 
11. Distler JH, Strapatsas T, Huscher D, Dees C, Akhmetshina A, Kiener HP, et al. Dysbalance of angiogenic and 
angiostatic mediators in patients with mixed connective tissue disease. Annals of the rheumatic diseases. 
2011;70(7):1197-202. 
12. Farouk HM, Hamza SH, El Bakry SA, Youssef SS, Aly IM, Moustafa AA, et al. Dysregulation of angiogenic 
homeostasis in systemic sclerosis. International journal of rheumatic diseases. 2013;16(4):448-54. 
13. Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, et al. Disturbed angiogenesis in systemic 
sclerosis: high levels of soluble endoglin. Rheumatology (Oxford, England). 2008;47(7):972-5. 
14. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of 
angiogenesis and tumor growth. Cell. 1997;88(2):277-85. 
15. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating 
angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000;43(4):889-93. 
16. Committee SfSCotARADaTC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). 
1980;23:581–90. 
17. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., et al. Scleroderma (systemic 
sclerosis): classification, subsets and pathogenesis. The Journal of rheumatology. 1988;15(2):202-5. 
18. Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. Best practice & research Clinical rheumatology. 
2008;22(6):1093-108. 
19. Medsger TA, Jr., Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for 
systemic sclerosis: development and testing. The Journal of rheumatology. 1999;26(10):2159-67. 
CHAPTER 4 | RESULTS 
140 | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
20. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular 
endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic 
sclerosis. Circ Res. 2004;95(1):109-16. 
21. Coral-Alvarado PX, Garces MF, Caminos JE, Iglesias-Gamarra A, Restrepo JF, Quintana G. Serum endoglin 
levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. 
International journal of rheumatology. 2010;2010. 
22. Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P, et al. Endoglin promotes TGF-beta/Smad1 
signaling in scleroderma fibroblasts. Journal of cellular physiology. 2011;226(12):3340-8. 
23. Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowska D. Angiopoietins-1 and -2 
are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are 
associated with greater severity and higher activity of the disease. Rheumatology (Oxford, England). 
2011;50(4):746-55. 
24. Ichimura Y, Asano Y, Akamata K, Aozasa N, Noda S, Taniguchi T, et al. Serum Angiopoietin-like Protein 3 
Levels: Possible Correlation with Progressive Skin Sclerosis, Digital Ulcers and Pulmonary Vascular 
Involvement in Patients with Systemic Sclerosis. Acta dermato-venereologica. 2013. 
25. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Impaired angiogenesis in systemic sclerosis: the 
emerging role of the antiangiogenic VEGF(165)b splice variant. Trends in cardiovascular medicine. 
2011;21(7):204-10. 
 
RESULTS | CHAPTER 4 
 PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | 141 
 
CHAPTER 4 | RESULTS 
142 | PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON 
Manuscript published in Clin Exp Rheumatol. 2015 Sep-Oct;33 Suppl 91(4):127-
130. Epub 2015 Aug 5 
 
Predictive value of vascular disease biomarkers for digital ulcers in systemic 
sclerosis patients 
 
Ivone Silva1*, Andreia Teixeira2, José Oliveira3, Isabel Almeida4, Rui Almeida5, 
Carlos Vasconcelos6 
 
1. MD, Angiology and Vascular Surgery Service and Clinical Immunology Unit, 
Centro Hospitalar do Porto, Portugal  
2. PHD, Health Information and Decision Sciences Department - Universidade do 
Porto; CINTESIS - Centre for Research in Health Technologies and Information 
Systems Porto, Portugal  
3. MD, Clinical Pathology Department, Clinical Chemistry, Centro Hospitalar do 
Porto, Portugal  
4. MD, Clinical Immunology Unit, Centro Hospitalar do Porto, Portugal 
5. MD, Angiology and Vascular Surgery Service 
6. MD, PHD, Clinical Immunology Unit, Centro Hospitalar do Porto; Instituto de 
Ciências Biomédicas Abel Salazar, University of Porto. Multidisciplinar Unit of 
biomedical investigation, Porto, Portugal  
 
 
 
RESULTS | CHAPTER 4 
 PERIPHERAL MICROVASCULAR COMPLICATIONS IN PATIENTS WITH RAYNAUD PHENOMENON | 143 
4.5 PREDICTIVE VALUE OF VASCULAR DISEASE BIOMARKERS FOR 
DIGITAL ULCERS IN SYSTEMIC SCLEROSIS PATIENTS 
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4.6 ENDOTHELIAL DYSFUNCTION AND NAILFOLD 
VIDEOCAPILLAROSCOPY PATTERN AS PREDICTORS OF DIGITAL 
ULCERS IN SYSTEMIC SCLEROSIS: A COHORT STUDY AND REVIEW 
OF THE LITERATURE 
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CHAPTER 5 | DISCUSSION 
With this observational cohort study, it was our main aim to answer the 
following research questions: 
 
i. Is endothelium-dependent flow-mediated dilatation an early diagnostic tool 
for severe peripheral vascular complications in patients with RP?  
ii. Can a qualitative “scleroderma pattern” or semi-quantitative 
“microangiopathy evolution score” identify patients at risk for DU? 
iii. Can serum levels of endothelial dysfunction (ET-1 and ADMA) and 
angiogenesis (VEGF, endostatin, and endoglin) biomarkers identify patients 
at risk for DUs? 
iv. What are the predictive roles of all these variables? 
 
We will discuss our results in 3 sections: 
 
5.1 Comparison between Primary and Secondary Raynaud patients  
5.2 Peripheral ischemic vasculopathy in patients with SSc-associated SRP 
a. Risk factors  
b. Predictive factors for new DU events 
i. DU Recurrence  
ii. First DU episode in the 3-year clinical follow-up 
c. Protective factors 
5.3 Overall considerations 
 
The presence of RP and the loss of normal regulation of cutaneous vascular 
tone predict the underlying disease in RP patients (1). RP occurs in almost all SSc 
patients and is usually the first sign of the disease. Compelling clinical and 
biological evidence suggests that the primary target for both initiating and 
propagating the disease is the blood vessel, from the very early onset of the 
disease through late clinical complications (2). Indeed, RP and morphological 
changes in nailfold capillaroscopy may occur months or even years before the 
onset of disease, suggesting a crucial role of the microangiopathy in the overall 
disease process (3). 
It has been suggested that RP in SRP patients may be triggered by 
endothelial injury.  The exact mechanism for the initial endothelial injury is 
unknown, but apoptosis induced by infection, immune-mediated cytotoxicity, 
anti-endothelial cell antibodies, and ischemia-reperfusion injury have all been 
implicated (2).  
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Vascular insufficiency from a progressive obliteration of both small arteries 
and microvessels is associated with a state of chronic tissue hypoxia (4). 
Recurrent RP episodes of ischemia-reperfusion injury to skin and other organ 
systems may contribute to tissue fibrosis, organ dysfunction, and significant 
morbidity and mortality. A number of patients with SSc exhibit the severe 
consequences of this vascular disease with catastrophic events, such as digital 
ischemia with ulceration, gangrene and amputation, scleroderma renal crisis, or 
pulmonary arterial hypertension; these jeopardize patients’ quality of life (5, 6).  
The nutritional skin flow of fingers is linked to the integrity of the 
microvasculature, which consists of a superficial subpapillary plexus, a profound 
cutaneous plexus, and interconnections between these 2 plexuses. These so-
called arteriovenous anastomoses (AVA) enable a fast increase or decrease of 
blood flow through the skin to regulate the body temperature. The AVA are 
innervated by the autonomous nervous system (a2c adrenergic receptors). In the 
fingers of patients with SRP, the absence of a correlation between skin perfusion 
and digital arterial flow is due to microvascular damage (giant capillaries, 
disorganization of the normal capillary array, avascular areas) and AVA shunts. In 
SSc, microvascular damage is responsible for the baseline digital blood flow 
reduction, while the AVA may be the main, but not exclusive, factor in controlling 
the digital blood flow during a cold stimulus. Therefore, local factors are also 
involved in the regulation of digital blood flow during a cold stimulus (7). 
 The development of DUs is a frequent and early complication in SSc. 
Surveys shows that up to 75% of patients will have their first DU episode within 5 
years after their first non-RP symptom, and 30% of patients will experience DU 
complications each year. In extreme cases, DUs lead to the loss of a digit as a 
consequence of infection and/or associated macrovascular disease. DUs have a 
significant impact on the quality of life and the cost of patient care (2). 
Several reports have identified different risk factors associated with DUs. 
Different disease subset cohorts, variable disease duration, sample size, and the 
risk factors analysed all might contribute to the different reported results. In our 
PRISMA-driven review of predictable factors for DUs, dcSSc, early onset of RP, 
early first non-RP symptom, high Rodman’s skin scores, and anti-scleroderma-70 
positive autoantibodies were considered strong predictors of DUs.  
Currently, there are no biological measurements (biomarkers) to assess 
subclinical vascular activity in patients with SSc, and therefore the clinician often 
does not detect the disease until a late and irreversible stage (8). Additionally, 
until now, no therapy has been able to modify vasculopathy disease evolution and 
progression in SSc-associated SRP patients (9).  
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5.1 COMPARISON BETWEEN PRIMARY AND SECONDARY RAYNAUD 
PATIENTS  
This is the first study that demonstrates that both endothelial dysfunction 
and an angiogenic stimulus are both already present in PRP. Increased serum 
levels of ET-1 and vascular endothelial growth factor (VEGF) might be a response 
to the repeated bouts of vasospasm. Our investigation revealed some new and 
useful information: i) an increased vasoconstrictor status due to increased serum 
levels of ET-1 is observed in PRP, although endothelial NOS inhibitor (ADMA) is 
not affected, suggesting overproduction of vasoconstrictors. No differences in 
endothelial nitric oxide (NO)-dependent FMD were observed between PRP and 
controls; ii) increased peripheral resistance, low FMD response to shear stress, 
and a high RI are features of SRP, mostly likely as a consequence of irreversible 
EC injury; iii) severe obliterative peripheral vasculopathy is present only in SRP 
patients with DU; and iv) patients with SRP and DU have an impaired angiogenic 
response to chronic ischaemia.  
Different mechanisms induce and perpetuate endothelial dysfunction and 
progressive vasculopathy in SSc-associated SRP patients. Among these, 
dysregulation of vascular tone (a consequence of an imbalance between 
vasoconstrictor and vasodilator mediators), defective angiogenesis, endothelial 
injury/activation elicited by the activation of innate and adaptive immune 
response, and functional defects of progenitor endothelial cells have been 
advocated as the main pathogenic mechanisms underlying endothelial damage in 
SSc (10). Moreover, chronic endothelial cell perturbation and activation induced 
by ischemia and reperfusion lead to dysfunction and an irreversible loss of 
integrity, with cell detachment and tissue injury, which constitute a major 
stimulus for increased expression of VEGF and abnormal angiogenesis (10). A 
recent study has shown that the anti­angiogenic VEGF isoform VEGF165b is 
overexpressed in SSc (9). This finding could explain, at least in part, the marked 
attrition of microvessels (11). 
Angiogenic biomarkers have not been extensively investigated in PRP. As in 
the studies of Distler et al. (12) and Farouk et al. (13), our study confirms 
increased VEGF in SSc-associated SRP patients, but increased VEGF serum levels in 
PRP have not been reported. Conflicting results and the lack of a sufficient 
response to hypoxia and the consequent vascular changes in SSc might be 
explained by impairment of mechanisms that are differently mediated by 
angiogenic or angiostatic factors (14).  
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5.2 PERIPHERAL ISCHEMIC VASCULOPATHY IN PATIENTS WITH 
SYSTEMIC SCLEROSIS-ASSOCIATED SECONDARY RAYNAUD 
PHENOMENON 
 
a. Risk factors  
No major differences were observed between SSc-associated SRP patients, 
PRP patients, and the control group regarding age, gender, mean arterial 
pressure, and total cholesterol.  
Concerning macrovascular disease evaluation, the Allen test was negative in 
all control patients and in 94.4% of PRP patients. SRP patient groups were 
different: patients with DU tested positive 75% of the time, whereas only 19.4% of 
DU-naïve SSc patients tested positive. This suggests an important role for 
macrovascular disease in the pathogenesis of the ischemic peripheral vascular 
lesions, and we propose the Allen test as a simple screening tool for DU risk 
assessment.  
Endothelium-dependent responses to various pharmacological 
(acetylcholine/bradykinin) and physical (shear stress) (15) stimuli have been 
described as important research tools to evaluate endothelial function.  
Several vasodilators (NO, PG2, ET-1 (16), and EDHF (17)) are released in 
response to increased shear stress, but their physiological importance is 
unknown. NO has been widely used as a clinical marker of endothelium function, 
determined by measuring the vasomotor response. The magnitude of the shear 
stress created with reactive hyperaemia is influenced by several factors, such as 
baseline diameter (18), age (19), sex (19, 20), cuff position (21), occlusion 
duration (22), and addition of ischemic exercise (23). Several reports with 
guidelines have been published, but the rationales of the critical conditions to 
induce a reliable NO-dependent response are still undefined (24).    
Comparing the results of FMD across studies is troublesome. The absolute 
mean FMD varies among studies, from between -1.9 to 19.2% (25). These 
differences may be due to different study populations, risk profiles, measurement 
techniques, and probable non-compliance with FMD recommendations and 
guidelines.  
In our study, baseline artery diameter was similar between groups. FMD% 
was significantly lower in patients with active DU than in all other groups. No 
correlation was found between FMD and disease duration (since the first RP 
episode). Regarding qualitative nailfold videocapillaroscopy (NVC) patterns, FMD 
was significantly lower in the late pattern than in the active and early patterns; no 
differences were found between the active and early patterns. Our data reveal 
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that severe vascular disease with EC injury and capillary dropout are strong 
contributors for the impaired endothelium-dependent FMD response. 
All RP patients had significantly decreased basal state PSV compared to the 
control group, with no differences between patients with and without DU. After 5 
minutes of brachial artery occlusion, PSV, and EDV were significantly reduced in 
active DU patients compared to all other groups. The Resistance Index (RI) was 
increased in active DU patients but was not significantly different in DU-naïve 
patients.   
PSV and EDV capillaroscopic patterns were significantly different from each 
other. We describe a successive decrease of PSV and EDV from early to late 
patterns.  Vascular resistance, measured by RI, increased progressively with the 
worsening of microvascular damage and progression of the capillaroscopic 
pattern. This is the first study that analyzed FMD and MES.  A decrease of FMD 
with progression of MES was observed; MES ≥ 7 had significantly lower FMD 
values.   
These data support overall microvascular and macrovascular dysfunction in 
RP patients and are in accordance with several previous studies. Patients with DU 
had a worse response to a shear stress stimulus than other groups. In proper 
palmar digital arteries (PPDA), blood flow is reduced and the RIs increase with 
progression of structural alterations of microvasculature (26); skin perfusion is 
maintained through compensatory mechanisms of microcirculation, both 
functional and structural (autonomous nervous system, arteriovenous 
anastomoses, neoangiogenesis) in the active pattern but not in the late pattern 
(7). In SSc patients, vessel fibrosis and calcification may reduce vascular 
compliance and affect NO signalling by limiting vascular stretch due to arterial 
stiffness (27). Anderson et al. (28) described endothelium dysfunction in SSc 
patients as a result of inflammation with a correlation between plasmatic markers 
of endothelium inflammation and brachial artery wall stiffness.  
Several studies previously reported macrovascular disease in SSc patients: 
reduced FMD and increased carotid IMT (29), reduced FMD and normal IMT (30), 
reduced FMD and increased artery stiffness (31), and lower FMD in dcSSc patients 
(29, 31). Controversial results were also published regarding FMD and non-
endothelium-dependent nitro-glycerine mediated dilatation (NMD) in SSc patients: 
reduction of FMD and NMD (29, 31, 32); only reduction of FMD (27, 33); 
reduction of FMD and preserved NMD (30); and similar FMD and NMD (28, 34). 
As in other studies, we conclude that structural macrovascular damage is 
present in our SRP group and that it progresses with worsening of SSc 
microangiopathy. 
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Vascular biomarkers of endothelial dysfunction have been extensively 
studied in SSc patients. Increased levels of ET-1 are associated with endothelial 
dysfunction. ET-A receptor antagonists improve FMD in patients with endothelial 
dysfunction and in patients with elevated ET-1.  Small or absent responses of FMD 
may be due to high levels of ET-1 with consequent endothelial dysfunction (16). 
 Our study has identified high serum levels of ET-1 and ADMA as 
independent risk factors of DU in patients, consistent with previous reports that 
reported increased serum ET-1 levels in patients with DU (35-38) and one (39) 
described no association between ET-1 serum levels and DU, suggesting major 
roles for ET-1 in vascular dysfunction and disease through vasoconstrictive 
effects and in vessel remodeling, ultimately leading to major changes in cellular 
and tissue architecture (40).  
SSc serum significantly reduces NO synthase activity in vitro, paralleled by 
decreases in intracellular cGMP and NO production in the cell medium, 
suggesting the presence of a factor that inhibits NOS (41). NO has vasodilating 
effects on vessels, inhibits the thrombogenicity and proliferation of vascular 
muscle cells, and has an important role in regulation of blood flow and 
maintenance of normal vascular wall structure (41). The loss of NO, the hallmark 
of endothelial dysfunction, is an attractive possibility as an overall mechanism for 
the pathogenesis of RP, since perturbations in the NO pathway may have 
pleiotropic effects on multiple effector pathways that may be relevant in RP, 
including ET-1 (42). Increased levels of the circulating endogenous inhibitor of 
NOS, ADMA, have been reported by Doodley et al. (43) in dcSSc and by Blaise et 
al. (44) in SSc, reflecting abnormal NO regulation and/or contribution to 
endothelial dysfunction in SSc. A novel finding in this study was elevated ADMA in 
patients with SRP and DU, compared to all other groups. 
As a research tool, qualitative and semi-quantitative capillaroscopic scoring 
has an indisputable value, but it has not yet found its way into day-to-day clinical 
practice (45). Several scores have been described. In our research, we adopted 
the qualitative classification of “scleroderma pattern” proposed by Cutolo (46) 
and a semi-quantitative score validated by Sulli et al. that paralleled the evolution 
of microangiopathy in SSc, although there is no reference to its association with 
DU (47).  
Significant differences were found between the SSc DU and SSc non-DU 
groups regarding qualitative evaluation: the late pattern was the most frequent 
pattern in DU patients (71.1%), whereas early and active patterns were the most 
representative patterns in non-DU patients (33.3% and 56.4%, respectively). 
Significant differences were related to the disease subset: patients with diffuse 
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disease predominately had late pattern disease (76.9%), whereas those with 
limited disease predominately had active pattern disease (46.9%). Concerning 
semi-quantitative MES scores, significant differences were observed, as the MES 
score was higher in the DU group than the DU-naïve group.  
We conclude that capillaroscopy has great value in identifying high-risk 
patients, as demonstrated by qualitative and semi-quantitative assessments. 
These results are in accordance with other studies that report late NVC pattern, 
disorganization of microvascular array with loss of capillaries, and worsening of 
capillaroscopic pattern as risk factors for DU occurrence (48-50).  
We considered the MES score, FMD, ET-1, ADMA, telangiectasia presence, 
NVC pattern (markers of endothelial dysfunction and microvascular damage), the 
Allen test (macrovascular disease), and disease subset to be potential predictors 
of DU. Univariate analysis identified higher MES scores, increased serum levels of 
ET-1, positive Allen Tests, telangiectasia, late capillaroscopic patterns, and dcSSc 
as risk factors for new DUs. Higher FMD% values indicated protection from new 
DUs.  
When all of these variables were included in a logistic regression, only the 
MES score (2<MES≤6, HR 428.44, 95% CI 4.36 to 4.21E4), FMD (5.7%<FMD≤9.5% 
HR 0.005, 95% CI 0.00 to 0.59) and positive Allen test (HR 71.64 95% CI 2.75 to 
1.87E3) remained significantly associated with DU. We then analysed the 
combined effect of these 3 variables to build a clinical model that predicted DU. 
Thus, we created a score reflecting the sum of these risk variables that were 
present in each patient (MES>2, FMD≤5.7%, and positive Allen test). When 
considering the 3 variables, all patients with 2 or more risk factors had DU. When 
considering only simple day-to-day office tools (MES and Allen test), patients with 
1 risk factor had a 75% chance of a new DU; all patients with 2 variables had a 
new DU. 
Tissue ischemia and hypoxia are usually the main triggers for angiogenesis 
via the upregulation of pro-angiogenic factors, which then initiate angiogenic 
sprouting from pre-existing microvessels by: i) inducing vasodilation, 
proliferation, and migration of endothelial cells; ii) invasion of the surrounding 
extracellular matrix by endothelial cells; and iii) formation and stabilization of the 
vascular lumen of newly formed capillary vessels. However, despite the loss of 
microvessels in multiple vascular beds, compensatory angiogenesis is 
deregulated, insufficient, and does not allow vascular recovery in the disease 
course (9). 
The functional role of angiogenic mediators in DU pathogenesis is poorly 
understood. Among the pro-angiogenic factors, VEGF-A (also referred to as VEGF) 
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is considered one of the most potent regulators of physiologic and pathologic 
angiogenesis and is overexpressed in most angiogenic conditions (9). 
Surprisingly, several studies published during the past decade have shown that, 
despite the lack of angiogenesis, VEGF-A expression is markedly increased both 
in the skin and in the circulation of patients with SSc (12, 51, 52). 
Our cohort study found no significant differences regarding VEGF 
biomarkers between the control, PRP, and DU-naïve SSc groups. Our results are in 
accordance with those of Distler et al. (52) and Farouk et al. (13), whose data 
suggest a functional deficit of VEGF in SSc patients, which can be overcome if the 
levels of VEGF exceed an individual threshold. 
Increased VEGF serum levels were present in SSc patients with early/active 
NVC pattern and without DUs, suggesting a protective role of increased serum 
values of VEGF with respect to DUs.  Reduced VEGF levels in the late pattern 
suggest that ineffective angiogenesis may contribute to the avascular areas 
observed in this pattern, largely responsible for the ischemic territory underlying 
DUs. This insufficient angiogenesis might be related to increased levels of 
angiostatic factors that were reportedly increased in the late stages of SSc (53). 
Another explanation is that a prolonged, uncontrolled, and chronic 
overexpression of VEGF in SSc may have a deleterious effect on the vascular 
network, resulting in a chaotic vascular morphology with reduced blood flow in 
the newly formed vessels (53, 54). Avouac et al. (54) reported increased levels of 
VEGF in the late pattern, suggesting that this upregulation might be an 
insufficient compensatory mechanism to stimulate angiogenesis and 
demonstrated an inverse correlation between capillary density and VEGF.  
Regarding angiostatic biomarkers, our research had similar results as those 
reported by Wipff et al. (55). Serum etonogestrel levels were higher in patients 
with the SSc vascular phenotype associated with the presence of DU, highlighting 
a possible contribution of this antiangiogenic protein in SSc vascular 
disturbances. We failed to identify increased serum levels of endostatin in SSc 
patients, similar to Hebbar et al. (56) and Farouk. et al. (13). Endostatin plays an 
important role in microvascular changes and balance in SSc patients, and its 
actions are likely mediated by other several angiostatic factors that remain to be 
identified. Larger observational studies are required to define the relationship 
between angiostatic biomarkers and DUs or other manifestations of vasculopathy 
in SSc patients. 
In summary, low FMD%, increased serum levels of ET-1, ADMA, and 
endoglin, and low VEGF serum levels were risk factors for DU episodes. 
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We failed to identify an association between DU and ACA autoantibodies, 
anti-Scl70, AFA, anti-PM-Scl, anti-NOR 90, and anti-RNA-polymerase. A trend 
towards an association between positive Anti-Ro52/TRIM21 and DU was verified. 
These antibodies can be detected across a number of autoimmune diseases with 
significant prevalence, but their clinical relevance remains controversial. 
Additional studies with more SSc patients with DUs are needed to identify specific 
autoantibodies as possible risk factors for DU. 
 
b. Predictive factors for new DU events 
In our study, new DU incidence was similar to the placebo group of the 
RAPIDS-1 study (57) (55.8%/61%). The diffuse disease subset had proportionally 
more new DUs (76.92%) compared to the limited SSc subset (46.88%) (p=0.048). 
No differences were found regarding disease duration between the new DU and 
DU-naïve groups. The median time to the occurrence of a new DU event in study 
period was 4.50 (1.25-16.25) months.   
The risk factors for the development of a new DU in the study period were a 
previous history of DU, anti-scleroderma-70 autoantibody, telangiectasia, NVC 
late pattern, high MES score, low FMD%, a positive Allen test, and increased ET-1, 
VEGF, and endoglin serum levels. Multivariate Cox analysis confirmed MES score, 
FMD, and ET-1, ADMA, and VEGF serum levels as independent predictors of the 
development of a new DU.  
Because the two groups studied were very different (active DU vs. DU-naïve) 
in a variable that could affect the main outcome (occurrence of DU during 3-year 
clinical follow-up) and was, by definition, a source of potential bias, we checked 
the incidence of ulcer recurrence and, in ulcer-naïve patients, the first DU episode 
in the study period, analysing their predictive value.  
 
i) DU Recurrence  
Of the 38 SSc patients with active DU at beginning of the study, 30 (79%) 
had at least one DU recurrence during the 3-year course of this investigation. 
Predictor factors of DU recurrence were: FMD>9.41%, ET-1 >11.85 pmol/L, and 
late NVC pattern. Kaplan-Meier analyses of freedom from the DU recurrence 
showed that the median values of FMD, ET-1, and qualitative scleroderma 
patterns in NVC were significantly associated with new episodes of DU. 
Multivariate Cox regression confirmed ET-1 and late NVC pattern as independent 
predictors of DU recurrence.  
Endothelial dysfunction assessment in SSc patients has had controversial 
results in the literature. Although not always available, FMD may be, in the near 
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future, a screening prognostic tool for vasculopathy in SSc patients. Most of the 
studies were not designed to analyse the relationship of FMD with DU. In our 
study, patients with DU recurrence had a reduced vasodilatation response to the 
increased shear stress. Values of FMD lower than 9.5% predicted DU recurrence, 
suggesting that impaired FMD might be an alert trigger for peripheral 
vasculopathy. 
Additionally, ET-1 serum levels > than 11.9 pmol/ml were a risk for new DU 
in the 3-year follow-up and an independent predictor of DU recurrence. These 
findings are consistent with previous reports that suggest that ET-1 plays a major 
role in vascular dysfunction and vascular disease through vasoconstrictive effects 
and is an important mediator in vessel remodeling, which ultimately results in 
major changes in cellular and tissue architecture (40). Capillaroscopy may be the 
most useful tool for targeting patients at risk for DU episodes. Patients with late 
pattern disease are closely monitored for alert signs for peripheral ischemic 
lesions. 
 
ii) First DU episode in the 3-year clinical follow-up 
Our research study identified late NVC pattern as the main alert sign for first 
DU occurrence.  Kaplan-Meier analyses of freedom from the occurrence of DU 
event strengthen these results.   
VEGF serum levels in these patients were half of the corresponding values of 
SSc patients without a DU in overall disease course, although not significant. This 
might be due to a small number of patients, ten, that developed a first DU event 
in the study period. Considering that only a small increase in VEGF protein results 
in efficacious new vessel formation in a variety of animal models and that 
angiogenesis is regulated by a balance of angiogenesis inducers and inhibitors, 
possible explanations for insufficient angiogenesis in SSc include a blockade of 
the biologic effects of VEGF by one or more angiostatic factors (52). Although 
other reasons, such as signaling defects or lack of VEGF receptors, cannot be 
excluded, this hypothesis is strongly supported by the fact that patients without 
fingertip ulcers showed highly elevated serum VEGF concentrations. A further 
increase of VEGF might be a therapeutic option for SSc patients with fingertip 
ulcers. In fact, encouraging animal studies led to clinical trials using recombinant 
VEGF or gene therapy in patients with different ischemic diseases. In a phase I 
study with recombinant VEGF165 in patients with coronary ischemia, the therapy 
was safely tolerated and resulted in improved perfusion and collateralization in a 
subset of patients (52). 
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The process of angiogenesis appears to be largely impaired in SSc, following 
the profound disarrangement of the microcirculation. The damage of the vessels 
evolves progressively from the early to late stages and is characterized by 
different morphological aspects (52). The fact that baseline NVC patterns are 
associated with future severe disease may be one of the first steps in positioning 
capillaroscopy as a welcome biomarker for the disease (50). 
 
c) Protective factors 
Median SSc disease duration in DU-naïve patients (n=29) was similar to the 
subpopulation of SSc patients that had at least one DU (n=48) in the study period. 
These DU-naïve SSc patients were largely lcSSc and anti-scleroderma 70 negative. 
They also presented less peripheral vascular impairment; fewer patients had 
telangiectasia and most were Allen test negative. These results were 
strengthened by a good response to shear stress with higher FMD%. They 
exhibited lower serum levels of vasoconstrictive ET-1, increased ADMA, and VEGF 
serum levels. The late scleroderma pattern was only present in one of the 
patients (3.4%).  
Values of FMD greater than 9.5% associated with protection from DU, 
suggesting that impaired FMD might be an alert trigger for peripheral 
vasculopathy. 
Vascular biomarkers, if not expensive and unavailable in daily clinical 
practice, could be a good predictor tool for new DU occurrence. 
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5.3 OVERALL CONSIDERATIONS 
 
There are some epidemiological, cross-sectional, and cohort studies that 
investigated potential predictors of DU in SSc patients, but additional studies are 
needed to ascertain the existing evidence in order to make the currently-available 
information more profitable. 
To our knowledge, this is the first study that simultaneously analysed 
macro- and microvascular disease, endothelial dysfunction, and angiogenesis 
markers as risk factors for DU and identified their predictive roles for new 
ischemic events. The prospective design of the study, with a clear definition of 
the protocol, a thorough data collection by a single, trained doctor, no missing 
data per item, and a complete follow-up of all patients in the 3-year period, 
minimized information bias. 
Although it’s a single-centre study with a restricted number of patients in 
each group, limited by the number of patients with active DU at time of 
enrolment, the variables we found were clinically significant and relevant, and 
some can be performed in daily clinical practice. This research enriches previous 
reports through its prospective design, with robust behaviour (AUC) in most of 
the vascular biomarkers and in the morphological and functional parameters 
analysed.  
There are some limitations that should be identified: 
1. We did not perform endothelium-independent shear stress evaluations. 
2. We did not study morphology and blood flow of the proper palmar digital 
arteries (PPDA) and their relationship with NVC. 
3. We did not study skin blood perfusion and digital arteries’ pulsatility by 
Laser Doppler Perfusion Imaging (LDPI) and photoplethysmography (PPG). 
4. Carotid artery intimal / medial thickness as an arterial stiffness parameter 
was not evaluated, as these tools have been extensively studied as a 
prognostic indicator of accelerated atherosclerosis, which was not our aim. 
 
The principal biases of our study were that a small number of men and 
patients with dcSSc were included. 
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5.4 CONCLUSIONS AND FURTHER RESEARCH 
 
The results of the this cohort study allowed the following conclusions as 
answers to research questions hypothesized in the beginning of the investigation:  
 
1. Macrovascular disease is a feature of severe peripheral ischemic lesions in 
patients with secondary RP and SSc as shown by patients with FMD levels ≤ 
9.5% had significantly more new DU in 3-year clinical follow-up as well as a 
predominance of positive Allen test in patients with DU. 
2. Microangiopathy is a dynamic process in SSc patients. Patients with DU had 
predominantly late pattern whereas early and active patterns were the 
most representative patterns in naïve-DU patients. Concerning semi-
quantitative MES score significantly differences were observed: MES score 
was higher in DU group compared to naive-DU group at baseline. A MES 
score greater than 2 in the beginning of the study was a risk factor for new 
digital ulcers occurrence in the 3-year follow-up.   
3. Vascular biomarkers play an important role as diagnostic and disease 
staging tools as well as prognostic indicators. In our study increased 
serum levels of ET-1, ADMA and low serum levels of VEGF were identified 
as independent risk factors for active ulcers. Patients with serum levels of 
ET-1>11.9pmol/ml and VEGF<422.47 pg/ml had significantly more DU in 
the 3-year follow-up. Although not significant, a trend towards increased 
serum levels of endoglin>4.215ng/ml was associated to a new DU episode. 
No predictive serum value was found for ADMA and endostatin. 
4. Endothelial dysfunction and microvascular damage identified in NCV are 
the best predictors of DU recurrence.   
5. Late NVC pattern was the only independent predictor for a first DU event. 
6. Capillaroscopy is the most useful tool in targeting patients at risk for DU 
episodes. Patients with late pattern need to be closely monitored for alert 
signs for peripheral ischemic lesions. 
 
Recommendations for future areas of research should focus on: 
 
1. It would be interesting to study skin blood perfusion and correlate with 
present findings. 
2. Propose an investigational observational study of consecutive very early/ 
early SSc disease patients to identify predictive vascular biomarkers of 
peripheral vasculopathy.   
3. Correlate all these finding with other organ involvement in SSc patients.  
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